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Thesis summary 
Whether to assess the functionality of equipment or as a determinate for the accuracy of assays, 
reference standards are essential for the purposes of standardisation and validation. The 
ELISPOT assay, developed over thirty years ago, has emerged as a leading immunological 
assay in the development of novel vaccines for the assessment of efficacy. However, with its 
widespread use, there is a growing demand for a greater level of standardisation across different 
laboratories. One of the major difficulties in achieving this goal has been the lack of definitive 
reference standards. This is partly due to the ex vivo nature of the assay, which relies on cells 
being placed directly into the wells. Thus, the aim of this thesis was to produce an artificial 
reference standard using liposomes, for use within the assay. Liposomes are spherical bilayer 
vesicles with an enclosed aqueous compartment and therefore are models for biological 
membranes. 
Initial work examined pre-design considerations in order to produce an optimal formulation that 
would closely mimic the action of the cells ordinarily placed on the assay. Recognition of the 
structural differences between liposomes and cells led to the formulation of liposomes with 
increased density. This was achieved by using a synthesised cholesterol analogue. By 
incorporating this cholesterol analogue in liposomes, increased sedimentation rates were 
observed within the first few hours. The optimal liposome formulation from these studies was 
composed of 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol (Chol) and 
brominated cholesterol (Brchol) at a 16:4:12 μMol ratio, based on a significantly higher 
(p<0.01) sedimentation (as determined by a percentage transmission of 59 ± 5.9 % compared to 
the control formulation at 29 ± 12 % after four hours).  
By considering a range of liposome formulations ‘proof of principle’ for using liposomes as 
ELISPOT reference standards was shown; recombinant IFNγ cytokine was successfully 
entrapped within vesicles of different lipid compositions, which were able to promote spot 
formation within the ELISPOT assay. Using optimised liposome formulations composed of 
phosphatidylcholine with or without cholesterol (16 μMol total lipid) further development was 
undertaken to produce an optimised, scalable protocol for the production of liposomes as 
reference standards. A linear increase in spot number by the manipulation of cytokine 
concentration and/or lipid concentrations was not possible, potentially due to the saturation that 
occurred within the base of wells. Investigations into storage of the formulations demonstrated 
the feasibility of freezing and lyophilisation with disaccharide cryoprotectants, but also 
highlighted the need for further protocol optimisation to achieve a robust reference standard 
upon storage. Finally, the transfer of small-scale production to a medium lab-scale batch (40 
mL) demonstrated this was feasible within the laboratory using the optimised protocol.  
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1.1 The ELISPOT assay 
The ELISPOT assay is an immunological assay which was originally developed to measure 
antibody secreting B cells and is now commonly used for the detection of cytokine secreting T 
cells (Czerkinsky et al., 1983). It is broadly based on the sandwich ELISA method, with the 
most significant difference being that live cells are used within the plate rather than antibody 
conjugates. The ELISPOT assay has become a useful tool as a prognostic immunological 
marker for predicting vaccine efficacy and disease monitoring especially in the quantification of 
CD8
+ 
T cell response (Cox et al., 2006). The reason for its wide spread use is primarily due to 
the sensitivity of the assay as it can detect cytokine producing cells at the single cell level and 
thus the assay is able to provide a greater level of sensitivity than the Enzyme linked 
Immunosorbent assay (Cole, 2005). There are various types of ELISPOT assays available to 
measure many other cytokines responding to antigenic or mitogenic stimulation including IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-α; however, the Interferon-γ (IFNγ) 
ELISPOT assay is the most commonly used (Slota et al., 2011). The level of sensitivity of this 
assay becomes particularly significant when studying responses to infection in which the T-cell 
responses can occur at low levels, such as with Mycobacterium tuberculosis (Lazarevic et al., 
2005). It has resulted in the development of a new test (T-SPOT.TB, Oxford Immunotech, UK) 
which is more specific than the tuberculin skin test as it measures the release of IFNγ in 
response to antigens present in Mycobacterium tuberculosis and not Bacilli Calmette- Guerin 
(BCG) (Lalvani and Pareek, 2010).  
One of the more significant recent developments with the use of this technique has been the 
implementation of this assay in the field of vaccine development. In fact, the IFNγ ELISPOT is 
one of the two most used immunological assays for the assessment of emerging HIV vaccines 
(Cox et al., 2006). In determining T-cell based responses, laboratories at the HIV Vaccine Trials 
Network (HVTN), the National Institute of Allergies and Infectious Disease (NIAID) and the 
National Institute of Health use it as their primary assay in vaccine trials (Moodie et al., 2006). 
Other immunological assays such as lymphoproliferation assays and cytotoxic T lymphocyte 
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assays have limiting factors, which include the use of radioactivity, decreased sensitivity with 
cryopreserved samples and other technical complications of the assay, whereas the ELISPOT 
has virtually no lower detection limit as it is able to detect 1 responsive cell in 100,000 (Currier 
et al., 2002). In addition, this eliminates the need for the use of radioisotopes and allows the use 
of cryopreserved samples, which becomes important for vaccine trials. Other developments in 
the field of ELISPOT assays include the dual spot assay, which enables the detection of more 
than one cytokine at the same time, and has been shown to differentiate between three subsets of 
cytokine secreting T cells (Okamoto and Nishida, 2005). In this assay, Th1 cells (producing IL-
2 and IFN-γ) and Th2 (producing IL-4 and IL-5) could be detected. Th1 cells were developed 
with horseradish peroxidase and amino-ethyl-carbazole/H202 for red spots and Th2 were 
developed with alkaline phosphatase and Vector blue. In addition, Th0 cells which have the 
ability to secrete both cytokines as they are a precursor for Th1 and Th2 cells were detected by 
chromogenic substrates visible by indigo spots. This shows that developments in this assay 
since its first emergence in the 1980s, has led to the assay becoming ever more complex.  
The different stages of the ELISPOT assay shown in Figure 1.1 briefly comprise cytokine-
specific antibodies being immobilised onto the ELISPOT plate to which cells (peripheral blood 
mononuclear cells isolated from whole blood are normally used) are added. These cells may 
also have undergone an additional pre-stimulation step prior to being placed onto the plate. At 
this stage the plates containing the immobilised antibodies and cells are left for between 18 – 48 
hours, during this time memory T cells will produce and secrete cytokine such as IFNγ. The 
cells are then removed prior to the addition of a secondary antibody for detection, which is 
either biotinylated or enzyme conjugated. If it is biotinylated, then a streptavidin enzyme 
conjugate is subsequently added. Finally, a substrate will then produce a coloured spot where 
the cell has released cytokine (Figure 1.1).  
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Figure 1.1 Illustrated principle of the ELISPOT assay with an example of a developed plate and 
an image of a representative well.  
(2) Cytokine secreting cells are 
incubated. 
(3) Cells are washed from the 
assay. The well is then 
incubated with biotinylated 
anti-cytokine antibodies. 
(4) Then a streptavidin- enzyme 
conjugate is added. 
(5) A substrate is added and 
spots form at the sites of 
secreting cells. 
(1) Wells of the ELISPOT plate 
are coated with antibody. 
Cytokine secreting cells 
Immobilised antibody 
Released cytokine 
Biotinylated antibody/ then streptavidin 
Substrate 
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The plates used within the ELISPOT assay fall under two categories depending upon the 
polymer used for the membrane: nitrocellulose based plates or poly(vinylidene fluoride) 
(PVDF). The use of PVDF plates for ELISPOT assays has become more widespread due to the 
drawbacks of using nitrocellulose-based membranes. The nitrocellulose membranes were prone 
to cracking and breaking due the brittle nature of the material thus PVDF plates overcame many 
of these disadvantages (Weiss, 2005). The PVDF membrane is resistant to chemical degradation 
(other than when in contact with alkalis greater than pH 12), and has a greater degree of 
elasticity, hence are not prone to breaking. However, PVDF is a very hydrophobic material 
(with a surface energy of 21 dynes/cm) and requires some modification in order for it to be used 
with aqueous solutions (Weiss, 2005). Therefore, protocols generally require a pre-wetting step 
in alcohol and then an immediate exchange with water prior to antibody solutions being placed 
on the membrane. Other important properties of the PVDF membrane include the pore size, 
which is 0.45 µm, a porosity of 65-70 % and a membrane thickness of 135 µm. These 
membranes are broadly compatible with a wide range of solvents; however, detergents such as 
sodium dodecyl sulphate may interfere with any antibody binding within the well (Weiss, 2005, 
Weiss, 2012).  
 
1.2 Standardisation issues with the ELISPOT 
Recent literature (Smith et al., 2009, Janetzki et al., 2009) has shown that with the growing use 
of the assay has also emerged concern, in regards to standardisation and validation protocols 
across laboratories. The assay has an added complication when compared to the ELISA assays 
of the use of live cells; although in terms of physiology their integration into an ‘in vitro’ assay 
(thus becoming ‘ex-vivo’) means that it is able to reveal more closely the true ‘in vivo’ events, 
there is an added degree of variability. Different laboratory protocols for using ELISPOT assays 
exist and although there is some disagreement in the scientific community as to the true extent 
of this variability and its implications, there have been studies carried out in regards to this area. 
For example, a recent study showed that ELISPOT assays from multi-institutional laboratories 
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differed in their results from 20 to 100 fold (Janetzki et al., 2009). The authors conclude that 
such variability compounds any attempts to compare the results between two laboratories and 
refer to it as ‘a game of chance’. There are many factors which can influence the different 
results obtained by laboratories; for example a study by Smith et al., (2009) examined factors 
such as the short in vitro stimulation step of cells prior to transference to the plate, differences in 
antibody coating concentrations, differences in cell incubation times and serum containing 
medium or serum free media. They found that in particular, the type of medium used, delays in 
processing of cells and the number of cells added all had a negative impact on the sensitivity of 
the assay. Even small differences can contribute to variation in results of the different 
laboratories and there are suggested procedures for standardisation. However, others have used 
such disparaging results to note that when assay procedure and data analysis is standardised, the 
detection of T-cells with precision was possible even with inexperienced operators (Zhang et 
al., 2009). Yet in this case laboratories were using the same reagents, following the same 
protocol and using the same data analysis techniques and in reality such conditions would not 
occur, as laboratories optimise individual protocols, source their own reagents, and have 
individual data analysis platforms. Therefore, this does highlight the need for standardisation 
and validation of assays to compare results between laboratories and to validate in-house 
results. There are currently programmes in place to bring this about, one such being The Cancer 
Vaccine Consortium of the Sabin Vaccine Institute which aims to bring a level of 
standardisation through recommendations (Janetzki et al., 2008). There are other consortiums 
which are also working to enhance the co-ordination across the many vaccine development 
research groups such as Transvac (European network of vaccine research and development), 
and through collaborations are working to develop reference standards which are essential for 
effective vaccine development (Transvac, 2013). 
Variability in results obtained from ELISPOT assays are compounded by the sensitivity of the 
assay; many factors can cause variability to occur and these can include cell recovery 
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subsequent to thawing of peripheral blood mononuclear cells, operator to operator variability, 
reagents used, the protocol itself and methods for spot counting and analysis (Slota et al., 2011). 
These main variables are divided into three areas: biological, reagent and technical. The 
biological variables can include the actual cell numbers added to the wells of the assay, the 
incubation time for the assay and the antigens used. The reagent variables can include the 
antibodies used for coating; some laboratories use self-coated plates although pre-coated are 
now also available, the use of serum and even the substrates used for development. The 
technical variables can include parameters such as, the incubator, washing procedures, pipetting, 
counting procedures and the way in which cells are frozen/thawed (Jantezki and Britten, 2012). 
When the assay is being used in clinical trials there are rigorous validation criteria that need to 
be followed and the first and perhaps most important of these is to produce a validated ‘standard 
operating procedure’ (Cox et al., 2006). If the assay procedure and the data analysis platform 
are standardised and validated then reproducible results are achievable. One method for 
assessing the variability of assays is using reference standards or controls.  
 
1.3 Reference standards 
Despite attempts to tackle the problem of the standardisation of immunological assays, it 
remains an on-going challenge, in particular for cytokines (Thorpe, 1998). Since the emergence 
of early crude ‘natural’ reference standards, significant progress has been made in this area and 
subsequently a large number have now been produced, overseen by the World Health 
Organisation that has a dedicated committee on biological standardisation. However, at present 
there are no commonly used standard references available for ELISPOT assays that could help 
standardise assay procedure and protocols thereby ensuring that the best vaccine candidates are 
put through to clinical trials (Janetzki et al., 2009).  
36 
 
As part of assay standardisation and validation, reference controls have an essential role. 
According to the World Health Organisation (WHO, 2006) the purpose of the reference 
standard is: 
 
 
 
 
The World Health Organisation is the body responsible for the standards for most biologically 
important proteins determined by immunoassay. These standards are validated by NIBSC 
(National Institute Biological Standards and Control), which are approved by the Expert 
Committee on Biological Standards (ECBS). There are many other organisations that work at a 
national and regional level, including the International Standard Organization (ISO), in projects 
concerning the standardisation of immunoassays (Stenman, 2001). 
A reference standard for this particular assay is integral in allowing comparability of data from 
different laboratories, and to confirm the validity and accuracy of the individual results obtained 
(Thorpe, 1998). According to assay validation guidelines there should be at least one positive 
and one negative control. The definition of a positive is a known amount of purified analyte of 
interest added to the matrix of samples (Mata and Lohr, 2008). In fact, it is advisable to have a 
control that falls in the middle of a response range and one which is two or three times that of 
the assay cut off or negative control. The negative control in immune based assays is generally a 
pool of normal human serum. Subsequent to sourcing a control, stability studies need to take 
place to ensure their reliability under common storage systems. The same need exists for 
ELISPOT assays, established reference standards that can validate assays and can monitor the 
inter-assay variability. It is thought that the variability found within the ELISPOT assay can 
differ with the level of responses; therefore, for the purposes of validation should include 
assessments at a low, medium and high range of the responses (Slota et al., 2011).  
“…to facilitate standardised characterisation of biological samples, whatever type of 
measurement or method used. Their use enables the achievement of consistency in the 
measurement of key attributes of biologicals…and thus the development of internationally agreed 
criteria for acceptability…”  
 
37 
 
1.4 The current status of controls for the ELISPOT assay 
Although the ELISPOT assay is an ex vivo assay there are currently controls which are used by 
various laboratories. For negative controls it is advised that six replicate wells are included 
which contain PBMCs without any stimulation and usually two types of positive control, 
namely a mitogen such as Phytohaemagglutin (PHA) and a pool of peptides (Cox et al., 2006). 
Currently used controls are mitogens such as Phytohaemagglutin, Concavalin A (ConA) or 
Phorbol 12-myristate 13-acetate (PMA) used in conjunction with Ionomycin. The largest 
drawback of using these as positive controls within assays is that although they stimulate cells, 
they do not specifically target memory responses from T cells, and can produce responses in 
other subsets of cells. These non-specific responses can cause an overstimulation of the cells 
that can lead to inaccuracies within the assay (Janetzki et al., 2004). Indeed, Janetzki et al., 
(2004) confirmed the need for controls through the assertion that ‘with assay-dependant controls 
for spot definition, the variability can be reduced to a minimum’.   
There is not only recognition for the need for standardisation, but also attempts have been made 
to produce reagents that can be used for controls (Currier et al., 2002). In this study a pool of 
peptides from Cytomegalovirus and Epstein Barr Virus were used, these are commonly 
encountered viruses for which T-cell responses have been elicited. The advantage of using such 
a pool is that it can provide information on the reliability of the PBMCs used in the assay 
whereas the use of other controls such as mitogens cannot. This is especially significant in 
vaccine trials where cryopreserved PBMCs are used. However, it is still very difficult to 
minimise the variability, even with a standard amount of this peptide pool, due to donor related 
differences from peripheral blood mononuclear cells added.  
The need still exists for a standard that when placed into a well of an ELISPOT assay can 
provide a defined response, for example 200 spots and has no reliance on the PBMCs used 
within the plate to elicit a response upon stimulation. Such a control, could be used to assess the 
integrity of the plate coating, reliability of antigen from batch to batch and standardisation of 
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spot counting procedures albeit manual or automatic. In order to achieve an artificial reference 
standard for use within the ELISPOT assay, it will need to mimic the actions of the cell closely. 
The vesicle needs to encapsulate the cytokine and then be able to release gradually within the 
well of an ELISPOT assay to produce a spot. Such requirements can be fulfilled by liposomes.  
 
1.5 Liposomes for use as artificial reference standards 
Liposomes are small spherical vesicles that are composed of one or more lipid bilayers and 
formed by the dispersion of water insoluble phospholipids in water (Bangham et al., 1965) 
(Figure 1.2). Initially it was their potential as artificial cells, more specifically in the study of 
biological membranes that was of interest. A significant development in the field of liposomes 
came with the realisation of their potential to encapsulate material and act as delivery systems 
for drugs, including proteins, enzymes, anti-tumour and anti-microbial agents (Gregoriadis and 
Ryman, 1971, Gregoriadis et al., 1971, Gregoriadis, 1973). 
Much of the research in liposomes has been directed towards their in vivo applications as drug 
delivery agents and decades of research have culminated in several liposome based products on 
the market for the delivery of drugs. As shown in Figure 1.3, liposomes have progressed from 
mere discovery in the late 1960s to the culmination of marketable formulations that are being 
used regularly for the treatment of diseases such as cancer presently. Liposomes not only have 
the ability to encapsulate material such as proteins, drugs and vaccines but can also be used for 
selective targeting of drugs; this can enhance the pharmacological effect and thus lead to a 
reduction in toxicity of the encapsulated drugs (Budai and Szogyi, 2001). The challenge has 
been to encapsulate the material of interest and also enhance the bioavailability (Allen and 
Cullis, 2012). The emergence of Visudyne® and very soon Thermodox® are the more 
sophisticated of liposomal delivery systems that have external trigger release mechanisms. 
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Figure 1.2 Schematic diagram of internal aspects of liposomes and the bilayer.  
The nature of the composition of liposomes results in the entrapment of hydrophilic substances 
within the aqueous core and hydrophobic substances being attracted to/or incorporated within 
the bilayer itself. Liposomes vary in charge and size due to the lipids and manufacturing 
methods used, with the nomenclature based upon size and lamellarity; these are summarised 
below in Table 1 (Storm and Crommelin, 1998). By the nature of the lipids chosen and the 
manufacture technique, liposomes are tailored for specific requirements. 
Liposomes can also be prepared from a variety of different methods depending upon the 
specific requirements of the formulation (Lasch et al., 2003). To summarise briefly a few of 
these fundamental methods, the most basic and perhaps ubiquitously used method for the 
formulation of liposomes is commonly referred to as the ‘dry film lipid hydration method’.
Aqueous core 
Liposome formulation 
Hydrophobic tail 
Hydrophillic head 
Lipid bilayer 
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Figure 1.3 Timeline for the development of liposome systems.
 First liposome- based antimicrobial drug AmBisome® for the treatment of visceral 
leishmaniasis was approved in1990 (Ireland) and in 1997 (USA). 
 Liposome- based antimicrobial drug Abelcet® was approved in 1995 (USA). 
 First liposome based gene therapy of Cystic Fibrosis patient (Caplen et al., 1995). 
 First marketed liposome based anti-cancer drug was Doxil®, approved in 1995 
(USA). 
 First liposome vaccine against Hepatitis A.  Epaxal Berna® 1995. 
 First approved liposome vaccine against Influenza Inflexal Berna V (1997). 
 First DNA liposomal vaccine; (Gregoriadis et al., 1997).
 
First liposomal photosensitive formulation Visudyne® licensed 2000.
 
 Liposomes first discovered and described as models for biological membranes 
(Bangham et al, 1965). 
 
 
 First pH sensitive liposomes (Yatvin et al, 1980). 
 First long circulating liposomes by the manipulation of lipid composition. 
(Gregoriadis and Senior, 1980, Hwang et al, 1980, Senior and Gregoriadis, 1982). 
 First monoclonal antibody- targeted liposome (Huang et al, 1983). 
 First cationic liposomes; delivering genes to cells (Felgner et al, 1989). 
 First long circulating PEGylated liposomes (Blume and Cevc, 1990, Klibanov et al., 
1990). 
  
  
 
 Liposomes first used as a delivery system for drugs, including proteins, enzymes, 
anti-tumour and anti-microbial agents (Gregoriadis and Ryman., 1971, 
Gregoriadis and Ryman., 1972, Gregoriadis, 1973). 
 Liposomes first used as immunological adjuvants for protein antigens (Allison and 
Gregoriadis, 1974, Gregoriadis and Allison, 1974). 
 Liposomes first targeted (with antibodies and asialoglycoprotein) to cells in vitro 
and in vivo (Gregoriadis and Neerunjun, 1975). 
 First humans injected with agent-containing liposomes (Gregoriadis et al., 1974);  
(Belchetz et al, 1977). 
 Liposomes first used for the delivery of nucleic acids to cells (Dimitriadis, 1978, 
Wilson et al, 1979), 
 
  
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Table 1.1 Liposome nomenclature with abbreviation and size ranges. 
Abbreviation Name Size range 
OLV Oligolamellar vesicles 0.1-1 μm 
ULV Unilamellar Vesicles All Size Ranges 
SUV Small Unilamellar Vesicles 20-100 nm 
MLV Multilamellar Large Vesicles >0.5 μm 
MUV Medium Sized Unilamellar Vesicles 20-100 nm 
LUV Large Unilamellar vesicles >100 nm 
GUV Giant Unilamellar vesicles >1 μm 
MVV Multivescular vesicles >1 μm 
 
A dry lipid film is formed after the solvent in which the lipids are dissolved is evaporated on the 
rotary evaporator. The resultant film is subsequently hydrated with an aqueous solution that is pre-
warmed above the phase transition temperature of the lipid. It is necessary for the suspension to be 
agitated for instance by vortexing and a heterogenous mixture of multilamellar vesicles (MLV) are 
produced. A further development resulted from the need to produce vesicles which were less than a 
micron in size; the process of sonication was introduced whereby pre-made multilamellar vesicles are 
sonicated either by placing the tip of a sonicator into the liposome dispersion or the sample is placed 
in the bath sonicator. 
Another important development in the formulation of liposomes came with the advent of freeze-dried 
rehydration vesicles (Senior and Gregoriadis, 1989). Similarly, it is necessary to have pre-formed 
vesicles and the aim, through this method is to achieve higher entrapment efficiency. The technique 
involves taking sonicated liposomes, which are then frozen, lyophilised and rehydrated with the 
aqueous buffer. Extrusion of the final formulation reduces the size and produces a more homogenous 
formulation. The method of reverse-phase evaporation does not rely on the formulation of pre-formed 
vesicles instead; lipids are added to 3 mL of diethylether (with a small amount of chloroform or 
methanol to increase solubility if necessary) to which 1 mL of the aqueous phase is added. The 
resulting suspension is kept under inert gas and then sonicated until a clear or opalescent one-phase 
dispersion is obtained (Szoka and Papahadjopoulos, 1980). The remaining organic solvent is removed 
under rotary evaporation leading to the formation of a highly viscous gel which at a critical point will 
collapse and become an aqueous suspension, and as a final step dialysis is used to remove 
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unentrapped material. These procedures are just a few examples of basic methods of which there are 
many adaptations used for manufacturing liposomes. 
 
1.5.1. Liposomal attributes 
Although lipids used for liposomal systems have a broadly similar structure in terms of a polar head 
group and two fatty acid chains, even slight variations of chemical structure can lead to a profound 
change in the properties and functionalities of liposomes produced from them. Differences can 
include the charge of polar head groups, the addition of polymers to the surface, the length and 
saturation of the fatty acid chains (Lian and Ho, 2001). For instance, lipid bilayers can exist in low 
temperature solid-ordered phase and above a certain temperature in a fluid disordered phase; this is 
called phase transition or Tm, it is at this temperature that the greatest liposome leakage is observed.  
 
Table 1.2 Phospholipids and their transition temperatures (Tm). 
 
Lipid Abbreviation No of 
Carbons 
No of 
double 
bonds 
Phase transition 
temperature Tm 
Dimyristoylphosphatidylcholine DMPC 14 0 23 
Dipalmitoylphosphatidylcholine DPPC 16 0 41 
Distearoylphosphatidylcholine DSPC 18 0 55 
Dioleoylphosphatidylcholine DOPC 18 1 -20 
 
 
 
 
The Tm is tailored by lipid selection, as it is dependent upon the length of fatty acid chains and 
whether they are saturated or unsaturated. DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) is a 
saturated phospholipid which has 18 carbons in each hydrocarbon chain and has a Tm of 55 °C. DOPC 
(1,2-dioleoyl-sn-glycero-3-phosphocholine) has a virtually identical chemical structure albeit the 
Unsaturated Saturated 
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presence of a single double bond in the chain yet it has a Tm of -20 °C (Table 1.2). The presence of 
this double bond results in decreased rigidity and an increase of the fluidity of the membrane and thus 
a decrease in the transition temperature results.   
Increasing the chain length for a lipid will result in an increase of the Tm, for instance an 18-carbon 
chain for DSPC has a Tm of 55 °C whereas a 22 carbon chain has a Tm of 75 °C. There are wide 
varieties of lipids available with varying transition temperatures and the lipids selected for 
formulations are dependent upon the requirements. Sterols such as cholesterol are often used in 
combination with other lipids in liposome formulations to alter membrane properties dependent upon 
the concentration used (Gregoriadis, 1991). At low concentrations, the incorporation of cholesterol 
leads to enhanced membrane permeability whilst higher amounts are able to decrease membrane 
permeability and eliminate the phase transition. For liposomes tailored for in vivo drug delivery 
cholesterol is included to adjust rigidity in addition to reducing instability due to binding of serum 
proteins to the membrane (Lian and Ho, 2001). 
 
1.5.2. Liposomes for the entrapment of rIFNγ 
Liposomes are ideal as drug carriers; they are generally composed of non-toxic lipids and are 
therefore safe as delivery systems in vivo as they do not produce unwanted immune responses and yet 
are able to encapsulate internally, or bind, a variety of molecules to their surface (Lasic, 1998). The 
potential of liposomes as carriers has been exploited for a wide variety of different molecules 
including chemotherapeutic agents, antimicrobial drugs, imaging agents, antigens, peptides, 
hormones, and cytokines as well as genetic material to name a few (Gregoriadis, 1991). Although 
there are a variety of different types of ELISPOT assays available to enumerate cytokine secreting 
cells, the IFNγ ELISPOT assay is the most widely used in vaccine trials. For instance, it is routinely 
used for the quantification and enumeration of the human immunodeficiency virus (HIV)-specific 
CD8+ T cell responses (Streeck et al., 2009). Therefore the aim of this study to encapsulate rIFNγ 
within liposomes and produce a reference standard that can mimic the action of T cell responses to 
facilitate assay standardisation. 
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Table 1.3 Properties of IFNγ adapted from (Farrar and Schreiber, 1993). 
Property IFNγ 
Major Inducer Antigens/ Mitogens 
Molecular Weight (KDa) 17 
Amino Acids  143 
N-linked glycosylation 2 sites 
Subunit composition Non Covalent homodimer 
pH stability Labile 
Cellular source T cells and Natural Killer cells. 
 
IFNγ is a dimeric protein, with an overall compact and globular shape. It is primarily helical with the 
absence of any β sheet in the structure. Thus, each dimer associates with another to form a non-
covalent homodimer and each IFNγ dimer may be able to bind two IFNγ receptors (Farrar and 
Schreiber, 1993). 
It should be noted the structure of all recombinant human interferon γ (rIFNγ) is different from the 
natural analogue (Table 1.3). There are structural differences in terms of the presence of additional 
amino acids not present in the natural form, most significantly all rIFNγ is not glycosylated and this is 
the reason that it is less stable in solution (Christova et al., 2003). In addition to the reduced stability, 
other studies conducted have shown that the rIFNγ is also susceptible to physical stresses such as 
increased temperature and pressure (Goosens et al., 2003; Tsanev et al 2007). 
Liposomes have the ability to carry a wide variety of molecules, and have versatile structures for 
physical manipulation of characteristics and more importantly have low toxicity for therapeutic 
requirements (Storm and Crommelin, 1998). Liposomes have previously been used for the successful 
entrapment of cytokines (Goldbach et al., 1995). More recently, liposomes encapsulated with 
cytokine have been used for in vivo purposes (Van Slooten et al., 2001). The reason for incorporating 
rIFNγ in liposomes is due to its ability to act as an adjuvant; this immunomodulatory activity offers 
potential for the activation of systemic immune responses, for instance when administered 
simultaneously with a vaccine. In this instance, no adjuvant activity was seen with the addition of free 
IFNγ at the site of injection. This is most likely due to rapid clearance, yet liposome encapsulated 
rIFNγ proved to be more effective (Van Slooten et al., 2001).  
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1.5.3 Liposomes and immunoassays 
Liposomes have previously been used in immune based assays to provide signal amplification as 
either intact or lysed vesicles. These have involved encapsulation of various types of markers 
including fluorescent markers whereby response amplification is achieved upon liposome lysis 
through proteins like complement or mellitin, detergents such as Triton X and enzymatic lysis through 
the addition of Phospholipase C (Gomez-Hens and Fernandez-Romero, 2005, Edwards and 
Baeumner, 2006). The methods used in such assays involve basic modification of the Enzyme-linked 
Immunosorbant Assay (ELISA), with either the covalent binding of the liposome to the antigen or 
conversely the liposome is bound to an antibody or secondary molecules (Rongen et al., 1997). Basic 
requirements for the use of liposomes in any kind of immune based assay would be to achieve high 
levels of encapsulation in order to meet the limits of detection of the assay. Therefore, the liposomes 
need to be very stable so that there is minimal unwanted leakage.  
The applications of liposomes as reference standards within immunoassays have not been previously 
considered. The need to do this within ELISA based immune assays has not been necessary as 
reference standards can be produced from sera with the presence or absence of the required antibodies 
for positive and negative controls respectively. Whereas within the ELISPOT assay a defined amount 
of cytokine pipetted into a well would not result in discrete spot formation. Thus, although the use of 
liposomes to encapsulate cytokines has been carried out before, the use of liposome encapsulated 
cytokine within ELISPOT assays has not. Due to the nature of the ELISPOT assay, where each well is 
coated with antigen for IFNγ, a reference standard is required that could contain the rIFNγ and release 
the contents in a similar way to the cells in the rest of the assay. The release needs to be precise and 
definitive and as such may require a trigger release mechanism. Liposomes not only offer the 
potential to encapsulate cytokines but are also a delivery system that is similar in morphology to the 
cells normally placed upon the assay. The basic premise of this project has been to formulate 
liposomes that can be used as reference standards within the ELISPOT assay, as shown in Figure 1.4.  
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Figure 1.4 Schematic showing the methodology for liposome incorporation into the ELISPOT assay. 
 
Unlike cells, which can be stimulated to release cytokines upon contact with an appropriate chemical 
or antigen, liposomes will only release in response to a trigger. It is important to consider these trigger 
release systems in the design of a standard for the ELISPOT assay (Figure 1.5). Although the 
encapsulation of proteins such as cytokines is well established, the dynamics of adding these vesicles 
to an existing immunoassay introduces a diverse set of challenges. For the liposomes themselves, it 
begins with the fundamentals of demonstrating the feasibility of encapsulation of rIFNγ in a sufficient 
concentration that will allow spot formation. In order to achieve this, the lipids chosen for the 
construction of such vesicles will need to allow release of the cytokine in a similar way to T-cells. 
Depending upon the lipids chosen, there will be other stresses on the cytokine to consider, such as 
heat, vortexing and centrifugation at high speeds.  
 
 
1. Coated ELISPOT plate to capture 
rIFNγ  
2. rIFNγ containing liposomes. 
3. Liposomes release rIFNγ at 37°C.  
4. Detection antibodies added and 
colour development solution. 
5. Plate is washed and spots counted. 
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Figure 1.5 Design considerations for the formulation of a reference standard. 
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Other important factors that require consideration are the differences between the sedimentation 
rates of a liposome formulation and whether this can be enhanced to ensure minimal leakage of 
liposomal contents before contact with the membrane; thus chemical modifications to enhance 
sedimentation may aid this requirement. Any modifications will need to have a minimal effect on 
the overall structure of the formulation or release of the cytokine.  
Once ‘proof of principle’ is established, there are still further challenges that need to be addressed 
such as the correct size, morphology, definition and number of spots. For the purposes of producing 
a final formulation, many other validation issues emerge such as producing a negative control and a 
formulation that can be stored either frozen or lyophilised. As shown in Figure 1.5, many pre-
design parameters need to be taken into consideration prior to formulation of the artificial reference 
standards. Due to the novel nature of this work the dynamic between artificial vesicles and the 
ELISPOT assay will only become apparent upon practical application and thus further challenges 
may emerge in the process of optimisation to achieve a final product. The consideration of 
triggered release of liposomes is an important parameter as there is not an active secretion of 
cytokine as with cells.  
 
1.6 Trigger Release Liposomes 
T-cells release IFNγ upon exposure to a specific antigen such as the viral protein. However, 
liposomes require disruption of their bilayer to promote release of their entrapped moiety, and the 
rate of release can vary depending on the liposome formulation and the characteristics of the 
substance entrapped, thus possible trigger release systems need to be considered if these systems 
are to be exploited within an ELISPOT assay.  
It is well established that liposome composition plays a significant role in liposome stability and 
many liposome formulations display limited stability. This is especially true within in vivo 
conditions; these include a fast clearance rate from the blood circulation due to the adherence of 
plasma proteins to the surface of the liposomes and a tendency to localise in the tissues of the 
mononuclear phagocyte system (MPS) particularly the liver and spleen (Allen, 1996). The in vivo 
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characteristics of such liposomes limits their effectiveness for the treatment of a wide array of 
diseases; however the ability of these systems to passively target the MPS has resulted in their use 
for the delivery of antimicrobial agents to infected macrophages as well as for antigen delivery 
(Allen et al., 1995). Early work investigating the effects of liposome composition and its 
relationship to in vivo clearance demonstrated that the susceptibility of liposome formulations to 
opsonins and high density lipoproteins found within a biological environment varies with the 
phospholipids used and the inclusion of cholesterol (Gregoriadis, 1991, Kirby et al., 1980). Such 
studies demonstrated that increasing the cholesterol content of liposomal formulations up to 50 
molar % increased the retention of fluorescent dyes encapsulated within phosphatidylcholine 
liposomes due to restrictions in the mobility of the bilayer (Kirby et al., 1980). Furthermore, it was 
shown that by using saturated lipids such as 1,2-distearoyl-sn-glycero-3-phosphocholine with 
transition temperatures greater than 37 °C and equimolar cholesterol, bilayer stability could be 
retained for over 48 hours in comparison to similar formulations using phosphatidylcholine 
(Gregoriadis, 1991).  
The establishment of such fundamental principles in the early stages of liposome design 
demonstrated the enhancement of liposome stability through the tailoring of the phospholipids used 
and the inclusion of cholesterol to confer greater in vivo stability. Indeed increased circulation 
times in vivo was considered to be one of the key elements for enhanced drug targeting of 
liposomal based carriers, and a significant development in this area came with the coating of 
liposomes with a hydrophilic polymer particularly polyethylene glycol (PEG) (Blume and Cevc, 
1990). The PEG coating was shown to enhance the steric stabilisation of formulations and reduced 
the binding of plasma proteins to the liposomal surface, resulting in longer circulation times (Lasic, 
1998). The ability of such formulations to avoid rapid clearance by the MPS led to them being 
termed stealth liposomes. The enhanced in vivo characteristics of such formulations resulted in 
their use as delivery systems for a selection of different diseases due to a reduction in toxicity 
compared with drug alone (Maeda, 2001). This was found to be particularly effective within 
cancerous tissues where the leaky vasculature combined with damaged lymph drainage systems 
(resulting from angiogenesis) promotes the accumulation of liposomes at the tumour site, a 
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mechanism often referenced to as the enhanced permeability and retention (EPR) effect 
(Matsumara and Maeda, 1986, Maeda, 2001). Long circulating liposome formulations are now 
available for commercial use including; Ambisome® (for serious fungal infections encapsulating 
amphotericin B), Doxil® and DaunoXome® for the treatment of cancer (Storm and Crommelin, 
1998). Even with such progress there remain further drug delivery hurdles to overcome. The 
increased permeability required for the penetration of the drug to within the tumour tissue varies 
within individuals and drugs such as doxorubicin have reduced therapeutic activity due to slow 
release and limited penetration deep into the tumour site, thus inhibiting effective drug distribution 
(Primeau et al., 2005, Zasadzinski et al., 2011). Not only can the effectiveness of the treatment be 
compromised, but in addition the cumulative effect of insufficient drug reaching the target site can 
increase drug resistance.   
Given that the release of the drug from liposomes generally relies on liposomal degradation and 
breakdown, there is a continued need for more control and optimisation of drug release 
characteristics. To address this, there are a wide array of studies that have examined the 
possibilities of using trigger release liposomes for the delivery of encapsulated material. This 
includes photosensitive, thermosensitive, ultrasound triggered, enzymatic and pH triggered release 
(Figure 1.6) and as such these need to be examined as possible release mechanisms for liposomes 
within the ELISPOT assay (Bibi et al., 2012). Although the application is very different, the 
requirements in terms of efficient encapsulation and release are much the same. Many of the 
studies for trigger release systems have focussed on the local environment of the tissue for target 
specific release. Although in the in vitro environment of the ELISPOT assay these conditions are 
absent, they can be designed to be a part of the assay, particularly for those wells containing the 
reference standards where the conditions required for ‘local release’ may include a change in pH or 
increased levels of specific enzymes. 
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Figure 1.6 Trigger release systems for the release of encapsulated rIFNγ. 
 
1.6.1 Enzyme triggered release from liposomes: Exploiting Phospholipase C  
Given the structural attributes of liposomes, the main consideration for triggered release is the 
breakdown of the lipid bilayer structure. One of the primary design considerations for liposomes at 
the initial stages of development is maximal encapsulation of the drug and minimal leakage. This 
can be achieved by incorporating high transition temperature lipids and/or cholesterol or through 
bilayer manipulation (Senior and Gregoriadis, 1982, Gregoriadis and Senior, 1980, Lian and Ho, 
2001, Zasadzinski et al., 2011). The need for the stability of liposome vesicles to retain 
encapsulated material prior to reaching the target site and consequently effectively release all the 
liposomal contents upon reaching the site can be difficult to achieve. Thus, exploiting the local 
environment of the target site allows such a balance to be achieved as only the presence of the 
trigger, albeit elevated levels of enzymes or a more acidic pH, can cause release of the encapsulated 
material. This simultaneously deals with two parameters for improving formulations; the first being 
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reduced toxicity as release occurs only at diseased sites, and secondly an improved therapeutic 
index, as there is a trigger for release, as opposed to reliance on eventual liposomal breakdown.  
However, in certain disease states the biological environment surrounding the affected tissue can 
become quite different to that of non-diseased areas. Exploiting the local environmental conditions 
for drug release is the premise for a range of prodrug therapies where compounds undergo 
biotransformation, either by chemical or enzymatic reaction, to release the active drug. The 
biotransformation is triggered through the exploitation of differences in the local environment at 
the site of action. For example, stilboestrol diphosphate is a phosphorylated synthetic oestrogen, 
which is cleaved to free stilboestrol through the action of phosphatase, which is found at higher 
concentrations in prostatic carcinomatous tissue. Similarly, in prostate, breast and pancreatic 
cancers there is a significantly higher expression of phospholipase A2 (PLA2), (Zhu et al., 2011, 
Davidsen et al., 2003). It is also well established that soluble extracellular enzymes are also found 
in inflammatory environments; for instance the synovial fluid from animals with arthritis contains 
enzymes such as lysozyme and cathepsins (Meers, 2001) and matrix metalloproteinases (MMPs), 
in particular MMP-2 and MMP-9 are widely thought to be associated with the development of 
human tumours (Sarkar et al., 2005). Thus, it is these local environmental conditions that are 
exploited in the development of enzyme-triggered release systems (Figure 1.7) and for triggered 
release from liposomes, enzymes able to degrade lipids are of primary interest.  
It is interesting to observe that even before the inadvertent official discovery of liposomes by 
Bangham et al., (1965), that studies on the effects of enzymatic activity on aqueous dispersions of 
synthetic lipids were being carried out. Much of the early work was using Phospholipase C (PLC) 
due to the ease of availability and similarity to mammalian analogues (Macfarlane and Knight, 
1941, Long and Maguire, 1954, van et al., 1961). These groups of enzymes catalyse the hydrolysis 
of phospholipids producing diacylglycerol and phosphocholine (Figure 1.8) (Liao et al., 2010). 
 
 
53 
 
 
 
 
 
 
 
 
Figure 1.7 Schematic summary of various enzymes and location of action for degradation of the 
bilayer. 
 
Whilst at this time not being termed liposomes, studies using PLC and liposomes were being 
carried out as early as the 1940s (Macfarlane and Knight, 1941, Long and Maguire, 1954) where it 
was found that saturated lecithins were resistant to the actions of the enzyme. However, these 
results were later contradicted in a study by Van et al (1961), where they used a similar 
methodology but concluded that it was not necessarily the difference between a saturated or 
unsaturated lipid that caused the differences in hydrolysis but rather the length of the lipid acyl 
chain. They found that PLC from Clostridium perfringens (C. welchii) was able to hydrolyse both 
saturated and unsaturated compounds; however, the rate of hydrolysis decreased significantly with 
increased acyl chain length. Whilst these early studies are not based on liposome vesicles but on 
aqueous dispersions, these findings have laid the foundations for the sophisticated enzymatic 
trigger release systems being designed today. Subsequent studies on the action of PLC on the lysis 
of lipid membranes (Hesketh et al., 1972) found that liposomes prepared from lecithin with, or 
without, cholesterol and dicetylphosphate in molar ratios of 7:1:2 (using a 1:1 w/w molar ratio of 
PLC preparation to phospholipid) exhibited over 50 % loss of marker. However, no lytic action 
was observed when the membranes contained saturated lipids. Using thin layer chromatography, 
the authors demonstrated hydrolysis of the lecithin by PLC whereas 
Lipopeptide 
MMPs 
PLC 
PLA2 
Drug molecules can be located 
in aqueous core or associated 
with the bilayer. 
Liposome 
Breakdown of the bilayer will 
cause release of entrapped or 
anchored material. 
Target Cell 
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dipalmitoylphosphatidylcholine (DPPC) showed no conversion to diglyceride (Hesketh et al., 
1972). 
 
 
 
  
Figure 1.8 The hydrolysis of phosphatidylcholine by Phospholipase C (PLC). 
Given the ability of PLC to digest lipid membranes, their potential to promote triggered release 
from liposomes was further exploited in the field of liposome-based immunoassays. In this type of 
assay, the enzyme detection element is replaced by a liposome encapsulating a marker molecule 
and lyses of antibody bound liposomes is caused by the presence of complement in serum or by 
mellitin, where inhibition of its lipid digesting action indicates the presence of the analyte (Rongen 
et al., 1997). In a study assessing the actions of PLC in an in vitro assay, liposomes were prepared 
using the reverse phase evaporation method and composed of DPPC and cholesterol (9:1 molar 
ratio), with the entrapped fluorescent marker calcein. Thus, a simple and inexpensive assay for 
testing ultra-trace amounts of biological substances such as insulin was developed due to the 
inhibition of the lytic activity of the conjugates in the presence of insulin antiserum (Lim and Kim, 
1997). Using an enzyme such as PLC within the ELISPOT assay to trigger release based upon 
these studies offers a feasible option as PLC woks at an optimal temperature of 37 °C. 
 
1.6.2 Enzyme triggered release: Phospholipase A2 
Whilst the above studies considered the ability of PLC as a trigger to promote drug release from 
liposomes, for in vivo targeted release exploitation of local conditions of the tissue or surrounding 
fluid can present an appropriate environment to trigger the release of liposomal contents. This has 
been the basic premise of numerous recent studies (Zhu et al., 2011, Davidsen et al., 2003, 
Kaasgaard et al., 2009). For example, PLA2 enzymes found throughout nature in the venoms of 
bees and snakes as well as within mammalian pancreatic juices are also involved in phospholipid 
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metabolism and numerous cellular functions, and can either be located intracellularly or 
extracellularly (Arni and Ward, 1996). However, increased levels of this enzyme are also 
implicated in various diseases such as rheumatoid arthritis, ischemia, atherosclerosis, and particular 
cancers such as colorectal and human familial adenomatous polyps (Kudo and Murakami, 2002).  
Thus, the presence of enhanced levels of this enzyme can offer a mechanism for the triggered 
release of liposomes that are stable under normal physiological conditions but release their contents 
at the above-mentioned sites. This was shown through a study in which elevated PLA2 levels in 
inflamed tissue were exploited for potential triggered release of siRNA from liposomal systems 
(Foged et al., 2007). Using the double emulsion technique, liposomes were formulated using 
DPPC, dipalmitoylphosphatidylglycerol (DPPG), and dipalmitoylphosphatidylethanolamine 
attached to polyetheylene gylcol (DPPE-PEG) to provide a hydrophilic stealth coating of the 
liposomes. Within these vesicles siRNA, which would target TNF-α silencing was entrapped. The 
cytokine TNF-α is over expressed by cells such as monocytes and macrophages in rheumatoid 
arthritis, and as such siRNA would be a highly specific way to silence the genes of interest (Foged 
et al., 2007). The study carried out in vitro using HeLa cells found that there was increased uptake 
of siRNA into vesicular compartments that was concentration dependant and increased by the 
presence of PLA2 suggesting the potential of such siRNA encapsulated liposomes in targeting and 
controlled release of siRNA in inflamed tissue (Foged et al., 2007). 
The idea of triggered release from liposomes does require appropriate stability and targeting of the 
liposomes to ensure accumulation of the liposomes at the site of action prior to their triggered 
release. PEGylated liposomes confer enhanced stability within the blood circulation, consequently 
various PEGylated nanoparticulate products are approved for clinical use (e.g. Doxil
®
/ Caelyx
®
). 
However their enhanced ability to accumulate at the site of the tumour is not matched by the rate of 
drug release, thus in a recent study Zhu et al., (2011) the increased levels of PLA2 associated with 
various malignant tumours was exploited to examine the effects on the rate of drug release from 
various lipid vesicles. Interestingly from this work, the authors noted that liposomal degradation 
and drug release is dependent upon the PLA2 isoform expressed. In this study two groups were 
examined, namely IIA and III. From the formulations examined, it was found that the presence of 
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DSPE-PEG within the bilayer enhanced PLA2 triggered release. This was attributed to the binding 
of PEG to DSPE; DSPE is zwitterionic under normal conditions yet when bound to PEG it 
becomes anionic, and this combined with the structural attributes of PEG may cause membrane 
restructuring which subsequently enhances the activity of the enzyme. In terms of the difference in 
isoforms used, there was a reduced level of release observed with group IIA when compared to 
group III (Zhu et al., 2011). Such studies highlight how enzymes can be used with liposomes for 
bilayer degradation and how changes in the composition of the liposomes can alter release kinetics 
in the presence of PLA2.  
 
1.6.3 Enzyme triggered release: Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of highly homologous zinc dependent 
endopeptides that hydrolyse most of the constituents of the extracellular matrix and basement 
membrane components (Birkedal-Hansen et al., 1993). They play a central role in a range of 
biological processes including embryogenesis, wound healing, angiogenesis and in diseases such as 
atheroma, arthritis, tissue ulceration and cancer (Visse and Nagase, 2003). Although these enzymes 
play an important role in the normal physiology of the body, they are also implicated in the 
development and metastasis of tumours. Whilst lipids are not a natural substrate for MMPs, which 
degrade components of the extracellular matrix, the presence of these enzymes in the local 
environment of tumours can be exploited for the purposes of liposome based trigger release. In 
order to achieve triggered liposomal release, peptides are incorporated into the liposomal bilayer 
that the enzymes can specifically target (Sarkar et al., 2005, Elegbede et al., 2008). For example, in 
a study carried out by Sarkar et al., (2005) the development of a trigger release mechanism via 
MMP-9 using endopeptidases was shown. A triple helical collagen mimetic peptide conjugated to 
stearic acid and this lipopeptide was then incorporated with DSPC at 10:90 mol % respectively. 
These modified liposomes encapsulating carboxyfluorescein, when subjected to the MMP-9 
enzyme digestion released 55 % of the marker after five hours. The authors also show specific 
release associated with this particular subgroup of enzymes because in the presence of a general 
proteolytic enzyme such as trypsin, there was no release (Sarkar et al., 2005). The range of 
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enzymes used for release of the encapsulated material from liposomes can be carefully selected for 
the most effective release within the ELISPOT assay. 
 
1.6.4 ADEPT - designing antibody-enzyme conjugate trigger release systems 
Liposome based immuoassays have previously shown to use enzyme-analyte conjugates for in vitro 
purposes, similarly antibody-enzyme conjugates have been used for in vivo targeted therapy. 
Although PLC is not commonly found in areas of diseased tissue, the ability of such enzymes to 
covalently attach to biological molecules such as targeting antibodies offers an advantageous route 
for targeted release. It allows attached prodrugs to be activated specifically at the diseased site this 
type of treatment is termed Antibody-Directed Enzyme Prodrug Therapy (ADEPT) (Francis et al., 
2002).  
ADEPT is a two-step targeted therapy with the antibody-enzyme conjugate targeting the tumour 
and then administration of a prodrug activated by the enzyme at the tumour site and is currently a 
growing area of research as a treatment option for advanced cancers. The emerging problems 
encountered during the developmental stages of this treatment have included toxicity issues related 
to the long half-life of the pro-drugs in circulation, subsequently leading to the additional 
administration of a clearing antibody (Mann, 2002). 
 
 
 
 
 
 
  Figure 1.9 The potential use of ADEPT in conjunction with trigger release liposomes. 
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In terms of liposomal drug delivery, a similar mechanism could be employed to target an enzyme 
to a disease site using antibodies but rather than the enzyme-triggered conversion of a prodrug, the 
enzyme could trigger liposomal breakdown and release encapsulated material (Figure 1.9). An 
advantage of such a system would be controlled release of the drug at the target site and an 
increased amount of drug reaching the target site within the liposomal carrier system compared 
with the prodrug conjugates. Within the in vitro environment of the ELISPOT assay the enzyme 
could be attached to a liposomal vesicle which is only activated at 37 °C (the incubation 
temperature) or by an antibody which is attached to a separate liposomal vesicle. The design of 
such a system would offer a sophisticated trigger release system. 
 
1.6.5 pH triggered release using fusogenic lipids 
Triggered release mechanisms for drug release within cells have also improved targeted delivery. 
For example, endosomal drug release was achieved by designing fusogenic liposomes that are 
stable in the extracellular fluid environment, but when they are taken up within the endosomal 
compartment, the drop in pH results in the liposomes fusing with the endosomal membrane (Shi et 
al., 2002). This can result in the delivery of the internal contents of the liposomes into the 
intracellular compartment either via endosomes or directly into the cytosol. Liposome triggered 
release in response to changes in pH can be achieved via a variety of methods including the use of 
fusogenic lipids (Connor and Huang, 1985, Simoes et al., 2004) and has been commonly used in 
gene therapy systems.  
pH triggered liposomes were originally designed to release encapsulated material in acidic 
environments especially areas surrounding tumours where the pH drops to around 5.0 (Lee et al., 
1996). The use of pH triggered liposomes is often designed for the acidic environment of endocytic 
vesicles. In this environment the pH is around 5 and sufficiently acidic to promote release 
(Drummond et al., 2000). There are different mechanisms by which pH sensitive liposomes have 
been achieved but they are generally composed of phosphatidylethanolamine or a derivative and a 
compound, which is a weakly acidic amphiphile. One particular drawback of such formulations has 
been the loss of pH sensitivity in the presence of serum (Shi et al., 2002, Simoes et al., 2004). 
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Although a recent study has shown that liposomes formulated from egg phosphatidylcholine, 
dimethyldiooctadecylammonium bromide (DDAB), cholestryl hemisuccinate (CHEMS) and 
Tween-80 (25:25:49:1) showed rapid release and more stability than liposomes formulated with 
DOPE. This study also examined specific targeting of the folate receptor found in many tumours 
and found increased cytostolic release of entrapped markers (Shi et al., 2002). For an in vitro 
environment such as the ELISPOT assay, the change in pH required for trigger release would have 
to be carefully controlled by the addition of a buffer in the wells with reference formulation. The 
main consideration with such pH-triggered release is the change in pH and the impact on the plate 
coated antigen and the encapsulated material. 
 
1.6.6 pH triggered release and inducing fusion with peptides 
 Other types of pH-triggered liposomes include the use of synthetic fusogenic peptides within the 
liposomes vesicles. For example, in a study by Li et al (2004), a peptide containing the amino acid 
sequence (GALA) was chosen to confer pH sensitivity through a negatively charged side chain. 
Since the peptide is water soluble at a neutral pH and hydrophobic in an acidic pH, a drop in pH 
will promote a re-arrangement of the peptide within the liposomal vesicles with the peptide moving 
into the membrane, fusion of small unilamellar vesicles composed of unsaturated phospholipids 
will occur causing release of encapsulated material (Li et al., 2004) . 
 
1.6.7  pH triggered release and improving stability with polymers 
The most current developments in this field of trigger release have come with the incorporation of 
pH titratable polymers. One of the problems of using phosphatidylethonolamine (PE) based 
formulations is rapid clearance and destabilisation by serum proteins; however, inclusion of 
polyethylene glycol has been shown to circumvent such issues with rapid elimination being 
observed when regular pH sensitive liposomes were tested in vivo but not for sterically stabilised 
liposomes (Simoes et al., 2004). Polymers have been used extensively in the study of 
thermosensitive polymers including N-isopropylacrylamide (NIPAM). However, previous studies 
have shown that the incorporation of such copolymers in liposomal systems result in an increase of 
the lower critical solution temperature above 37 °C and the vesicles becoming pH sensitive. When 
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studied for the release from PC and PC/cholesterol liposomes, enhanced release of fluorescent 
markers was observed at 37 °C in acidic conditions similar to those found in vivo, with similar 
results observed with the incorporation of doxorubicin (Drummond et al., 2000). Interestingly, it 
was also observed that the inclusion of PEG on the liposome surface did not affect the contents 
release in an acidic environment (Drummond et al., 2000). 
 
1.6.8 Remote triggered release 
Although using the external environment of the target cell seems ideal to achieve site-specific 
delivery there are no guarantees that release will solely occur here. For instance, inflamed areas can 
have high levels of Phospholipase enzymes (Meers, 2001); therefore, treatment of tumours or 
cancers with patients with inflammation due to rheumatoid arthritis may interfere with the targeted 
release. Thus, an even higher level of sophistication is sought to achieve target specific release and 
the inevitable next step has been remote triggered release. Instead of relying on the biological 
environment of the target cell, release would be reliant on an independent external trigger. One of 
the strategies examined for this purpose has been the use of ultrasound; this is a desirable method 
for release because it offers area specific penetration into the body without being invasive. In terms 
of in vitro applications such as the ELISPOT assay there is potential for controlled release 
subsequent to the settling of the liposomes at the bottom of the well thus this type of release could 
offer reduced background. 
 
1.6.9. Ultrasound triggered release 
Ultrasound has been used for many years within the clinical setting for a wide variety of diagnostic 
imaging including obstetrics, gynaecology and cardiology (Abramowicz, 1997). However, in some 
instances the reflected signal intensity received by the detector from the tissue can become highly 
attenuated and therefore ambiguous for useful diagnosis (Cosgrove, 1997). In the late 1960s, it was 
found that small air bubbles caused within supravalvular injections of saline led to enhanced signal 
intensity. However, these dissolved rapidly within the blood and therefore more stability was 
required. Therefore, a combination of low diffusivity gases and materials to stabilise the outer shell 
such as lipids, polymers, and proteins were developed (Marxer et al., 2011, Kaur et al., 2009). 
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These are termed echo-enhancers or contrast agents and are effective at increasing signal intensity 
and reducing tissue attenuation, and there are several products on the market which are used for 
this purpose, of which Sonovue® uses phospholipids (Calliada et al., 1998). The scope of 
microbubbles as contrast agents within more sophisticated imaging techniques such as magnetic 
resonance imaging (MRI), for the purposes of imaging fluid pressure has been examined for a 
stability assessment of two different gases; namely air filled gas (Vangala et al., 2007) and nitrogen 
gas (Kaur et al., 2009). For the stabilisation of these bubbles they were formulated with 
phospholipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) in the presence or absence of 
cholesterol and/or poly (ethylene glycol distearate) (PEG-distearate). The nitrogen gas 
microbubbles exhibited an enhanced level of stability in comparison to air-filled microbubbles 
(Kaur et al., 2009, Morris et al., 2008). 
Liposomes designed for the purpose of ultrasound-triggered release are generally termed as 
echogenic liposomes; the basic requirement is an area of air to make them sensitive to ultrasound 
release. It is thought that the sound wave causes expansion of the contained air and thus of the 
vesicle itself, to a point where the increase in pressure can exceed the elastic limit of the bilayer 
and damage occurs to the bilayer thereby releasing the internal contents (Huang and MacDonald, 
2004). Exposing liposomes to low frequency ultrasound can cause formation of transient pores due 
to the effect of ultrasound on the packing arrangement of the lipid chains within the membrane; this 
results in an increase in the permeability of the membrane and thus drug release (Schroeder et al., 
2009). The basic structure of liposomes used for ultrasound activation can be divided in three 
subtypes, the first would be a liposome which contains the entrapped drug with an internal 
compartment of air space bound by a monolayer (Huang, 2008). The second would comprise a 
more complex monolayer covered air bubbles within the aqueous compartment of the liposome 
prepared by reverse phase evaporation, and sterically stabilised with polyethyleneglycol, before 
being placed in vials of perfluoropropane gas, bath sonicated and the final subtype are liposomes 
which are conjugated to air bubbles through a biotin-avidin linkage (Huang, 2008).  
It has also been suggested that lipid composition influences drug release from liposomes using 
ultrasound as a trigger (Evjen et al 2011). In this study, calcein was used as a model drug and 
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release was monitored by fluorescence self-quenching. Increased cavitation dose, resulted in a 
greater amount of release from DOPE based liposomes in comparison to formulations composed of 
DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine). At a cavitation dose of 2000 (1.13 MHz) 
the formulation of DSPE:DSPE-PEG 2000:cholesterol 68:8:30 mol % showed release of 34 % 
whereas with the formulation incorporating DOPE (DOPE:DSPC:DSPE-PEG 2000:cholesterol 
58:11:5:26 mol %) 49 % release was observed. It is interesting to note that in this study cholesterol 
had a negative effect on sonosensitivity. The differences in the observations are thought to be due 
to the bilayer packing arrangements of the lipids which, when exposed to ultrasound can produce 
perturbations in the membrane (Evjen et al., 2011). 
Further investigations of liposome-microbubble complexes for drug delivery applications have 
been shown through constructs of microbubbles conjugated to the surface of gas-filled 
microbubbles used for the purpose of ultrasound-triggered release. It was found that short 
ultrasound treatment resulted in complete destruction of the bubble and release of a third of the 
entrapped dye and thrombin release was confirmed to be around 11 % (Klibanov et al., 2010). 
There is an obvious potential in taking forward ultrasound triggered release particularly as it offers 
the potential for precise release at the target area and it is preferred alternative to more invasive 
techniques. In terms of the design, a formulation as a reference standard within an ELISPOT assay, 
microbubbles may not be able to sediment as effectively as the normal vesicles due to the gas that 
is used. This may influence effective spot formation. 
  
1.6.10 Thermosensitive liposomes: exploiting phase transition temperatures of lipids. 
In taking the literal meaning of thermosensitive, all lipids used in liposome formulations are 
thermosensitive because the nature of the bilayer will change in response to the surrounding 
temperature. The bilayer will undergo phase transitions from a more crystalline gel state to a more 
disordered fluid state (Figure 1.10) at increased temperatures and this affects the permeability of 
the membrane resulting in leakage of encapsulated material. The phase transition temperature of a 
liposome formulation is dependent upon the phospholipids used and formulations can therefore be 
designed for the application required (Vemuri and Rhodes, 1995). 
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Figure 1.10 The effect on the bilayer with increased temperature. 
Long circulating liposomes have the ability to evade destruction by the immune system prior to 
reaching the target site; however, the rational design of liposomes is now expanding to become 
even more specific with trigger release and target specific delivery. For instance, a recent study has 
examined the use of thermosensitive liposomes conjugated with a ligand attached to the liposome 
surface. These liposomes had a human epidermal growth factor 2 specific ligand which is used to 
target breast cancer cells. These liposomes were loaded with the cancer drug doxorubicin and the 
effects of hyperthermia were examined (Smith et al., 2011). Formulations were made from DPPC 
and DSPE-PEG 2000 and cells treated with liposomes showed a 10-fold increase in binding to 
HER2+ cells in comparison to HER2- cells at 37 °C. The doxorubicin liposomes also exhibited a 2-
3 fold higher accumulation in cells in comparison to unencapsulated liposomes. By using 
specialised ligands incorporated into the liposomes, termed affibody molecules, as alternatives to 
antibodies the high affinity ligand is able to bind with specificity to target proteins, which are 
upregulated in tumour tissues. They are composed of a three helix scaffold and are relatively small 
(6-9 kDa) yet they are extremely stable and can be readily expressed in bacteria or by peptide 
synthesis (Smith et al., 2011).  
The aim of the design process in such systems is to produce a vesicle that is not only target specific 
to the intended tissue but one that will also have the capability to release at the target area in order 
for the enhancement of drug delivery. Similarly, to this study the leaky character of liposome 
formulations during phase transitions can be exploited to design thermosensitive liposomes, 
especially as DPPC undergoes phase transition at 41°C (Needham and Dewhirst, 2001, Kono, 
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2001). However, instead of relying solely on the lipids themselves other techniques to modify the 
membrane characteristics are being used, such as the addition of lysolipids and polymers. 
 
1.6.11 Thermosensitive liposomes and modifying phase transition with lysolipids 
A recent study examined the formulation of liposomes using DPPC and 
monopalmitoylphosphatidylcholine (MPPC) for the delivery of arsenic trioxide (ATO;AS2O3) in 
thermo-triggered liposomes formulations. Similarly to cisplatin, this drug is an effective anti-cancer 
treatment but at higher doses there are toxicity problems. Liposomes are ideal carrier systems 
because they are generally composed of non-toxic lipids and able to encapsulate or bind a wide 
variety of molecules (Lasic, 1998). Liposome formulations in this study included a combination of 
DPPC and corresponding lysolipids, which have single chains (Winter et al., 2011). In this study, a 
10 % addition of lysolipid allowed release over 24 hours whereas formulations with a 5 % 
reduction of MPPC release reached a plateau after 10 hours. This elucidates the nature of tailoring 
phospholipids used and release kinetics as temperature affects the permeability of the membrane. 
Although release rates were comparable at 37 °C and 42 °C the presence of 10 % lysolipid resulted 
in a 15 % higher release rate when compared to formulations using 5 % lysolipid within the first 
hour (Winter et al., 2011).  
Similarly, the MPPC lysolipid incorporated into DPPC formulations with entrapped 
carboxyfluorescein enabled the liposome formulations to become more thermosensitive (Needham 
and Dewhirst, 2001). The presence of lysolipids in liposome formulations can reduce the stability 
of vesicles by partitioning in to the bilayer. It was found that the lysolipid containing liposomes 
showed a much more rapid release at 42 °C. These formulations were also tested in vivo in mice 
with tumours and it was found that that the growth delay for the tumours was extremely effective 
as none of the tumours showed regrowth for up to 60 days compared to non-thermosensitive stealth 
liposomes where tumours grew back 15 days after treatment. The hyperthermia, which is 42 °C for 
1 hour, is thought to have produced enhanced permeability, thus long circulating stealth liposomes 
are able to accumulate at the site of the tumour because of increased vascular permeability 
(Needham and Dewhirst, 2001). Studies using lysolipids within formulations to enhance the 
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thermosensitive effects of liposome formulations appear to show promise. The rational design for a 
formulation to release at a specific temperature, slightly higher than the physiological temperature, 
would allow more target specific release, through heating of local areas where the drug has 
accumulated. This would offer many advantages, primarily reduced cytotoxicity as free drug will 
not be available in non-target areas as is the case with many anti-cancer drugs. This method allows 
greater control of release, which addresses one of the drawbacks of stealth liposomes, that although 
they can reach the target site the release from the vesicles is slow (Shum et al., 2001). 
 
1.6.12 Thermosensitive liposomes and modifying phase transition with polymers 
Instead of relying solely on the melting point of individual lipids, thermosensitive polymers can be 
incorporated into the formulations (Kono et al., 1999, Kono, 2001, Chandaroy et al., 2001). There 
are a wide range of synthetic and natural polymers available that have the ability to be water 
insoluble below the lower critical solution temperature (LCST) and water soluble above the LCST. 
The change in the polymer chains from a hydrated or hydrophilic state to hydrophobic whereby the 
polymer chains contract and cause destabilisation of the membrane of the liposomes can be 
controlled by the exposure temperature (Figure 1.11), thus the liposomes become thermosensitive 
(Kono, 2001).  
Association of the polymers is either through the aqueous incubation of polymers with liposome 
formulations (attached only to the outer liposomal membrane) or alternatively they can be a 
mixture of lipids and polymers used prior to formulation with polymer chains associated with both 
the internal and outer membrane. In a study by Kono et al., (1999) where co-polymers were used, 
two different types of anchoring was investigated, one was in the middle of the chain and one at the 
end of the chain. These were combined with dioleoylphosphatidylethonolamine (DOPE) in calcein 
loaded liposomes. It was found that the polymers anchored at the terminal region exhibited 
significantly more release at 42 °C, with almost complete release of the contents within 5 minutes.  
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Figure 1.11 The effect of temperature on liposomes modified with polymers.  
The polymer used is a poloxamer and these are tri-block polymers with a hydrophobic poly 
(propylene oxide) group in the middle of two polyethylene oxide hydrophilic groups (Chandaroy et 
al., 2001). The results from this work showed that the presence of increasing percentages of 
cholesterol in the composition of the formulation resulted in a sharper transition for the release of 
contents, and that the temperature for the onset of release increased with decreasing pluronic 
concentration. Understanding the effects of release by modifying the composition of the 
formulations is a significant issue to consider in the rational design of liposome formulations. The 
use of di-stearyl poly (ethylene glycol 5000) was found to have no effect on the release 
characteristics of the formulations, which suggests that the presence of PEG does not hinder the 
pluronic molecules. 
 
1.6.13 Light sensitive liposomes 
Ultrasound as a technique is already widely employed within the medical field (Abramowicz, 
1997) and therefore using liposomes to carry drugs to affected areas and triggering release via this 
method seems logical step forward. Light is not used to the same extent within the clinical setting, 
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which may explain the reduced number of research articles available in this area and the lack of 
success for in vivo applications of this particular trigger release system. Photo-triggered release 
requires an element within the liposome formulation to be light reactive; this can either be the lipid 
itself which may have been modified or a membrane anchored probe and contact of light of the 
appropriate wavelength to achieve release. In a study by Yavlovich et al., (2011), in order to tailor 
the liposomes formulations for use within an in vivo environment, DPPC liposomes were 
formulated with diacetylene phospholipid (DC[8,9] PC) and DSPE-PEG200 with the encapsulated 
doxorubicin. Assessment of the released drug showed that laser treatment of cells with a 514 nm 
wavelength resulted in a 2-3 fold improvement in cells killed compared to untreated samples 
(Yavlovich et al., 2011).  
More novel uses of photo-reactive liposomes have been shown with the use of 3D tissue constructs 
(Smith et al., 2007). This application is not aimed at drug delivery although theoretically can be 
applied to in vivo situations. In this instance photosensitive liposome formulations were made using 
a light sensitive lipid (1,2 –bis (4-(n-butyl) phenylazo-4’-phenylbutyroyl) Phosphatidylcholine) to 
be triggered by long wavelength ultra violet light. The entrapped calcium chloride upon release 
resulted in cross linking of the alginate solution and immobilisation of bone-derived cells for the 
construction of 3D cultures. By combining the lipid with a stable lipid, such as DPPC, trapped 
solutes are released upon with the appropriate trigger (Smith et al., 2007). Light triggered release 
does not only have the option of a single parameter for causing release such as temperature as the 
formulation can be tailored for wavelength, intensity and duration of application. Currently, 
Visudyne® is one of the only approved liposome formulation which uses the principle of light 
triggered release and is used for a condition which occurs as a result of age related macular 
degeneration. Thus, theoretically light triggered release could be applied within an in vitro setting 
although this would require an additional step within the assay that is not a part of the normal 
protocol. The modification of the protocol itself to enable the use of a reference standard is not 
ideal as it may introduce further variability.  
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1.7 Triggered release systems and applications for the ELISPOT assay 
The emergence of ThermoDox
® 
for the treatment of a wide range of cancers highlights how trigger 
release systems are moving closer to becoming available for treatment (Allen and Cullis, 2012). 
This liposome formulation has been designed to release entrapped doxorubicin under conditions of 
mild hyperthermia and is now at the Phase III stage of clinical trials. Hence, the progression of 
trigger release systems is translating into relevant medical applications. Trigger release systems 
currently studied are broadly divided into two categories; those reliant on an external trigger such 
mild hyperthermia, ultrasound or light and those dependent on the local environment as in the case 
of enzymatic and pH triggered release.  
The obvious advantage of an external trigger is that there is complete control of release if the 
formulations are completely stable; it is precisely this ability, which makes these systems 
interesting options for the release of encapsulated material in an ELISPOT assay. For instance, the 
success of enzymatic release relies on a successful interaction of the enzyme and the substrate and 
this may be governed by several factors as described in Table 1.4. Such factors include chain length 
and saturation of lipids chosen and although there have been no comprehensive studies examining 
these parameters the various studies in this field have shown that the ability of the enzyme to 
hydrolyse the substrate varies when these factors are changed. For instance, PLC was less effective 
with lipids of longer chain lengths (Van et al., 1961) or saturated chains (Macfarlane and Knight, 
1941, Long and Maguire, 1954). However, the impact of lipid choice may not be as significant for 
instance with the MMP based release systems as the target was not the bilayer itself but the 
endopeptidases attached to it. Thus, the actual composition of the bilayer is not going to play as 
significant a role as those enzymes such as PLA2 that directly hydrolyse the lipid chains. 
Although the aim of many, if not all, of these studies is to enhance the effectiveness of targeted 
delivery for in vivo purposes, for the purpose of producing an artificial reference standard the 
concept of triggered release systems needs to be applied to an in vitro environment. By carefully 
designing the liposomal system to be as stable as possible and incorporating a triggered release 
system this may lead to enhanced release, and possibly more effective spot formation. 
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Table 1.4 Liposome composition factors and their impact on enzymatic trigger release systems. 
Parameters Effect 
Chain Length Increased chain length leads to a more tightly packed bilayer. This 
may affect how the enzyme is able breakdown down the bilayer. 
Saturation Saturated phospholipids are able to pack more tightly; this can lead to 
more stable formulations for in vivo purposes, but conversely it has 
been shown to inhibit enzyme action.  
Transition Temperature Enzymes work at an optimal temperature range; in vivo this needs to 
be 37 °C thus the transition temperatures of the lipids must be chosen 
to achieve stable formulations, as it will vary as a direct result of 
composition of the overall phospholipid mixture. 
Cholesterol Increases the stability of the liposomes resulting in tighter packing 
therefore there may be a direct impact on the rate of release by the 
enzyme. 
Polymers The insertion of a polymer into the bilayer may also effect the 
dynamics of enzyme-lipid interaction as there maybe changes to the 
charge or the overall structure of the liposome 
Charge Lipids can be anionic, neutral or cationic and this may directly affect 
the interaction between the enzyme and substrate. 
 
Any triggered release system considered for use in the ELISPOT assay needs to be compatible with 
the assay and the way in which it is used on a daily basis, therefore some of the triggered release 
systems may not be appropriate. Overall trigger release systems offer potential for enhanced release 
and if used in conjunction with the ELISPOT assay would require careful consideration for their 
integration within the assay. Therefore options such as light triggered release and ultrasound, 
although offering remote release in a controlled manner, would result in an additional step in the 
procedure of the assay which may affect other live cells present in the assay. However, options 
such as careful lipid selection for thermo-triggered release, enzymatic release and pH triggered 
release may offer more effective alternatives. 
 
1.8 Aim and objectives 
The aim of this project was to produce a liposomal system that could encapsulate recombinant 
interferon gamma (rIFNγ) for use as an artificial reference agent in an ELISPOT assay. The 
reference standard produced would aid in enhancing the reliability of the assay and would be 
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particularly useful in the assessment of inter- and intra- assay variability. In order to achieve this 
aim, the objectives for the study were; 
 To show the feasibility of encapsulating the cytokine within a range of liposomal 
formulations including a formulation of increased density, and an assessment on the impact 
of the cytokine of the formulation process. 
 To assess ‘proof of principle’ as to whether liposomes can produce spots within an 
ELISPOT assay and consequently which liposome compositions are most effective.  
 To achieve defined spot formation of an appropriate size and morphology similar to those 
produced by peripheral blood mononuclear cells added to the assay. To produce a negative 
control with empty liposomes and a positive control with rIFNγ encapsulated cytokines. 
 To consider trigger release systems as part of the design for more effective release of the 
liposomal contents for the production of increased spot numbers. 
 To demonstrate low background levels with an optimised protocol for production that will 
allow clear visualisation of spots formed whether using manual or automated enumeration 
techniques.  
 To assess the feasibility of the controls as reference standards through an external 
assessment with live cells. 
 To assess product storage either as a frozen formulation or as a lyophilised standard with 
the inclusion of cryoprotectants and examine the feasibility of scale-up to produce a larger 
batch. 
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Materials and Methods 
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2.1   Materials 
 
Chemicals/Materials      Supplier 
Ascorbic acid      Sigma-Aldrich, Poole, Dorset, UK 
Alkaline phosphatase     Sigma-Aldrich, Poole, Dorset, UK 
Biosieve filter      Fisher Scientific, Loughborough, UK 
Bovine serum albumin     Sigma-Aldrich, Poole, Dorset, UK 
Bovine serum albumin-Fluoroscein Isothiocyanate Sigma-Aldrich, Poole, Dorset, UK 
Bromine      Fisher Scientific, Loughborough, UK 
Calcium chloride dihydrate    Sigma-Aldrich, Poole, Dorset, UK 
Cholesterol      Sigma-Aldrich, Poole, Dorset ,UK 
Chloroform      Fisher Scientific, Loughborough, UK 
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiIC), 
       Sigma-Aldrich, Poole, Dorset, UK 
ELISA kits (Human interferon-γ)   Mabtech, Sweden. 
ELISPOT plus (Human interferon-γ)   Mabtech, Sweden. 
Ethylenediaminetetraacetic acid tetrasodium  Sigma-Aldrich, Poole, Dorset, UK 
Frame seal chambers     Bio-Rad, Hertfordshire, UK 
Glacial acetic acid     Fisher Scientific, Loughborough, UK 
Interferon-γ Human     Sigma-Aldrich, Poole, Dorset, UK 
Methanol      Sigma-Aldrich, Poole, Dorset, UK 
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Microplates 96 well black non-binding plates  Greiner, Stroutwater, UK 
Microslides      Cam Lab, Cambridge, UK 
Microscope slides     Fisher Scientific, Loughborough, UK 
Molybdic acid      Sigma-Aldrich, Poole, Dorset, UK 
Polycarbonate 1.2 μm and 3 μm filters   Millipore, Abingdon, UK 
Phosphate buffered saline     Sigma-Aldrich, Poole, Dorset, UK 
Phospholipase C from Clostridium Perfringens  Sigma-Aldrich, Poole, Dorset, UK 
Phospholipase A2 from honey bee venom.  Sigma-Aldrich, Poole, Dorset, UK 
Phosphorus standard solution    Sigma-Aldrich, Poole, Dorset, UK 
Rhodamine –B      Sigma-Aldrich, Poole, Dorset, UK 
RPMI without Glutamine    Biosera, Uckfield East Sussex, UK 
Sodium phosphate dibasic    Sigma-Aldrich, Poole, Dorset, UK 
Sucrose       Sigma-Aldrich, Poole, Dorset, UK 
Trehalose Dihydrate     Sigma-Aldrich, Poole, Dorset, UK 
Tris maleate buffer     Sigma-Aldrich, Poole, Dorset, UK 
 
Lipids        
2-dipalmitoyl-sn-glycero-3-phosphocholine  (DPPC) Avanti Lipids, Alabama, USA 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)  Avanti Lipids, Alabama, USA 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) Avanti Lipids, Alabama, USA 
L-α Phosphatidylcholine (PC)                       Sigma-Aldrich, Poole, Dorset, UK 
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2.2   Methods 
2.2.1 Liposome Preparation 
Liposomes were prepared using the dry film hydration method (Figure 2.1) (Bangham et al., 1965). 
A range of lipids were used throughout the study including 2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), phosphatidylcholine (PC) and cholesterol (Chol); which were 
dissolved in chloroform: methanol 9:1 at a concentration of 10 mg/mL.  
 
 
 
 
 
 
 
 
 
Figure 2.1 Method of (MLV) liposome preparation for protein encapsulation.  
The majority of the preliminary work was carried out with either a total lipid amount of 32 μMol or 
16 μMol with cholesterol containing formulations at a 1:1 equimolar ratio. The lipids were placed 
into a 50 mL round bottom flask and the solvent evaporated on a rotary evaporator to obtain a thin 
dry lipid film. The flask was further dried with nitrogen to remove any residual solvent. The 
hydration media with the moiety to be incorporated was warmed above the transition temperature 
for the lipids before being added to the flask. The suspension was allowed to stand for 
approximately 30 minutes in a water bath above the transition temperature with intermittent periods 
of vortexing, during which time multilamellar vesicles are formed and a milky suspension is 
obtained.   
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2.2.2 Liposome characterisation 
2.2.2.1 Particle size characterisation  
Size is an important characteristic to measure for liposomal formulations in the evaluation of the 
sample produced and laser diffraction techniques are commonly used. Advantages of this technique 
include a broad size range can be considered, small amounts of sample are used, robustness and 
precision of data (Tinke et al., 2008). This is a technique based on the principle that particles 
present in the path of a laser beam will cause scattering of light and this scattering is related to the 
size of the particle. The scattering diffraction patterns occur because of all the particles present in 
the pathway of the beam and therefore information is provided in terms of the number of particles 
and size (Ma et al., 2000). In the characterisation work carried out in this study all liposomes 
formulation underwent size characterisation using the Sympatec Helos (UK) particle sizer. For the 
measurements of size, 100 µL of a liposome formulation was pipetted into a glass quartz cuvette (a 
signal of at least 15 % was required for an adequate reading). Three measurements were taken for 
each formulation and an average result obtained for size and polydispersity. The Sympatec Helos 
(UK) uses a Helium Neon laser of 632.8 nm (Sympatec) with an R2 lens. Calculations for particle 
size distribution require a mathematical process to assess the scattering pattern using an optical 
model. There are various mathematical equations that can be used, the Sympatec uses the Phillips-
Twoney method (Sympatec Limited, UK).  
 
2.2.2.2 Measurement of zeta potential. 
Zeta potential is an important characterisation aspect to consider in liposome characterisation, as 
electrostatic interfaces play a significant role in particle interactions and stability. The electrical 
charge on the surface of particle is related either to the ionisation of surface groups or to the 
adsorption of charged ions. The ions directly attracted to the surface form the stern layer and the 
ions, which surround this layer, form the diffuse or electrical double layer and contain both 
negative and positive ions (Florence and Attwood, 2011). The zeta potential is the measurable 
electrical potential at the shear plane (Hunter et al., 1981). 
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Zeta potential measurements were carried out using the Zetasizer Nano (Malvern, UK). A 1:10 
dilution was made of each liposome formulation in buffer and placed into the zetasizer cuvette, 
avoiding air bubbles. The Zetasizer Nano takes multiple readings for each formulation before 
providing an average with the standard deviation, this was repeated three times for each 
formulation with the average reading obtained for each formulation.  
 
2.2.3 Morphological analysis of liposomes 
2.2.3.1 Microscopy techniques and sample preparation 
In conjunction with particle size characterisation, morphological assessment of formulations was 
carried out using microscopy. Light microscopy was used for the visualisation of prepared samples 
dispersed in an aqueous medium with different options available for the preparation of the sample 
as shown in Figure 2.2. The advantages and disadvantages of each method are also listed (Figure 
2.2).  
Figure 2.2 Summary of methods for sample preparation for visualisation of lipid vesicles. The 
advantages and disadvantages of each method with images taken on the light microscope using 
Zeiss Axioscope A1 under 40 X objective (Bibi et al., 2011). 
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For the vast majority of liposomal images a standard glass slide/cover slip can give good 
visualisation of large vesicles such as multilamellar vesicles. This technique allows confirmation of 
the formulation heterogeneity and particle size data obtained using other methods. However 
microscopy can also substantiate other quantitative data for instance to show that encapsulation of a 
protein which is fluorescently labelled with a fluorophore, or to highlight the bilayer which can 
have the fluorescent marker incorporated inside (Szoka and Papahadjopoulos, 1980). 
 
2.2.3.2 Light Microscopy 
Light microscopy was used to consolidate data obtained from particle size characterisation and to 
assess the morphology of the vesicles. Generally, samples were viewed using standard glass slides 
with cover slips under a 40 X objective (Figure 2.2). The light microscope used was an upright 
Zeiss Axiovert A1 microscope with Axiovision software employed for image capture. On the glass 
slide 20–30 μL of sample was placed centrally, before a coverslip was placed on top. Images were 
viewed either in bright-field or phase contrast. 
 
2.2.3.3 Confocal Microscopy 
A 60 X oil objective was used with Helium and Argon lasers using a Leica confocal microscope. 
The fluorescent dye DilC (1,1'-dioctadecyl-3,3,3' ,3'-tetramethylindocarbocyanine perchlorate) was 
dissolved in chloroform at 0.2 mol% and incorporated in to the bilayer prior to rotary evaporation 
of the dissolved lipids. Once the thin lipid film was obtained the formulation was rehydrated with 4 
mL of BSA-FITC at a concentration of 5 μg/mL. The unentrapped marker was removed by 
centrifugation at 29,771 g for 30 minutes at 4 °C. The formulation was then taken up into a 
microslide which is fixed onto a glass slide for viewing (Figure 2.2). This avoids immediate drying 
out of the sample if just a coverslip is used. Filters used were FITC for the BSA-FITC and TRITC 
for the DilC dye. 
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2.2.3.4 Freeze fracture microscopy 
Electron freeze fracture is an important technique that can serve to highlight the structure and 
structural changes that have occurred in both biological and artificial vesicles, by assessing the 
fractured planes (Forge et al., 1989). This technique was used for the analysis of liposomal 
membranes during the stability study assessment of liposomal formulations containing brominated 
cholesterol. A drop of each incubation mixture (approx. 5 µL) was placed on a ridged, gold 
specimen support or was sandwiched between two copper plates, for fracture in a double replica 
device. Samples were frozen by rapid plunging into a constantly stirred mixture of propane: 
isopentane (3:1) and cooled by liquid nitrogen. Fracture was subsequently performed on a Balzers 
BAF 400D apparatus at a temperature of – 110 oC. Replicas were floated free on distilled water, 
and cleaned in 40 % chromic acid. Images were viewed using a transmission microscope. The 
electron freeze fracture was carried out at the UCL, department of Audiology, UK by Professor 
Andrew Forge. 
 
2.2.4 Centrifugation procedures used for the removal of unentrapped marker 
To remove unentrapped protein the formulations were placed into 3.9 mL tubes, which were heat 
sealed and placed into an Ultramax centrifuge (Protocol 1; Table 2.1). The centrifuge cycle began 
once the vacuum was switched on and had reached < 50. Protocol 1 was used for the removal of 
unentrapped BSA-FITC. Subsequently for the removal of rIFNγ variations of the protocol were 
required for size selection and optimisation of the background in the ELISPOT wells (Protocol 2 to 
5; Table 2.1). The ultra-centrifuge was used for speeds of 29, 771 g with the TLN-100 SN 32 rota 
or the standard universal centrifuge H232 for 10 mL tubes.  
 
 
 
 
 
 
79 
 
 
 
 
2.2.5 Bromination of cholesterol 
For the purpose of producing a reference standard in the ELISPOT assay it was thought that by 
producing an analogue of cholesterol the overall density of liposome formulations could be 
enhanced and would thus mimic more closely the density of live cells placed in the assay. By 
having an increased density, the aim was to enhance the sedimentation characteristics of such 
formulations.  
 
 
 
 
Protocol 1 Protocol 2 Protocol 3 Protocol 4 Final Protocol 5 
     
     
     
     
Table 2.1 Centrifugation protocols used for the removal of unentrapped protein. The ultra-centrifuge was 
used for speeds of 29, 771 g with the TLN-100 SN 32 rota or the standard universal centrifuge H232 for 
10 mL tubes. Protocol 1 was used for the removal of unentrapped BSA-FITC and IFNγ. The protocol was 
further optimised to reduce background for the ELISPOT assay (protocol 2 – 5). 
3. Place in 10 mL 
centrifuge tube 
and make up to 5 
mL with RPMI 
Centrifuge at 205 
g at 4°C. 
1. Place in 3.9 mL 
centrifuge tubes 
make up to 
volume with PBS. 
Centrifuge at 29, 
771 g for 30 mins. 
 
2. Remove 
supernatant and 
resuspend in 2 mL 
of PBS. 
1. Place in 3.9 mL 
centrifuge tubes 
make up to 
volume with PBS. 
Centrifuge at 29, 
771 g for 30 mins. 
 
2. Remove 
supernatant and 
resuspend in 2 mL 
of PBS. 
1. Place in 3.9 mL 
centrifuge tubes 
make up to volume 
with PBS. 
Centrifuge at 29, 
771 g for 30 mins. 
 
3. Place in 3.9 mL 
centrifuge tubes 
make up to volume 
with PBS. 
Centrifuge at 29, 
771 g for 30 mins. 
 
2. Remove 
supernatant and 
resuspend in 2 mL 
of PBS. 
4. Remove 
supernatant and 
resuspend in 2 
mL of PBS 
1. Make up to 5 
mL with PBS and 
centrifuge at 4°C 
for 15 minutes at 
2660 g. 
2. Remove 
supernatant and 
resuspend in 2 mL 
of PBS. 
 
4. Resuspend in 
1 mL in RPMI 
1. Make up to 5 
mL with RPMI 
and centrifuge at 
4°C for 15 
minutes at 2660 
g. 
 2. Remove 
supernatant and 
make up to 5 mL 
with RPMI and 
centrifuge at 4°C 
for 15 minutes at 
2660 g. 
 3. Remove 
supernatant, 
resuspend in 5 mL 
of RPMI, and add 
to 10 mL tube.  
 
4. Centrifuge at 205 
g for 10 minutes and 
resuspend in 1 mL 
of RPMI medium. 
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2.2.5.1 Method for the synthesis of brominated cholesterol 
A basic laboratory method for a bromination reaction for cholesterol was carried out (Kabara et al., 
1960). The reaction involves nucleophilic attack by the cholesterol C=C bond on bromine (Figure 
2.3) with the formation of a tertiary carbocation. The formed cation undergoes secondary 
bromination via an attack from the back by the bromide ion to form the dibromocholesterol 
derivative, with the bromine atoms in the trans and diaxial configuration. 
 
 
 
 
 
Figure 2.3 Schematic of the reaction steps for bromination of cholesterol (Fieser and Williamson, 
1992).  
 
The method for synthesis was as follows:  
 In a 50 mL round bottom flask, 1 g of cholesterol was dissolved in 10 mL of ether.  
 The solution was stirred and 5.0 mL of a 10 % solution of bromine in glacial acetic acid 
was added (0.10 g of bromine /1.0 mL). 
 The mixture was left to stand at room temperature for 30 minutes so that the developing 
dibromocompound could precipitate from the solution. The solution was then cooled on an 
ice bath to complete the precipitation. 
 The product was collected by suction filtration. This was then washed in the funnel, once 
with 5 mL of acetic acid and finally with water. After washing, the compound was left to 
dry under vacuum overnight. 
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2.2.5.2 Melting point determination of synthesised dibromocholesterol 
The melting point was determined using basic Gallenkamp MP apparatus by visualisation after 
placing a small amount of pure cholesterol and the product into a glass capillary tube and into the 
apparatus. The temperature was increased gradually until a visible change occurred. This observed 
melting point was recorded and the process repeated three times. Clear defined melting point 
ranges can be used when compared to literature melting points to confirm the product required has 
been produced. 
 
2.2.5.3 Differential Scanning Calorimetry for determination of melting point 
Differential scanning calorimetry (DSC) is defined as the measurement of the change of difference 
in the heat flow rate to the sample and to a reference sample while they are subjected to a control 
temperature program (Höhne et al., 2003). Although this analytical technique is primarily used to 
measure thermal phase transitions for this study, it was used for an accurate measurement of the 
melting point and for assessing the purity of the sample. 2 mg of each sample was placed into a T-0 
aluminium pan and sealed. A sample and a reference pan were placed inside the instrument (DSC 
TA Instruments Q200,UK) Scans were run for the pure cholesterol (Sigma) and the product 
dibromocholesterol. The scan rate was 10 °C per minute commencing at 30 °C. 
 
2.2.5.4 Thin Layer Chromatography 
This method is used to differentiate between substances that differentially partition between two 
phases, the mobile phase and the stationary phase. Migration of the substance is a result of its 
varying affinity for the stationary and mobile phase (Sherma and Fried, 2003). The thin layer 
chromatography (TLC) method was used to assess the formation of the synthesised product by 
using cholesterol as the reference. 
The prepared TLC plates had an adsorbent silica gel coating with aluminium backing. Small strips 
(2.5 cm x 6.5 cm) were cut from a 20 cm x 3 cm sheet of the solid support. A straight line was 
drawn horizontally 1 cm from the bottom of the strip. Three spots were applied in pencil 
equidistant apart as a guide for the application for spots for the product and pure cholesterol. Thus, 
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0.5 mg of the cholesterol and product were dissolved in 1 mL of chloroform. This was applied with 
a glass pipette to allow a small uniform spot to be formed. The solution for both the product and 
cholesterol were applied a few times in this way allowing the solvent to evaporate between 
additions. This was then checked under a short wavelength UV light to determine if enough had 
been applied. The chamber used for the development of the chromatogram was a large glass jar 
with a screw top lid. Solvent is poured into the jar to the depth of a few millimeters. The solvent 
was allowed to saturate the development chamber. The spotted plate was then placed into the 
container with the spotted end down with the solvent level below the spots. Various compositions 
were trialed including initially the literature method of hexane:ether:acetic acid 85:15:2 (Kabara 
and Mclaughlin, 1960). Visualisation was examined of this plate via both 10 %  phosphomolybdic 
acid in ethanol and vannilin solution. The solvent used after optimisation was ether:acetic acid  
98:2. Visualisation of the product via 10 % phosphomolybdic acid was carried out. When the 
solvent front had reached near to or exactly at the top of the plate it was removed from the 
devoloping chamber with clean forceps. The position of the solvent front was marked and allowed 
to evaporate. The plate was then immersed in 10 % phosphomolybdic acid. This was dried and then 
individual spots were marked. 
 
 2.2.5.5 Infrared Spectroscopy  
The melting point data using the DSC was slightly different to the literature melting point and 
showed slight discrepancies between the two batches after the main melt, therefore for further 
characterisation an IR spectrum was carried out of the obtained product, as this technique can be 
used to ascertain identity and purity (Kalinkova, 1999). The IR spectrum produces sample peaks, 
which correspond to the frequency of vibrations of parts of the sample molecule thus information 
in regards to the structure in particular the presence of functional groups, can be ascertained 
(Stuart, 1997). The wavelengths were assigned using described absorption bands (Mendham et al., 
2000).  
Infrared Spectroscopy is a technique that uses the vibrational frequencies of bonds between atoms 
in molecules. It is obtained by passing infrared radiation through the sample and the energy at 
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which the peaks appear in the absorption spectrum corresponds to the frequency of a vibration of a 
part of the sample molecule. The specific frequencies of IR radiation absorbed correspond to the 
functional groups present in the sample. It is widely used for the determination of structures and 
compounds (Mendham et al., 2000). The Infrared spectroscopy machine used was Nicolet IR200, 
using potassium bromide (KBr) disks.  
 
 2.2.5.6 Preparation of KBr disks 
The sample was prepared by weighing out 150 mg of potassium bromide (KBr) with 1 mg of the 
sample product. The KBR was of spectroscopic grade and was dry. The powders were then ground 
together with a mortar and pestle until the mixture was very fine. The disks and the die were 
cleaned with tissue to ensure they contained no residues. The disk was then placed into the die with 
the shiny side up and the slightly bezzled edge on the outer surface. A micro-spatula was used to 
add 150 mg of the powder into the tube and it was shaken in gently to ensure an even distribution. 
The die was then tapped in order to distribute the powder. The second disk was placed on top with 
the shiny side inwards towards the powder and the plunger was pushed down. The holder was 
screwed down when aligned with the die until it is firmly in place. The tube for the vacuum was 
then placed on the left hand side of the die and the dial on the right hand side turned until it was 
tight before the vacuum was switched on. The vacuum was left on for 2 minutes and then the 
pressure was increased to 8 tonnes and left for 10 minutes. The disk was then placed in a holder 
and put into the machine and the cover placed on top. Disks were prepared and analysed for both 
cholesterol and dibromocholesterol.  
 
2.2.5.7 
1
H NMR and 
13
C NMR 
NMR is a spectroscopic analytical technique that uses the magnetic properties of nuclei. The 
instrument contains a strong magnet with a coil that supplies energy in the radio frequency range of 
the electromagnetic spectrum. Nuclei are able to absorb this energy and flip from a lower energy 
state to a higher energy state. There is another coil, which is able to sense these small energy 
changes. This information was analysed to provide information about the number, type and 
environment of the 
1
H and 
13
C atoms (Sanders and Hunter, 1993). 
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The carbon NMR spectrum allows not only the number of carbons to be established but also 
provides information in regards to how many hydrogens each carbon is bonded to, dependent on 
whether the peak is above or below the baseline (Malet-Martino and Holzgrabe, 2011). 
Approximately 2 mg of sample was placed into 0.5 mL of CDCL3 solvent, this particular solvent is 
used as it does not contain H atoms, which too would absorb energy in the same range as the other 
protons. This sample was placed in a thin glass tube that is placed into the NMR machine (Bruker 
250MHz).  
 
2.2.5.8 Calculation of percentage yield 
The quantity of product produced during a chemical synthesis was determined by calculating the 
percentage yield. In order to this, the theoretical yield was calculated initially to determine the 
amount that would be obtained in perfect conditions. Then using the final weight of the product the 
actual percentage yield can be calculated (Equation 2.1). The following equation was used to do 
this: 
 
Equation 2.1 Calculation for percentage yield. 
Percentage yield =  Amount in moles     ×     Ratio of limiting reagent      ×    Molecular weight                                    
   of limiting reagent                and Product                            of Product 
             
The theoretical yield is the maximum amount, which can be obtained from a reaction. During a 
synthesis, the actual product obtained is normally less than this. This may be due to loss during 
synthesis or purification, or the reaction maybe incomplete and not converting all the reactants to 
product (Kotz et al., 2009). 
 
2.2.5.9 Second batch production of dibromocholesterol 
Having synthesised and characterised the initial batch of dibromocholesterol a second batch was 
required within the project. In this instance, reproducibility of production was assessed alongside 
stability testing of the first batch. For comparative characterisation purposes TLC, DSC, 
13
C NMR, 
1
H NMR and TGA was carried out on both powders.  
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2.2.5.10 Stability assessment of dibromocholesterol and thermogravimetric analysis (TGA) 
Subsequent to the synthesis and validation of the dibromocholesterol, it was important to assess its 
stability to ensure that it remained stable over the duration of the study. Thus after a six month 
period similar techniques were carried out including TLC, DSC, 
13
C NMR, 
1
H NMR and in 
addition thermogravimetric analysis. Thermogravimetric analysis (TGA) is an analytical method, 
which is used to provide an assessment of structural decomposition, oxidation and moisture gain or 
loss amongst other aspects. It measures the change in mass of the material as a function of 
temperature (Mansfield et al., 2010). This was carried out by placing a small amount of the sample 
onto the TGA instrument using a Perkin Elmer Pyris 1 TGA. The samples were analysed between 
the temperature ranges of 50 °C and 140 °C at a scan rate of 10 °C/min. The values reported are the 
percentage loss in weight of the product. 
 
2.2.6 Improving the sedimentation of liposomes 
Sedimentation is defined as the migration of molecules or colloids in a centrifugal or gravitational 
field (Vesaratchanon et al., 2007). Having carried out the chemical synthesis to modify the 
cholesterol it was necessary to assess the impact that the modification had on the ability of the 
liposomes to settle; it is interesting to note that in fact sedimentation of the liposome formulations 
is generally thought to be the indicator for an unstable system (Gregoriadis and Senior, 1984). 
However, the sedimentation requirements can vary, thus some uses will require a slower rate of 
sedimentation to aid stability; however, for the purpose of this study it was desirable to have an 
enhanced velocity of sedimentation. 
 
2.2.6.1 Quantification of sedimentation 
In order to assess liposomal sedimentation five different liposome formulations were examined 
(Table 2.2). All formulations were encapsulated with BSA-FITC to mimic the entrapment of 
cytokine, with the unentrapped material removed by centrifugation at 29, 771 g for 30 minutes at 4 
°C.  
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Table 2.2 Formulations used for qualitative and quantitative sedimentation studies. 
 
Percentage transmission was measured using a Jenway spectrophotometer; PBS was placed in a 
clear 5 mL cuvette and used as the reference blank. A wavelength of 592 nm was chosen from the 
visible electromagnetic spectrum to read the samples. Samples were measured at the start of the 
study and at 1, 2, 4, 12, and 18 hours.  
 
2.2.6.2 Qualitative assessment of sedimentation 
To substantiate the above quantitative data, a qualitative assessment was also carried out by placing 
the appropriate sample formulations in a 5 mL bijoux tube and taking photographs at 0, 1, 2, 4,12 
and 18 hours. The camera used was a Kodak Easyshare Z86121S 8.1 Mega Pixels. 
 
2.2.6.3 Viscosity Measurements 
A comparison of viscosity was carried out to compare formulations of DPPC:Chol 16:16 μMol  
with the brominated cholesterol formulation chosen for continuing studies i.e. DPPC:Chol:BrChol 
16:4:12 μMol. The viscosity measurements were carried out on an Anton Paar AMVn automated 
micro viscometer using a 1.6 mm bore tube with a ball diameter of 1.5 mm at 20.0 °C. In this 
viscometer a steel ball rolls down a glass tube containing the test liquid. The rate at which this ball 
falls of a known density and diameter is the inverse function of viscosity. In this way sedimentation 
can be related to Stokes Law (Equation 2.2.); 
 
 
 
Lipid Composition Morphology Ratio of Lipids  (μMol) 
DPPC:Chol MLV 16:16 
DPPC:Chol SUV 16:16 
DPPC:Chol:Brchol MLV 16:8:8 
DPPC:Chol:Brchol MLV 16:4:12 
DPPC:Brchol MLV 16:16 
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Equation 2.2 Stokes Law 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.7 Fluorescence assay optimisation. 
It was essential to have a basic screening assay that would provide quantifiable release data for the 
formulations. Fluorescent assays are well established and have many advantages over other 
techniques including sensitivity, specificity, accuracy and flexibility (Vogel, 2008). The marker 
which was selected for entrapment for the initial studies was BSA-FITC; the advantage being that 
it was a protein with a conjugated fluorescent marker which allowed ease of detection. A similar 
assay format was used to measure temperature controlled contents release from liposomes 
containing Pluronic F127 (Chandaroy et al., 2001). In this work, the excitation wavelength used 
was 492 nm and the emission wavelength was 519 nm.  
 
2.2.7.1 Optimisation of wavelengths; spectral scans 
An important aspect of validation was choosing the correct wavelengths for the fluorophore, as this 
needs to be optimised for the fluorometer used (Lakowicz, 2006). The best results are obtained 
when the excitation and emission wavelengths used for reading are not the same as the wavelengths 
of the excitation and emission of the fluorophore (Figure 2.4). If they are separated, a smaller 
V =  dst (ps- po ) g 
                        18ŋo 
V   =  Rate of settling   
dst    =    The mean diameter of particles based on velocity of sedimentation 
ps    =  The density of the particles 
po    =  The density of the dispersion medium 
g   =  The acceleration due to gravity                     CONSTANT             
ŋo =   The viscosity of the medium 
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amount of excitation light will pass through the emission monochromator and onto the PMT 
(photomultiplier tube) resulting in a purer emission signal and more accurate data.  
 
 
 
 
 
 
 
Figure 2.4 Excitation and emission peaks with Stokes shift.  
Spectral scans were carried out at literature wavelengths, initially at 492 nm for excitation and 519 
nm for the emission wavelength. However, to determine more precise wavelengths further spectral 
scans were carried out for excitation and emission, from 450 nm to 500 nm in increments of 10 nm. 
The assay was read on a microplate reader Spectramax Geminix (Molecular Devices Corporation). 
The plates used for all the fluorescence work were black non-binding 96 well plates. The excitation 
and emission wavelengths were optimised using spectral scans to obtain a purer emission signal.  
 
2.2.7.2 Optimisation of the fluorescent assay with BSA-FITC 
In establishing a fluorescence based release assay for the evaluation of the amount encapsulated 
within liposome formulations and their release characteristics it is essential to consider the 
validation of the assay. Validation characteristics, which should normally be taken into 
consideration, include accuracy, precision, repeatability, specificity, detection limit, quantification 
limit and range (ICH, 2006). These were considered a part of the protocol optimisation. Three 
calibration curves were prepared for BSA-FITC from a stock solution of 20 µg/mL. These were 
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assessed for linearity, accuracy and reproducibility using the calculation of linear regression and by 
the method of least squares as recommended by ICH guidelines (ICH, 2005).      
 
2.2.7.3 Confirmation of speed, time, and frequency of centrifugation 
In the establishment of the above method (2.2.6.2), the centrifugation procedure needs to be 
sufficient in terms of speed, time and frequency to ensure effective removal of unencapsulated 
BSA-FITC. Thus, the initial supernatant was measured for fluorescence and then the pellet was re-
suspended and centrifuged again for 30 minutes. This was carried out for a further two steps to 
establish if all BSA-FITC was removed.  
 
2.2.7.4 Effects of lysis chemicals on the BSA-FITC concentration curve 
As the chemical used for lysis will still be present when the fluorescent marker would be analysed 
in the assay it was essential to assess how such components affect the final result as this impacts on 
the specificity of the assay. Three set of calibrators were made of BSA-FITC with concentration 
range up to 20 μg/mL in PBS. One set of calibrators were made from BSA-FITC 20 µg/mL, using 
25% v/v of a 10% v/v Triton X solution, at each concentration the final volume was made up with 
PBS. The second set of calibrator dilutions were made using BSA-FITC 20 µg/mL with 25 % of 
isopropanol 1:1, the final volume is made up with PBS. Then 200 μL of each concentration was 
pipetted into the wells in triplicate. Thus, there were three calibration curves on a plate i.e. normal, 
Triton X and isopropanol. This was repeated in triplicate. 
 
2.2.7.5 Determination of BSA-FITC release from liposomes 
Having established and validated the various parameters for the release assay the method for 
measuring the amount of material entrapped within the pellet and total recovery was also carried 
out which is illustrated in Figure 2.5.  
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Liposome Preparation 2 mL containing BSA-FITC  5 µg/mL. 
(Total amount 10 µg.) 
Centrifuge Liposome preparation at 
29,771 g for 30 minutes in an 
Ultracentrifuge using 3.9 mL tubes.  
 Resuspend with 800 μL of PBS. 
Remove 400 µL and add an equal 
volume of 10 % of Triton X for 30 
minutes 
 Centrifuge at 29,771 g for 30 minutes in 
an Ultracentrifuge. Remove supernatant. 
 . Remove 3 X 200 μL and pipette 
directly into plate. 
 Measure exact volume of  supernatant 
 Remove 3 X 200 μL and pipette 
directly into plate. 
 
SUPERNATANT CALCULATION: 
1. Obtain concentration from mean RFU. 
2. Multiply by total volume in centrifuge 
tube 
3. Quantify using calibration curve. 
4. Use to calculate total recovered 
        PELLET CALCULATION: 
1. Obtain concentration from mean RFU 
2. Multiply by total volume in centrifuge 
tube 
3. Multiply by 2 as 400 μL was removed 
from the total 800 μL. 
4. Quantify using the calibration curve 
5. Calculate percentage entrapment 
SUPERNATANT 
PELLET 
Figure 2.5 Flow chart describing method for the calculation of entrapment and recovery of 
BSA-FITC 5 µg/mL from the liposome formulations. 
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2.2.7.6 Limits of detection and quantification 
According to ICH guidelines detection and quantitation limits of the background can be based on 
analysing an appropriate number of blank samples and calculating the standard deviation of these 
responses (ICH, 2006). The limit of the detection (LoD) is the lowest concentration which can be 
distinguished from replicates of a blank sample when they are tested without the presence of any 
analyte. The limit of quantification (LoQ) is used for the lowest level of analyte which can be 
precisely defined (Armbruster and Pry, 2008). The LoQ can be equal to the LoD but not lower; the 
limit of the detection was calculated from triplicate samples from three separate assays. The limit 
of quantification was defined as the lowest concentration with a coefficient of variation of < 20 % 
(Armbruster and Pry, 2008). 
The following equations will be used to assess entrapment efficiency (Equation 2.3 and 2.4):    
 
 
 
 
 
 
 
2.2.8 Stability study of liposome formulations for reference standards 
For the production of a liposome reference standard stability is an important aspect that needs to be 
considered, it is well established that liposomes are susceptible to a range of physical and chemical 
instabilities such as hydrolysis of lipids and oxidation (Mohammed et al., 2006). Three batches of 
liposomes each for, 1) DPPC 32 μMol and 2) DPPC:Chol 16:16 μMol, 3)DPPC:Chol:BrChol 
16:4:12 μMol were prepared by the dry film method. These formulations were characterised for 
particle size using the Sympatec and for zeta potential using the Malvern Nanosizer. One mL was 
Equation 2.3 Calculation for percentage entrapped in liposomes.  
%   Entrapped in liposomes          =               Amount in Pellet   x       100             
                                 Amount added 
 
         
 
                              
Equation 2.4  Calculation for total recovery. 
%  Total recovered                        =          Amount in Pellet + Amount in Supernatant    x      100                                                     
       Amount added 
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taken from each formulation and then placed at 4 °C, 25 °C and 40 °C stability cabinets. These 
were then characterised for particle size and zeta potential after formulation and then at specified 
time intervals; Day 1, 4, 7, 14 and 28. Microscope images were also taken of formulations to 
confirm stability using a Zeiss Axioscope A1 using a 40 X objective.  
 
2.2.9 Size separation of liposomes 
Centrifugation is arguably one of the simplest techniques for size separation and has been shown to 
be effective for nanoparticle separation of heterogenous batches (Gaumet et al., 2007). In order to 
achieve separation using this technique two parameters were examined; speed and time of 
centrifugation. Low speeds and two centrifugation times were examined (five and ten minutes).  
Density gradients have previously been used by Goormaghtigh and Scarborough et al., (1986), for 
the removal of larger particles to obtain several size populations of small unilamellar vesicles. 
More recently liposome populations have been characterised using sucrose density gradients 
(Sanchez-Lopez et al., 2009). By modifying sucrose concentrations, the viscosity of each solution 
is modified; thus the centrifugation process can be refined as the liposomes should distribute in 
different concentration bands of the sucrose (Goormaghtigh and Scarborough, 1986). Ultimately, 
when using this technique it is heavier particles that need to be retained. Where there were distinct 
bands both layers were removed and (subsequent to one wash to remove the sucrose) measured for 
particle size. 
Filtration is a basic laboratory technique used for separation; and similar to centrifugation it is a 
ubiquitously used technique due to its ease of use and could also be applied to polydisperse systems 
to isolate specific size populations (Gaumet et al., 2007). The aim was to find techniques, which 
were able to remove the smallest vesicles yet, retain the larger ones thus different filtration 
techniques were assessed. A biosieve was tested initially as this can be used for the separation of 
cellular debris and cells and thus was considered applicable for liposome vesicles. A basic buchner 
flask was set up and a weak vacuum was used. Other types of filters assessed were polycarbonate 
filters of 2 μm and 3 μm pore size. The formulations were assessed as previously by measuring 
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particle size of recovered liposomes from above the filter and the filtrate (formulation obtained 
once it has gone through the filter). 
 
2.2.9.1 Centrifugation for the size separation of liposomes 
Liposome formulations were centrifuged at 51 g, 115 g and 205 g (subsequent to centrifugation at 
29,771 g for 30 mins to remove unencapsulated BSA-FITC). The pellet was re-suspended in 12 mL 
of PBS and 4 mL was subsequently placed into three tubes and centrifuged at the various speeds 
for five minutes the process was then repeated for ten minutes. This was carried out for three 
separate formulations, which were characterised for particle size and zeta potential. Two types of 
centrifuge were used in this study, the ultra-centrifuge and the TLN-100 SN 32 rota or the standard 
universal centrifuge H232. 
 
2.2.9.2 Centrifugation with density gradients 
Liposomes were prepared as described previously. 10 mL of density gradients were prepared of 
various strengths (w/v) using sucrose in distilled water. The following variables were examined; 
10 %, 20 %, 40 %, 60 %, and 80 %  sucrose 
20 % and 80 % sucrose                                                                          2660 g for 30 min. 
5 %, 15 %, 25 %, and 35 % sucrose 
Initially 2 mL each of a wide range of density gradients were used for a preliminary screen, layered 
on top of each other and 2 mL of liposome formulation. To also consider a simpler option, as only 
the smaller particles were not required, a heavy and a low density gradient were chosen. Then as it 
became clear that separation was occurring around the lower bands, a wider range was chosen 
across the lower concentrations. The lower range was then repeated but at a greater speed of  
354,000 g and a longer time point of 3 hours. 
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2.2.9.3 Filtration  
Filtration was considered for size separation because of the relative ease of this technique. 
Ordinarily filtration is used to remove unwanted larger particles to retain the filtrate. In this 
instance, the liposomes of a smaller size would theoretically pass through the filters. Sample 
formulations of: DPPC:Chol:BrChol 16:4:12 μMol were prepared as described previously and re-
suspended after centrifugation to remove unencapsulated BSA-FITC (29, 771 g for 30 minutes) and 
the pellet was re-suspended in 12 mL of PBS. A Buchner flask was set up with a weak vacuum 
(Figure 2.6) with a funnel (5 mm width). The filters were then placed inside, and the sample poured 
through. 
 
 
 
 
 
 
 
Figure 2.6 General set up for the assessment of filtration techniques.  
 
The filtrate was collected and the filter was washed in 10 mL of PBS and then centrifuged at 2660 
g for 30 minutes at 4 °C and then re-suspended in 1 mL of PBS. Three different filters were 
assessed;   5 µm biosieve filters, a 1.2 µm and 3 µm polycarbonate filters. 
 
2.2.10  IFNγ ELISA assay for the measurement of entrapment in liposomes  
The ELISA kit was provided with a cytokine standard which was used to construct the calibration 
curve. The standard is reconstituted to 1 µg/mL with the provided buffer, mixed thoroughly for five 
Buchner flask 
Filter paper 
To vacuum 
filtrate 
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minutes and aliquoted to be stored at -20 °C. A serial dilution was prepared 30 minutes prior to the 
start of the experiment with the stock standard and ELISA diluent to produce a calibration curve 
with a standard range of  3.16 – 1000 pg/mL. All sample dilutions were made with ELISA diluent. 
The following protocol was then carried out; 
1. The strips were washed with 5x 300 µL/well of diluted wash buffer.  
2. 100 µL/well of diluted cytokine standard and assay background control was added. Also 
the ‘unknown samples’ were added at this stage diluted in ELISA diluent at 1:1 ratio. The 
plate was covered with the adhesive cover and incubated at room temperature for 2 hours.  
3. The wells were then washed with 5x 300 µL/well of diluted wash buffer.   
4. The detection antibody was added which was also prepared in ELISA diluent to a final 
concentration of 1 µg/mL. The plate was then incubated at room temperature for a further 
60 minutes.   
5. The wells were then washed with 5 x 300 µL/well of diluted wash buffer. 100 µL/well of 
streptavidin-horseradish peroxidase conjugate was added which is diluted (1:1000) in the 
SA-HRP diluent.  
6. Blank wells were left empty and the plate incubated at room temperature for 60 minutes. 
The wells were then washed with 5 x 300 µL/well of diluted wash buffer.  
7. The wells were then developed with 3,3,5’,5’ Tetramethylbenzadine enzyme solution and 
incubated at room temperature in the dark for 15 minutes.  
8. The colour development was then stopped using 100 µL/well of stop solution 1M H2SO4. 
 
2.2.10.1 Reproducibility of the IFNγ assay 
Three calibration curves of the kit associated calibrators were run in duplicate across three plate 
batches on three separate days. The standard deviation across the replicates was less than 1, 
therefore confirming the reproducibility of results across different plates and different days. 
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2.2.10.2 Preliminary titration for the estimation of cytokine concentration 
In order to determine a suitable concentration to dilute the lyophilised rIFNγ (Sigma) cytokine; 
using the kit provided calibrators, a standard curve was run on the IFNγ ELISA assay (Mabtech). 
Three dilutions of the purchased cytokine at 1000, 500 and 250 pg/mL were assessed on the assay. 
To extrapolate unknown concentration, the four parameter logistic equations is used within Graph 
pad 4.0. These concentrations were diluted in a 1:1 ratio with ELISA diluents. 
 
2.2.10.3 Titration optimisation for the estimation of cytokine concentration 
In order to obtain an optical density which is near the optimal binding capability of the plate a 
repeat titration was carried out. The aim was to find the most suitable concentration of the 
recombinant IFNγ for use in the formulation of multilamellar vesicles to produce spots on the 
ELISPOT plate. The concentrations assessed were 5000 ng/mL, 2500 ng/mL, 1250 ng/mL, 625 
ng/mL, 312.5 ng/mL, 156.25 ng/mL and 78.125 ng/mL subsequent to a 1:1 dilution in ELISA 
diluent. 
 
2.2.10.4 Examining the effects of Triton X on the coating antibody  
The coating antibody used for the ELISPOT plate was the same as the one used for the ELISA. 
Thus to prove that Triton X did not interfere with either the coating antibody or the rIFNγ to be 
used for encapsulation, the calibration curve was run alongside a calibration curve which included 
50 % by volume of 10% v/v Triton X for each calibrator. This was run in triplicate. 
 
2.2.10.5 Determining the effect of temperature on rIFNγ 
As the formulation stages of producing liposomes involves the rehydration phase of the lipid film 
at a temperature above the Tm of the lipid, this will also result in exposing the cytokine to such 
higher temperatures. It was therefore important to ascertain what the effects of the temperature 
would be on the activity of the cytokine. The stock solution of 2.5x10
7
 U/mL diluted with ELISA 
diluent at a 1:1 ratio was placed at the various temperatures in a heat block for either 30 minutes or 
1 hour time points. Once removed from the block they were allowed to cool to room temperature 
before adding to the ELISA plate with a 1:1 dilution with calibrator diluents. 
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2.2.10.7 Determining the effect of centrifugation on rIFNγ 
1 mL of stock solution of IFNγ at 2.5x105 U/mL was serially diluted to produce a calibration curve. 
The serial dilutions were divided into two portions. One set was centrifuged at 29,771 g for 30 
minutes, then they were both ran on the IFNγ ELISA assay. This was repeated in triplicate to 
ascertain the effect of centrifugation on the cytokine. 
 
2.2.10.8 Determining the effect of vortexing on rIFNγ 
The stock solution of rIFNγ at 2.5x105 U/mL was taken and aliquoted into 7 vials and then exposed 
to various times of vortexing to ascertain the effects on the cytokine. The time points assessed were 
0, 0.5, 1, 2, 5, 10 and 15 minutes. The aliquoted solutions were tested for optical density on the 
IFNγ ELISA assay. 
 
2.2.11 Calculation of entrapment efficiency of rIFNγ liposome formulations 
For the purposes of quantifying the entrapped rIFNγ the liposomes were formulated as described in 
2.2.9; however, additional steps were required to separate the pellet from the supernatant as both 
were assessed for the amount of rIFNγ present (Figure 2.7). 
 
2.2.12 Formulation of rIFNγ liposomes as a positive and a negative control. 
For the formulation of rIFNγ containing liposomes where the initial lipid concentrations were 16 
μMol total these were rehydrated with 2 mL of 2.5 x 105 U/mL rIFNγ. After centrifugation (Table 
2.1), the liposomes are re-suspended in 1 mL of RPMI. If 32 μMol total lipid amount was used then 
rehydration of the lipid film was with 4 mL of 2.5 x 10
5
 U/mL rIFNγ. The liposome formulations 
were re-suspended in 3 mL of RPMI. The negative control consisted of liposomes rehydrated with 
PBS.     
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Figure 2.7 ELISPOT testing of liposome formulations; method for calculating entrapment 
efficiency. 
 
 
Place in 3.9 mL centrifuge tubes make up 
to volume with PBS. Centrifuge at 29,771 
g for 30 minutes. 
 
Resuspend pellet in 2 mL of PBS. Remove 
200 µL and add 10%  v/v Triton X (c) 
for 30 mins. 
 
Remove supernatant (B) and measure 
volume. 
 
Take 150 µL of the Supernatant  and pellet disrupted with Triton X and add an equal volume of 
ELISA diluent. 
 
Pipette 100 µL in duplicate into the wells and carry out the ELISA.  
 
All dilutions and volumes are taken into consideration subsequent to 
extrapolation of optical densities from the calibration curve to obtain the 
amounts in the original volume. 
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2.2.13 ELISPOT protocol for the testing of liposome formulations 
The ELISPOT kit contains plates, coating antibody, biotin for detection of the IFNγ and the 
secondary antibody streptavidin. The development reagent is BCIP/NBT-plus. The following 
protocol was followed as per the kit instructions: 
 
1. The coating antibody was diluted to 15 µg/mL, in sterile PBS pH 7.4. 
2. The ELISPOT plate was removed from the packaging and the membrane was pre-wet by adding 
50 µL of 70 % ethanol for a maximum incubation time of 2 minutes. 
3. The plate was washed 5 times with sterile water 200 µL/well. 
4. 100 µL/well of coating antibody at 15 µg/mL was added and incubated overnight at 4 °C. 
5. Excess antibody was removed by washing the plate in sterile water as above. 
6. 200 µL of RPMI medium was then added to the wells containing 10 % FCS and incubated for 30 
minutes at room temperature. 
7. The plate was then washed with 5 times with sterile water 200 µL/well. 
8. 100 μL/well of liposome formulations were pipetted into each well. The plate was then placed at 
37 °C for 12 hours (minimum incubation time). Movement of the plate was avoided and wrapped 
in foil to avoid evaporation.  
9. Addition of enzymes and Triton X; the enzymes were added at the same time as the liposome 
formulations. A volume of 100 µL/well was added per well. The Triton X was added upon removal 
of the plate subsequent to the liposome formulations being incubated overnight. 
10. Then the plate was washed 5 times with sterile water 200 µL/well. 
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11. The detection antibody was added (100 µL/well) at a concentration of 1µg/mL in PBS 
containing 0.5 %  FCS for 2 hours at room temperature. 
12. The plate was washed 5 times with sterile water 200 µL/well. 
13. The substrate solution (BCIP/NBT-plus) was filtered through a 0.45 µm filter and 100 µL was 
added to each well until distinct spots emerged. 
14. The plate was then washed extensively in tap water and left to dry. 
 
2.2.14 Assessment of enzyme activity of PLC   
Prior to carrying out work with the Phospholipase enzymes it was necessary to establish that the 
enzyme activity was acceptable, thus a basic Sigma quality control procedure was followed. The 
principle of the assay is based on the following: 
 
L-α- Lecithin + H2O                  Phospholipase C                      1,2-Diglyceride + Choline Phosphate 
Choline phopshate + H2O         Alkaine Phosphatase                    Choline + Pi 
 
2.2.14.1 A quality control PLC assay for confirmation of enzymatic activity 
Briefly seven vials were labelled: test, test blank, standards 1-4 and a standard blank. 2 mL was 
added of 50 mM Tris Maleate Buffer pH 7.3 and 0.5 mL of 50 mM Calcium Chloride solution to 
each vial. Subsequently 1.5 mL was added of 2.0% w/v L – α- phosphatidylcholine to all vials. 
Then 0.9 mL of the enzyme dilution solution (1.0% w/v) bovine serum albumin (BSA) prepared 
with 50 mM tris maleate buffer) was added to the test and the test blank. To prepare standards 1- 4: 
0.25 mL, 0.50 mL, 0.75 mL and 1.0 mL were added of the prepared phosphorus standard stock 
solution (20 µg/mL, 0.645 µ/mole) to each vial with 0.75 mL, 0.50 mL and 0.25 mL of deionised 
water added to standards 1-3 consecutively. 1.0 mL of deionised water was added to the standard 
blank. 
The vials were then mixed by swirling and allowed to equilibrate at 37 °C and 0.1 mL was added 
of prepared PLC solution containing 0.1 – 1.0 U/mL in cold 1.0% w/v BSA (using 50mM Tris 
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maleate buffer pH 7.3 at 37 °C). All vials were incubated at 37 °C to allow the PLC solution to 
hydrolyse the lecithin for an incubation time of 15 minutes. Then 0.9 mL of a 270 mM 
ethylenediaminetetraacetic acid (EDTA) solution (pH 7.3) was added to all vials to stop the 
reaction of the PLC. In order to quantify the choline phosphate 0.1 mL of alkaline phosphate was 
added to all vials and 0.1 mL of PLC to the ‘Test’ blank. The vials were mixed by swirling before 
incubated at 37° C for 120 minutes. During the incubation time and 30 minutes before use, the  
AMES colour reagent was prepared by adding 10 mL of 10%  w/v ascorbic acid Solution  and 6 
mL molybdic acid solution and 54 mL of deionised water. Vials were mixed by swirling and stored 
in the dark at room temperature.  
From the vials 1 mL was transferred from the ‘test’, ‘test blank’, standards 1 - 4 and ‘standard 
blank’ into fresh vials 0.5 mL is added of 20% w/v sodium lauryl sulfate solution (SDS) and 3.0 
mL of the AMES colour reagent. All vials were mixed and then incubated at 37 °C for 60 minutes. 
These were then transferred to cuvettes and the absorbance was read on the spectrophotometer at 
660 nm. Background was taken into account; all the standard blank readings were subtracted from 
all the readings of the standards and the test blank from the test readings. A standard curve was 
then plotted for absorbance at 660 nm versus micromoles of phosphorus in 5 mL. The activity of 
the enzyme was confirmed with that stated on the purchased vial of PLC. One unit will liberate 1 
micromole of water soluble organic phosphorus from α- phosphatidylcholine at pH 7.3 at 37 °C, 
this was carried out using the below equation (Equation 2.5) once the micromoles of phosphorus is 
extrapolated from the curve.  
 
Equation 2.5 Calculation for the activity of the enzyme. 
 
 
2.2.14.2 Microscopy assessment of enzyme activity 
For confirmation of enzyme activity using microscopy two liposome formulations of PC and 
PC:Chol were made from 16 μMol and 8:8 μMol without IFNγ as the size of the cytokine is too 
Units/mL enzyme =      (Micromoles of phosphorus)      (df) 
                    (15)  (0.1) 
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small to be visualised by means of light microscopy. 100 μL of liposome formulation was added to 
100 μL of the following enzymes at the specified concentrations (Table 2.2.): 
Table 2.3 PC:Chol liposome formulations tested with various enzyme concentrations with 
phospholipase A2 and phospholipase C using bright field microscopy. 
Microslide 
number 
Liposome 
formulation 
  PLA 2 added 
  U/mL 
Microslide 
number 
Liposome 
formulation 
PLC  added 
U/mL 
   1. PC 0    1. PC 0 
2.   PC 1 2.   PC 1 
3.   PC     5 3.   PC     5 
4.          PC 10 4.          PC 10 
5. PC:Chol  0 5. PC:Chol  0 
6.         PC:Chol  1 6.         PC:Chol  1 
7. PC:Chol  5 7. PC:Chol  5 
8.        PC:Chol  10 8.        PC:Chol  10 
 
 
. 
 
 
 
 
Figure 2.8 Enzymatic degradation (using PLC and PLA2) of liposome formulations in microslides 
of (a) Control formulations of PC 16 μMol  and PC:Chol 8:8 μMol and (b) 1 U/mL,(c) 5 U/mL and 
(d) 10 U/mL  of  PLC.  
 
Axioscope A1 light microscope. The microscopy pictures were taken at the start , after 1 hour and 
after an overnight incubation at 37 °C. The mixtures were prepared at room temperature and 
immediately placed into the microslides as shown (Figure 2.8). 
 
2.2.15 Evaluation of the pre-wetting stage of the ELISPOT assay 
Evaluation of the pre-wetting stage was carried out at the ethanol incubation time of one minute 
prior to antibody coating. As a control there were wells with no ethanol and then 15 µL, 25 µL and 
50 µL of 70% v/v alcohol for PC:Chol formulations. Subsequent to testing various amounts of 
a 
b 
c 
d 
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ethanol for the pre-wetting stage, for further confirmation the effects of adding 25 µL and 50 µL 
was assessed across liposome formulations of various compositions. 
 
2.2.16 Trigger release assessment; enzymatic and detergent triggered release 
A microscopy study was carried out, to confirm the optimal buffer and concentration for enzymatic 
release within the ELISPOT assay using PC:Chol formulations. The enzymatic concentrations were 
assessed in two two buffers 1) 10 mM Tris, 150 mM NaCl and 10 mM calcium chloride and 2) 10 
mM PBS. Subsequent to the selection of the Tris based buffer increased concentrations of the 
enzyme were assessed for both PLC (1 U/mL, 4 U/mL and 16 U/mL) and PLA2 (1 U/mL, 5 U/mL 
and 10 U/mL) respectively. 100 µL of the enzyme dilutions were added to each well. For detergent 
triggered release, Triton X 10% v/v was pipetted into the wells at the end of the overnight 
incubation step. It was left for 15 minutes prior to washing at room temperature. 
 
2.2.17 Manual counting of spots formed on the ELISPOT plates 
The spots were counted manually by taking an enlarged image of the well using a stereomicroscope 
(Figure 2.9).  
 
 
Figure 2.9 Image captured of an ELISPOT well and highlighted spots to illustrate counting 
procedure. 
. 
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An ELISPOT puncher was used to remove individual wells from the plate, each well was pushed 
out on to a foam pad and then placed onto a glass slide and secured in place by placing a coverslip 
on top. This was due to the difficulty of visualisation from the plate. A stereomicroscope was used 
for the magnification of the wells and a camera was used to take a picture through the eyepiece. 
The spots were then counted from uploaded images (Figure 2.9) as these could be enlarged for 
clarity. Each formulation was run in triplicate. 
 
2.2.18 Automated Counting 
Plates for automated counting were sent to NIBSC after colour development. These were read 
using the Jenner (University of Oxford settings).  
 
2.2.19 Dynamic viscosity measurements 
Dynamic viscosity measurements were carried out to compare the viscosity of the different 
liposome formulation in PBS, RPMI and RPMI with 10 % FCS. These were carried out using an 
Anton Par AMVn automated micro viscometer. Approximately 1 mL of liposome formulation was 
filled into the glass capillary tube and the measurements recorded at an angle tilt of 50° and -50° 
and carried out at 20 °C. 
 
2.2.20 Establishing a calibration curve in the ELISPOT assay 
In order to test the feasibility of a calibration curve the resuspending volume was changed from 2 
mL to 1 mL. From this stock, a serial dilution was made in RPMI at a 1:1 ratio (Figure 2.10). There 
were 6 calibrators or dilutions in total. ‘Empty’ liposome formulations can serve as the negative 
control.    
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Figure 2.10 Serial dilution for the positive control in 1:1 RPMI.  
 
2.2.21 Freeze dried liposomes with rIFNγ 
The formulations were frozen at -70 °C for at least 30 minutes. The freeze drier was pre-cooled to -
50 °C which takes 50 minutes. Primary drying was initiated at -40 °C (50mTorr) for 36 hours and 
then secondary drying at 20 °C (50mTorr) for 6 hours. The freeze drier used was the Virtis 
Advantage Bio- Pharma process Systems UK.  
After the formulation of liposomes they were re-suspended in 500 μL of buffer and then 500 μL of 
cryo-protectant solution to make a final amount equivalent to the amount required prior to freeze 
drying. The lyoprotectants assessed were the disaccharides trehalose and sucrose at concentrations 
ranging from 50 mM to 200 mM for PC formulations and at 50 mM and 100 mM for PC:Chol 
formulations. Upon completion of the freeze-drying cycle, the liposome formulations were re-
suspended with 1 mL of RPMI 1640 medium.  
 
2.2.22 Freeze- thaw experiment of liposomes with rIFNγ 
Liposomes formulations of PC 16 μMol and PC:Chol 8:8 μMol were made and then re-suspended 
in 1 mL of 100 mM trehalose cryoprotectants. These were split into two 500 µL volumes with one 
Positive control 
resuspended in 1 mL 
of RPMI (Positive 
control). 
 
CALIBRATOR 1 
Remove 500 µL 
and add to 500 µL 
RPMI. 
Serial dilution 
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vial for each placed at -70 °C for 1 hour. After the formulation had thawed completely both were 
placed onto the assay in triplicate and incubated at 37 °C.  
 
2.2.23 Preparation of liposomes and characterisation for scale up 
The small 4 mL batch was prepared as described previously using a 50 mL round bottom flask, for 
the larger batch it was necessary to use a 500 mL flask (Figure 2.9). An assessment of the 
entrapped BSA-FITC was carried out using the fluorescence assay as described previously (2.2.7). 
The calibration curve constructed from the serial dilution used for quantification is shown in figure 
2.10. Size characterisation was carried out using the Sympatec Particle sizer. Ordinarily 100 µL of 
liposomes formulation is pipetted into a glass quartz cuvette (A signal of at least 15 % is required 
for an adequate reading). Three sample readings were taken for each formulation and an average 
result was obtained for size and polydispersity. 
 
 
 
 
 
 
 
Figure 2.11 Calibration graph for BSA-FITC 5 µg/mL from the stock solution for the calculation 
for the amount of protein entrapped. 
 
The time on the rotary evaporator was increased from 20 minutes to 45 minutes to ensure the 
evaporation of solvents for the larger batch. The flask was purged with nitrogen for four minutes, to 
remove any residual solvent. 1 mL of the small and large batch was removed for the assessment of 
y = 60.248x 
R² = 0.9967 
0
100
200
300
400
500
600
700
0 2 4 6 8 10 12
R
FU
 
Concentration μg/mL 
107 
 
recovery and entrapment efficiency. The rest of the large batch was divided into triplicate aliquots 
to allow the assessment of the effect of freeze-drying with three different lyoprotectant 
concentrations namely 50 mM, 100 mM and 200 mM of trehalose in H2O, 20 mM Tris buffer, PBS 
and three samples were left without any cryoprotectant. Subsequently the size of both the liposome 
formulations was measured and for the larger batch size characterisation was repeated again once 
all the freeze-dried vials were re-suspended. An assessment of the entrapped BSA-FITC was 
carried out using the fluorescence assay as described previously (2.2.7). The calibration curve 
constructed from the serial dilution used for quantification is shown in figure 2.10. Size 
characterisation was carried out using the Sympatec Particle sizer. Ordinarily 100 µL of liposomes 
formulation is pipetted into a glass quartz cuvette (a signal of at least 15 % is required for an 
adequate reading). Three sample readings were taken for each formulation and an average result 
was obtained for size and polydispersity. 
 
2.2.24 Statistical analysis 
Where appropriate, the data has been examined for statistical significance using one way analysis 
of variance (ANOVA) and a multiple comparison post-test Tukey to compare all data sets. Graph 
pad software was used. Significance is set at P<0.05; for an extremely significant result p<0.01. 
ANOVA Two way analysis and the Bonferroni post-test has also been used where appropriate 
Significance is set at P<0.05 and for an extremely significant result p<0.01. In addition, the 
similarity factor F2 has been used to determine the similarity of the curves this is a logarithmic 
transformation of the sum-squared error of differences between the test T2 and the reference values 
between 50 – 100 are acceptable according to the FDA regulations (Yuksel et al., 2000). 
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Chapter 3 
Design considerations for the formulation of liposome reference 
standards for the ELISPOT assay 
 
 
Graphical abstract 
a. Bromination of cholesterol to increase sedimentation rates; 
 
 
 
 
b. Size selection of heterogenous liposome formulations; 
 
 
 
 
 
 
 
Increase spot size 
and number. 
Reduce smaller 
liposomes and 
background. 
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3.1 Introduction 
 
There are many advantages in using liposomes for the encapsulation of cytokines over other 
colloidal systems, with the most significant being their versatility thus, structural and 
physicochemical characteristics such as size, lipid composition, charge and fluidity of the 
phospholipid bilayers can be modified (Storm and Crommelin, 1998). Liposomes have been used 
for the entrapment of a variety of different molecules, ranging from small molecules and drugs 
through to therapeutic proteins however, their application within an ELISPOT assay was a novel 
concept (Gregoriadis and Ryman, 1971, Gregoriadis et al., 1974). The novel application of 
liposomes within an immunoassay setting requires careful consideration of the design aspects for 
the formulations to produce an effective reference standard to replace stimulated cells normally 
used for positive controls. 
 
3.1.1 Liposomes as artificial cells 
The basic premise of this study was to produce liposomes that can mimic the actions of cells by the 
steady release of entrapped cytokine onto a pre-coated membrane. The surface area of the 
membrane for an ELISPOT well is approximately 0.3 cm
2
. The T-cells placed into the well are 
spherical with a diameter of 10-15 µm and thus a cell count of 150,000 cells would constitute a 
monolayer (Weiss, 2012). The cells placed into the well have the ability to sediment and once in 
contact with the membrane they release cytokine to produce a spot. T-cells are lymphocytes and 
such cells have a minimal cytoplasm with small mitochondria and small amounts of polyribosomes, 
rough endoplasmic reticulum, and a small golgi apparatus (Turgeon, 2004). They have a 
predominant nucleus, which is approximately 7 µm (Henrikson and Mazurkiewicz, 1997). In 
attempting to produce an artificial vesicle that is able to mimic the actions of a lymphocyte the 
aforementioned physical attributes of the liposomes must also be taken into consideration such as 
the morphology, size of the vesicle and their ability to sediment in a manner similar to cells. 
Initially the discovery of liposomes was considered important as a potential model for the cell 
membrane and as an important tool for the study of membrane biophysics (Bangham et al., 1965, 
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Gregoriadis, 1991). Although liposomes are structurally similar to cells in terms of their bilayer, 
they also have many notable differences, which may affect their behaviour as artificial reference 
standards when designed to mimic the action of cells. There have been many studies in which it has 
been necessary to describe cells as spherical colloidal particles however such descriptions over 
simplify the complex nature of the membrane (Dan, 2003). It is precisely such differences between 
cells and liposomes that are important pre-design considerations for this study; however, in their 
simplest form liposomes lack any other physical structures within the internal compartment and 
encapsulate only aqueous media. Furthermore, the liposomes formed are often variable in the size, 
lamerallity and size distribution (Sanchez-Lopez et al., 2009). 
 
3.1.2 Manipulating liposome formulations for the ELISPOT assay 
The structural differences between liposomes and cells may affect the ability of the liposome 
vesicles to sediment to the bottom of the wells in a similar way to the cells as according to Stokes’ 
law; the size of the vesicles and their density affects the sedimentation rate. The dominant initial 
interactions between cells and surfaces are electrostatic interactions, with ligand interactions 
becoming more significant when cells are within close enough proximity to surfaces to form such 
interactions (Marshall et al., 1971 and Dan, 2003). Thus, to tackle such fundamental differences the 
method chosen to enhance sedimentation characteristics of the liposome vesicles was a basic 
modification to increase the molecular weight of either the phospholipid component or the sterol 
component. After consideration, the method chosen was the bromination of the cholesterol 
component of the liposome preparation as it is a relatively straightforward laboratory synthesis and 
achieved in a short period of time (Grant and Latimer, 2003). By modifying cholesterol the 
majority of the formulation remains the same, thus the aim was to retain the overall 
physicochemical characteristics of the liposomes other than the density of the vesicles. 
Unlike T-cells, which are generally between 10-15 µm in size, when a liposome formulation is 
produced it is a heterogenous mixture of vesicle sizes (Sanchez-Lopez et al., 2009). The mean 
diameter of a formulation could be for instance, 10 µm; however, within each preparation there will 
be liposomes both larger and smaller than the desired size range. Given that, the particle size is also 
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a controlling factor in sedimentation; a more homogeneous particle size range is desirable to reduce 
variation in sedimentation rates. Previous studies have shown the use of filtration with liposomes to 
produce a more homogenous population; using polycarbonate filters and extrusion methods 
multilamellar liposomes are forced through the filters reducing the size from several microns to less 
than a micron (Olson et al., 1979, Vemuri and Rhodes, 1995). However to achieve homogeneity 
size has been reduced, other strategies which can be adopted to select the desired size  and are 
routinely used with cells include centrifugation at different speeds and combining centrifugation 
with the use of sucrose density gradients (Alberts et al., 2008, Weissig et al., 1991). Such 
techniques can be adopted to select a given size range from a heterogenous liposome batch 
(Weissig et al., 1991).  
 
3.2 Aims and Objectives 
 
In order to produce an artificial reference standard for the ELISPOT assay that can release cytokine 
in a way similar to T-cells, the main aim of this project was to design the formulation so that it 
closely mimicked the action of cells. The sedimentation velocity of the particles was an important 
aspect of the pre-formulation considerations. Therefore to enhance sedimentation rates, synthesis of 
brominated cholesterol and subsequent incorporation within the formulations was a means to 
increase mass of each individual vesicle. A second factor was to produce a vesicle suspension of 
large vesicles with a low particle size range. To achieve this it was necessary to investigate some 
basic methods for size separation, thus the objectives of the study were: 
 To synthesise and validate brominated cholesterol. 
 To incorporate brominated cholesterol, at various ratios, within liposome formulations and 
assessment of the effect on the rate of sedimentation. 
 To measure and validate a fluorescence assay for the measurement of the entrapment 
efficiency of various liposome formulations with bovine serum albumin conjugated with 
fluorescein isothiocyanate (BSA-FITC). 
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 To investigate various basic size separation techniques to assess their effectiveness to produce 
a more homogeneous size population. 
 To integrate the most effective techniques for size selection into a method for the production 
of liposome-entrapped cytokine formulations as artificial reference standards. 
 
3.3 Results and Discussion 
3.3.1 Synthesis and characterisation of dibromocholesterol 
A basic laboratory method for the bromination reaction of cholesterol was identified (Kabara et al., 
1960, Fieser et al., 1992).   
 
        
Figure 3.1 The organic synthesis reaction for the formation of dibromocholesterol from 
cholesterol. 
 
The reaction itself involves the breaking of a double bond and the addition of two bromine atoms in 
the specified positions (Figure 3.1). For the purposes of this study, two batches of 
dibromocholesterol were synthesised (batch 1 and 2 respectively). In order to validate the initial 
batch of dibromocholesterol the techniques used were; thin layer chromatography, melting point 
determination, and infrared spectroscopy. Due to the results obtained, further validation was 
necessary, including a more precise melting point determination using differential scanning 
calorimetry, 
1
H-NMR and 
13
C-NMR. For the second batch, similar characterisation techniques 
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(other than infrared spectroscopy were carried out due to the close comparability of the results to 
the first batch) and where possible this data was combined for both batches. 
 
 3.3.1.1 Thin Layer Chromatography (TLC) 
The dibromocholesterol product was assessed using TLC; the solvent used after optimisation was 
ether:acetic acid  98:2. This solvent provided clear spots for the product which had a different 
migration rate to the well defined spot for cholesterol (Figure 3.2).  
 
 
 
 
 
 
 
 
 
Figure 3.2 TLC plates for (a) dibromomocholesterol compared to (b) cholesterol.  
There was also a good correlation between the Rf values for both of the batches which confirmed 
the reproducibility of the method for synthesis. The reference substance used was cholesterol and 
the values of 0.55 for the Rf values across the two chromatograms (Figure 3.2 a and Figure 3.2 b) 
indicated that the experimental parameters were consistent (Kar, 2005). The actual Rf values 
cannot be compared directly to other literature values as they are not definitively constant. They 
vary with many experimental factors such as temperature, humidity, the nature of the solvent and 
even the size of the container, the values indicate that a new compound has been formed for both 
Solvent Front: 
6.0 cm 
Product: 
3.9 cm 
Rf 0.65 
Cholesterol: 
3.3 cm 
Rf 0.55 
Solvent Front: 
5.0 cm 
Product: 
3.5 cm 
Rf  0.70 
Cholesterol: 
3.3 cm 
Rf  0.55 
a b 
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batches and there were no distinct spots above the product to indicate impurities (Krupadanam et 
al., 2001; Sharma, 2005). 
 
3.3.1.2 Melting point determination 
Using the Gallenkamp melting point apparatus a small amount of pure cholesterol and the product 
were placed into a glass capillary tube and into the apparatus for assessment. For reference, pure 
cholesterol was used and this was in the range of the literature values expected of 149-150 
o
C 
(Table 3.1; Barton and Miller, 1950). However, the melting point of the product was found to be 
higher (119-121 
o
C; Table 3.1) than previously reported in the literature (112-114 
o
C; Barton and 
Miller, 1950).  
 
Table 3.1 Visualised melting points of cholesterol and obtained product with the related literature 
values (Barton and Miller 1950). 
Melting point determination is dependent upon several factors including the quantity of sample 
used, rate of heating and the purity and chemical characteristics of the substance, thus observed 
melting point values can differ from true values due to a lack of uniformity in the distribution of 
heat during the process of melting (Gilbert et al., 2011). For further confirmation, the technique of 
differential scanning calorimetry (DSC) was used (Figure 3.3) for a more precise melting point 
determination (Palermo and Chiu, 1976). DSC can accurately determine the melting point and 
differentiate between different crystal forms (Storey et al., 2011). In addition to the previously 
discussed TLC, DSC can further support chromatographic methods (Giron et al., 1997). 
The DSC thermogram showed the onset for the melting of cholesterol was 148.29 °C and the main 
peak at 149.38 °C (Figure 3.3); this was within the literature melting value range. The melting 
point for the dibromocholesterol using the DSC was not within the literature stated value of 112-
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114 ° C (Barton and Miller, 1950):  the onset of melting was 111.20 °C (Figure 3.3) and the main 
melt was at 117 °C. The scans show that the peak for cholesterol is sharp; however, the peak for the 
dibromocholesterol is broader with an additional secondary peak after the main melt. The reference 
peak of cholesterol was similar to that obtained in a previous study by Cui et al., (2010) with a 
sharp melt observed at 149.8 °C. The broader peak and the presence of the secondary peak for 
dibromocholesterol suggested there may be an impurity (Palermo and Chiu, 1976). Although 
generally the nature of a DSC experiment results in some degree of broadening associated with 
phase changes which occur during melting (Storey and Ymen, 2011). 
 
Figure 3.3 DSC thermograms for melting point determination of cholesterol and 
dibromocholesterol; (a) Cholesterol, red, top thermoscan, (b) dibromocholesterol batch 1, blue 
thermoscan, (c) dibromocholesterol batch 2, black thermoscan. 
 
Any differences between the scan after the main melt could be due to impurities or residual 
components from the synthesis, as even small amounts of impurities can broaden the melting range 
(Palermo and Chiu, 1976). For assessment and determination of the presence of such impurities, 
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spectroscopic techniques are generally used, such as infrared spectroscopy to determine structural 
analysis through determination of functional groups (Ahuja, 2007).  
 
3.3.1.3 Infrared spectroscopy    
Cholesterol and the dibromocholesterol were both analysed by IR spectroscopy (Figure 3.4). One 
of the main functional groups present in dibromocholesterol and cholesterol is the –OH attached to 
the carbon on position 3 of the first ring.  
 
                 
                                                                                
                                                                    Acetic Acid                                     
                                                     
        
Figure 3.4 Infrared Spectrum for cholesterol (Blue) and product (Red). 
 
The spectrum shows that it was present on both the starting material and the synthesised product. 
Other similar peaks include C-H bends and stretch at 1500 cm
-1
 and 2750 cm
-1
 respectively. 
However, there were two peaks present in the synthesised dibromocholesterol, which were not 
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present in the cholesterol. There is a peak at 550 cm
-1
 which corresponds to a C-Br bond and in 
addition a C=O peak at around 1700 cm
-1
 (Figure 3.4). Both the DSC scans (Figure 3.3) and the 
presence of the above C=O peak at 1705 – 1720 cm-1 (Figure 3.4) suggested an impurity may be 
present. In the reaction mechanism proposed by Fieser and Williamson, (1992), they state that 
‘when material prepared is dried to constant weight at room temperature, it is obtained as the 1:1 
dibromide/acetic acid complex’. Through the process of chemical synthesis, chemical impurities 
can result and their origin could be from raw materials, solvents, intermediates and by products 
(Ahuja, 2007). Given the DSC scans show the melting point to be slightly different from the 
literature, combined with the presence of the second melt and the C=O in the infrared spectrum, 
suggested that this could be the case. Also of note is that ordinarily this reaction is for purification 
of crude cholesterol; whereas the starting material for this study is of 99 % pure (Grant et al., 2003, 
Fieser and Williamson, 1992). The infrared spectrum obtained for pure cholesterol was similar to 
that observed in other studies and the direct overlay of the pure and synthesised material served to 
highlight the strong presence of the additional C-Br band at 550 cm
-1
 (Laugel et al., 2005). It is 
interesting to observe that acetic acid for the purposes of drug synthesis has a low toxic potential, 
and its presence within defined low quantities is acceptable according to ICH guidelines (ICH, 
2006). A further technique that is commonly used for analysis of synthesised products is nuclear 
magnetic resonance (NMR). This technique is used to study the behaviour of nuceli when subjected 
to an externally applied field and thus for this study 
1
H and 
13
C nuclei were examined for the 
purposes of structural characterisation of any present molecules (Lohr et al., 2006). 
 
3.3.1.4 Hydrogen NMR.  
Cholesterol was analysed (Figure 3.5), as well as the synthesised batches of dibromocholesterol 
shown by a representative scan (Figure 3.6) to assess how the environment of bonded hydrogens 
changed subsequent to chemical synthesis. Highlighted in Figure 3.5, are the two hydrogen atoms 
most affected by the attachment of the strongly electronegative bromine atoms during the synthesis 
in the cholesterol NMR.  
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Figure 3.5 
1
H NMR of cholesterol. 
 
 
 
 
 
 
 
 
 
Figure 3.6 
1
H NMR of dibromocholesterol. 
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There were two downfield peaks which were multiplets (Figure 3.5); there was a peak at 3.5 (ppm) 
which can be attributed to the hydrogen attached to the oxygen and a second peak which was from 
the hydrogen attached at around 5.5 (ppm) carbon 6 associated with the double bond. It can be seen 
that with the synthesised product (Figure 3.6) both these peaks have shifted; the 3.5 (ppm) shifts to 
4.5 (ppm) and the peak attributed to the hydrogen attached to the OH group moves from 5.5 (ppm) 
to 4.75 (ppm). There was also no evidence of a second compound within the spectrum. Hydrogen 
NMR can also provide information about the number, type and environment of the 
1
H atoms 
(Malet-Martino and Holzgrabe, 2011). 
If the double bond from the cholesterol is broken as predicted by the reaction mechanism (Figure 
2.3), and bromine atoms attached, there should be a specific change visible in the 
1
H NMR 
spectrums. The 
1
H-NMR data (Figure 3.6) suggests that the proposed synthesis has taken place and 
there are no obvious indications of impurities or complexes being present. 
 
3.3.1.5 Carbon NMR  
Further characterisation was carried out using 
13
C NMR. Figure 3.7 shows the structure of 
dibromocholesterol with all the carbons labelled in colours corresponding to the number of 
hydrogens attached. In Figure 3.8, quaternary and C-H carbons were shown to be above the base 
line and CH2 and CH3 were shown to be below. The red represented the CH2, the green CH3, the 
lilac CH and the blue were quaternary carbons with no attached hydrogens. The Carbon NMR 
(Figure 3.8) confirmed the presence of 27 atoms (Figure 3.7), as well as the bonding environment 
of each. Carbon NMR was used to determine the presence or absence of the suggested 
dibromide/acetic acid complex (Fieser and Williamson, 1992). 
If such a complex was present, there should have been more than the 27 carbons in the NMR 
spectrum not accounted for by the structure of dibromocholesterol; this technique is sensitive 
enough to detect low molecular weight compounds in solution provided they contain the nuclei of 
interest (Malet-Martino and Holzgrabe, 2011). 
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Figure 3.7 Structure of dibromocholesterol with all carbons numbered. 
Figure 3.8 
13
Carbon NMR of dibromocholesterol. 
 
The most significant aspect of the NMR results is that there was no such evidence of a dibromide 
complex as initially indicated by the IR spectrum. Confirmation was due to the absence of an 
additional two carbon atoms. Overall, the validation data suggests that dibromocholesterol is the 
synthesised product and slight discrepancies between literature and obtained melting points could 
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be due to differences in the purity of the starting material. The NMR data suggests that the reaction 
has taken place as expected and resulted in the formation of dibromocholesterol. 
 
3.3.1.6 Percentage yield 
It was necessary to calculate the yield obtained from the synthesis of the product to assess the 
efficiency of the reaction, if the yield was substantially low it would suggest further manipulation 
of the method chosen for synthesis was required (Smart, 2002).  
 
Table 3.2 The percentage yields of the two batches of synthesised dibromocholesterol. 
Batch 
Number 
Initial Weight of 
cholesterol (g) 
Theoretical 
Yield (g) 
Final weight 
of Product (g) 
      Actual 
Yield (%) 
1 1.0  1.632  1.0151  62 
2 2.0  2.720  2.0100  74 
  Average  68 
 
The overall average yield obtained from the two synthesised batches was 68 % (Table 3.2). The 
theoretical yield is the mass of the product, which should be formed in the chemical reaction 
according to the stoichiometry of the balanced equation whereas the actual yield is the mass of the 
product formed in the chemical reaction (Bettelheim et al., 2004). It is difficult to conclude exactly 
where the loss may have occurred, this may be due to transference loss or an incomplete reaction. 
If the percentage yield is too low, then consequently a small amount of final product would be 
formed from even with a large amount of starting material and the process maybe too inefficient to 
be useful; however, an average yield of 68 % was considered suitable for the required amounts of 
lipid needed for subsequent studies.  
 
3.3.1.7 Six month stability assessment of dibromocholesterol 
Having synthesised dibromocholesterol the stability of the synthesised product, when stored as a 
powder, was an important aspect to consider. The product needs to show stability upon storage and 
subsequently its incorporation into the liposome formulations needs to fulfil minimum stability 
requirements. The dibromocholesterol powder was stored at -20 °C for 6 months and was validated 
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as previously outlined with characterisation techniques including; TLC, DSC, 
1
H NMR and 
13
C 
NMR. In addition, moisture gain was assessed using thermogravimetric analysis. The data obtained 
was compared either directly to a newly synthesised batch (TLC, TGA) or to the original data (
1
H 
NMR and 
13
C NMR).  
 
3.3.1.8 TLC of dibromocholesterol (6 months vs. newly synthesised) 
Thin layer chromatography was used to compare the newly synthesised batch to the 6 month old 
dibromocholesterol to assess any change in the product. In this chromatogram (Figure 3.9), the 
original product was the dibromocholesterol, which had been stored for 6 months.  
 
 
 
 
 
 
 
Figure 3.9 TLC plate showing a newly synthesised batch and dibromocholesterol stored for 6 
months. 
 
The Rf value was slightly different to the value originally obtained which was 0.65; however, the 
value obtained of 0.74 was directly comparable to the newly synthesised batch of 0.7. Moreover, 
there were no definitive additional spots to indicate impurities from degradation. Having 
knowledge of the basic stability characteristics of synthesised products is essential for practical 
aspects of the study; the loss of stability could lead to decomposition or the formation of new 
substances (Voronin, 2000).   
 
Solvent Front 5.0 cm 
6 month 
dibromocholesterol 
3.7 cm    Rf  0.74 
New Product  
3.5 cm       Rf  0.70 
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3.3.1.9 DSC for melting point confirmation of stored dibromocholesterol 
DSC was used previously for the determination of an accurate melting point and was therefore 
repeated to ascertain if any changes had occurred upon storage of the dibromocholesterol. The 
sample of the 6 month dibromocholesterol was tested and this scan was compared to the original to 
determine stability. The overlaid scans (Figure 3.10) showed that the main melt for the newly 
synthesised product and a batch stored for 6 months were very similar (117 °C and 119 °C 
respectively). This slight difference in melting point may be a result of the storage of 
dibromocholesterol at -20 °C (in the absence of a desiccator).  
 
   
 
 
 
 
 
 
 
Figure 3.10 DSC thermogram of initial batch overlaid with dibromocholesterol after 6 months 
storage.  
 
It is well established that the presence of water is a destabilising factor and that a higher water 
content is associated with a higher rate of chemical degradation (Ohtake and Shalaev, 2013). 
Although the vial was stored in a sealed container the dried powder may have absorbed water 
which could affect the melting point; this can be confirmed through thermogravimetric analysis as 
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this is a quantitative measurement which can determine the moisture content related to weight loss 
for stability studies (Yu, 2001) (see section 3.3.2.4).   
 
3.3.1.10 
13
C NMR and 
1
H NMR of stored dibromocholesterol 
Stability testing of the stored dibromocholesterol involved repeating 
1
H NMR and 
13
C NMR 
studies. This would elucidate any structural changes that may have occurred over time. The 
1
H 
NMR scans obtained were directly comparable to the initial scan, and neither scan showed any 
structural differences in terms of the signals obtained (Figure 3.11 vs. Figure 3.6). Similarly there 
were no visible difference in the carbon NMR scans, with the signals being highly reproducible 
(Figure 3.12 vs. Figure 3.8), suggesting no measurable structural degradation had taken place. 
 
Figure 3.11 
1
H NMR scans of dibromocholesterol retested after 6 months. 
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Figure 3.12 
13
C NMR scans of newly synthesised batch of dibromocholesterol (6 month stability). 
3.3.1.11 TGA analysis of newly synthesised and stored dibromocholesterol 
To provide an assessment of structural decomposition, oxidation and moisture gain or loss, 
thermogravimetric analysis (TGA) was carried out on both batches of dibromocholesterol in 
triplicate as shown in Figure 3.13. The TGA scans showed the older batch of dibromocholesterol 
had a mean moisture loss at 5.14 ± 0.54 % (Figure 3.14 b) compared to the newly synthesised batch 
which had a loss of 4.40 ± 0.21 % (Figure 3.13). Statistical analysis of the data showed no 
significant difference between the moisture loss from either the freshly prepared or the 6 month 
stored samples. This suggests that moisture gain over storage was not significant and that the 
samples were not hygroscopic in nature. Other studies assessing the hygroscopicity of samples 
consider an increase in mass of material between 0.2 % to 2 % to be slightly hygroscopic; as 
defined by the European Pharmacopoeia (Murikipudi et al., 2013). However, given the starting 
material had a moisture content of around 4 % this may still be sufficient to enhance chemical 
degradation over longer term (May, 2013). FDA guidance for industry for pharmaceutical 
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development recommends a moisture content of less than 2 % and between 1 % to 3 % for freeze-
dried products (ICH, 2009, May, 2013).  
 
Figure 3.13  TGA scans of newly synthesised batch of dibromocholesterol  . 
 
 
 
Figure 3.14 TGA scans of previous batch  of dibromocholesterol. 
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3.3.2 Sedimentation studies of liposomes and physicochemical characterisation 
Subsequent to the synthesis and characterisation of the dibromocholesterol, it was necessary to 
assess the impact of its incorporation within liposomal formulations. An assessment of the 
comparative effect on the sedimentation efficiency of liposome formulations of DPPC:Chol as 
multilamellar vesicles (MLV) and small unilamellar vesicles (SUV) with those containing 
dibromocholesterol in differing ratios was made (Table 3.3). For all the formulations included in 
the study physicochemical characterisation of the particle size and zeta potential were carried out. 
The results (Figure 3.15) from the particle size data showed there was no significant difference 
between the brominated MLV liposomes of DPPC:Chol:Brchol and the non-brominated 
DPPC:Chol MLV formulations. The particle sizes for the brominated vesicles of 
DPPC:Chol:BrChol 16:8:8 μMol, DPPC:Chol:Brchol 16:4:12 μMol and DPPC:Brchol 16:16 μMol 
were 10.7 ± 1.3 µm, 11.1 ± 2.5 µm and 8.5 ± 0.7 µm respectively (Figure 3.15). The DPPC:Chol 
16:16 μMol MLV formulations had an average particle size of 10.18 ± 2.7 µm (Figure 3.15). 
However, there was a significant difference (p<0.001) between the zeta potential for the non-
brominated MLV formulations and the brominated formulations. The non-brominated formulations 
of DPPC:Chol 16:16 μMol had an average zeta potential of -6.92 ± 1.17 mV (Figure 3.14). The 
brominated formulations of DPPC:Chol:Brchol 16:8:8 μMol, DPPC:Chol:Brchol 16:4:12 μMol and 
DPPC:Brchol 16:16 μMol had average zeta potentials of -33.87 ± 3.87 mV, -37.70 ± 4.65 mV and -
43.47 ± 5.42 mV respectively (Figure 3.15). There was no significant difference observed between 
the formulations containing increasing amounts of brominated cholesterol.  
The size distribution (span) for each of the formulations showed that although similar values were 
obtained across the MLV formulations, the span is significantly decreased (p<0.001) for the SUV 
formulations. For instance for DPPC:Chol MLV formulations and DPPC:Chol SUV formulations 
this decreased from 2.3 ± 0.01 to 0.42 ± 0.05 respectively. The process of sonication is a widely 
used to technique for the production of SUV vesicles which are normally less than a micron and the 
resultant decrease in span is thus expected (Lapinski et al., 2007). 
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It was interesting to observe that there was no significant difference in size across the formulations 
as the aim in using a synthesised derivative of cholesterol was to retain the physiochemical 
characteristics of normal liposome formulations. The lack of differences observed in the particle 
size when comparing the formulations suggested that the cholesterol and dibromocholesterol have 
inserted into the bilayer in a similar way. Cholesterol fills into the spaces within the acyl chains of 
the lipid bilayer as it orients itself so that the hydroxyl group is towards the aqueous phase and the 
hydrophobic steroid ring is parallel to and buried within the chains of the phospholipids (Ohvo-
Rekila et al., 2002).  
Table 3.3 The five Liposome formulations used in the sedimentation study.   
Lipid Composition Morphology Ratio of Lipids         
(μMol) 
DPPC:Chol MLV 16:16 
DPPC:Chol SUV 16:16 
DPPC:Chol: BrChol MLV 16:8:8 
DPPC:Chol: BrChol MLV 16:4:12 
DPPC: BrChol MLV 16:16 
 
  
 
 
 
 
 
 
 
Figure 3.15 The size (µm), zeta potential (mV) and span of MLV and SUV formulations of 
DPPC:Chol with and without dibrominated cholesterol. Formulations of DPPC:Chol 16:16 μMol 
MLV and SUV with formulations containing brominated cholesterol of DPPC:Chol:BrChol 16:8:8 
μMol, DPPC:Chol:Brchol 16:4:12 μMol and DPPC:Brchol 16:16 μMol used within the 
sedimentation studies. Results represent mean ± SD of n =3 batches.  
0.423 ± 0.05 
2.30 ± 0.01 
±± 2.34 ± 0.01 
±± 
2.39 ± 0.03 
±± 
2.36 ± 0.013 
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The difference observed in the zeta potential was more notable in the liposome formulations 
incorporating dibromocholesterol; the electrical potential at the membrane surface becomes more 
anionic thus changing an important physiochemical characteristic of the formulation (Figure 3.15). 
The nature and extent of the charge on the surface of liposomes impacts upon stability, kinetics and 
within the in vivo environment even the biodistribution of the vesicles (Lian et al., 2001).  
However, negatively charged liposomes can have longer stability due to reduced aggregation and 
fusion (Lasic and Papahadjopoulos, 1998). Thus subsequent to characterisation sedimentation was 
assessed qualitatively (through images taken of formulations at specified time points) and 
quantitatively (by measuring percentage transmission using a spectrophotometer). Microscope 
images of the MLV formulations were used to assess the formation of liposomes further to the 
physicochemical characterisation. 
 
3.3.2.1 Consideration of liposome morphology using bright field microscopy 
The images obtained (Figure 3.16) for the MLV liposome formulations of (a) DPPC:Chol 16:16 
μMol showed that the formulation produced spherical vesicles in general and were heterogenous in 
nature. The images for the formulations containing brominated cholesterol (Figure 3.16 b – d) 
confirmed that the liposomes were spherical in nature and were similar to the DPPC:Chol liposome 
formulations. As was suggested by the more negative zeta potential of the brominated-liposomes 
(Figure 3.15) there appeared to be a decreased level of aggregation of liposomes with the inclusion 
of the brominated cholesterol in the vesicles (Figure 3.16 b to d respectively). The higher negative 
surface potential could account for the vesicle repulsion (Lian et al., 2001).  
In many previous studies light microscopy techniques have been used in addition to particle size 
characterisation for the confirmation of size distribution and the morphological nature of MLV 
preparations, although this cannot be a complete picture due to the limits of the microscope (Szoka 
and Papahadjopoulos, 1980). However, this technique highlights clearly the heterogenous nature of 
the MLV vesicles within the samples, which may become more important during the 
developmental stages of liposomal reference standards. 
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Figure 3.16 Light microscope images viewed under a 40X objective of formulations of DPPC:Chol 
with and without dibrominated cholesterol; (a) DPPC:Chol 16:16 μMol MLV, (b) 
DPPC:Chol:Brchol 16:8:8 μMol, (c) DPPC:Chol:BrChol 16:4:12 μMol and (d) DPPC: Brchol 
16:16 μMol. 
 
3.3.2.2 Sedimentation rates for liposome formulations; a quantitative and qualitative assessment 
Liposome formulations with increasing dibromocholesterol (Table 3.3) were quantitatively 
assessed for their ‘settling time’ using a spectrophotometer (Figure 3.17). As the liposomes settle to 
the bottom of the cuvette, more light is able to pass through. Liposomes formulations were also 
placed into bijoux tubes for qualitative assessments of sedimentation and images were taken at the 
beginning of the study then at defined time points of 1, 2, 3, 4, 12 and 18 hours (Figure 3.18).  
The results from the quantitative assessment (Figure 3.17) showed that that over the period of 18 
hours the ability of the liposome formulations to sediment was significantly different (P<0.001) for 
the SUV formulations (DPPC:Chol 16:16 μMol) compared to all other MLV formulations. Even by 
the first hour of the study there was a low percentage transmission for the formulations of 
DPPC:Chol SUV, which was significantly different (P<0.001) when compared to the formulations 
a b 
c d 
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of DPCC:BrChol 16:16 μMol (1.3 ± 0.12 % and 19 ± 8.8 % respectively). At this time point there 
was a significant difference between the control formulations of DPPC:Chol 16:16 μMol (MLV) 
and the formulations of DPPC:BrChol 16:16 μMol (P<0.01) showing percentage transmissions of 
0.13 ± 0.06 % and 19 ± 2.75 % respectively, with the formulation containing the brominated 
cholesterol at a 1:1 mole ratio showing effective sedimentation.  
The observed trend was not consistent for the remaining time period of the study and after 4 hours 
the DPPC:Chol:BrChol, 16:4:12 μMol formulations had a significantly higher (p<0.01) percentage 
transmission of 59 ± 5.9 % compared to the control formulation at 29 ± 12 %. This was not 
significantly different from the formulations containing the highest dibromocholesterol content 
(DPPC:BrChol 16:16 μMol 46 ± 7.0 % (Figure 3.17). 
By the 12 hour time point the percentage transmission was significantly (p<0.001) lower for the 
DPPC:Chol 16:16 μMol (SUV) formulations compared to those formulations incorporating 
brominated cholesterol and for the control DPPC:Chol 16:16 μMol (MLV) formulation (p<0.001). 
However, there was no significant difference between the control MLV formulations of 
DPPC:Chol 16:16 μMol and the brominated formulations at this time point or at the final time 
point of 18 hours. The qualitative results (Figure 3.17) confirmed that DPPC:Chol 16:16 μMol 
MLV formulations required over 4 hours to show physical evidence of settling, and the SUV 
formulations showed the slowest rate of sedimentation with some physical evidence of settling; 
however the suspension remained turbid, even after 18 hours. Figure 3.18 also confirmed that the 
formulations containing brominated cholesterol were clearer over the first few hours compared to 
the control formulations of DPPC:Chol 16:16 μMol (MLV). 
In terms of application, the smaller vesicles are not practically applicable for the ELISPOT assay, 
however they do elucidate the behaviour of the smaller particles within formulations. Smaller 
vesicles are less dense and as outlined by Stokes’ Law have a slower sedimentation rate 
(Versaratchanon et al., 2007). In addition, aggregation of liposomes is ordinarily associated with 
larger liposomes due to the greater flatness of the membranes that allows greater contact between 
areas of membranes (Casals et al., 2003). 
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Figure 3.17 Percentage transmission over an 18 hour period of liposome formulations 
containing brominated and non-brominated cholesterol. (1) DPPC:Chol (MLV) (2) DPPC:Chol 
(SUV) (3) Dppc:Chol:Brchol 16:8:8 µMol, (4) Dppc:Chol:Brchol 16:4:12 µMol and (5) 
DPPC:Brchol 16:16 µMol. Results represent mean ± SD, n =3 batches. 
 
Figure 3.18 Photographic images over an 18 hour period of liposome formulations containing 
brominated and non-brominated cholesterol; (1) MLV and (2) SUV formulations of DPPC:Chol 16:16 
µMol and MLV formulations containing brominated cholesterol of (3) DPPC:Chol:Brchol 16:8:8 
µMol, (4) DPPC:Chol:Brchol 16:4:12 µMol and (5) DPPC:Brchol 16:16 µMol.  
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Thus, it can be anticipated from the observed results that smaller vesicles, which have a slower rate 
of sedimentation would be detrimental for an ELISPOT assay as they may not settle effectively at 
the bottom of the individual wells. These results show that by four hours, formulations with 
brominated cholesterol show enhanced settling ability compared to the non-brominated MLV 
formulations (Figure 3.18). This initial enhanced sedimentation rate suggests the increased density 
has a greater impact over this period, whilst this effect does not remain over longer periods (12 or 
18 hours) which are normal endpoints for ELISPOT assays although they can even be as long as 24 
hours (Smith et al., 2009). By the final time point the majority of vesicles have settled. Stokes’ law 
dictates that observed increase in sedimentation rates occur due to an increase in various factors 
including the size and density of the particle (Banker and Rhodes, 2002). However in the case of 
the liposome formulations containing brominated cholesterol a linear increase was not observed in 
the sedimentation velocity across all of the time points, perhaps due to the observed differences in 
surface charge between the formulations. The presence of charge (as observed with the 
formulations containing dibromocholesterol) is normally associated with increased stability (Casals 
et al., 2003). 
The negative charge also leads to greater repulsion between the vesicles; this would hinder caking 
and lead to a more diffuse and less compact sediment layer (Martin, 2003). The increase in 
sedimentation rate of the brominated vesicles in the first few hours could be of particular 
significance once applied to the ELISPOT assay to minimise leakage, until the liposome vesicles 
have reached the bottom of the well. For further studies the formulation of DPPC:Chol:BrChol at 
16:4:12 μMol (which were most effective by the four hour time point) were considered to be a 
promising formulation for further assessment alongside other neutral formulations. The enhanced 
sedimentation efficiency in the early stages of the assay may prove to be important. 
 
3.3.2.3 Dynamic viscosity data for the assessment of liposomal formulations 
The synthesis of the dibromocholesterol and its incorporation into liposome vesicles was 
considered to increase the density of the vesicles, however another factor controlling sedimentation 
according to Stokes’ law is viscosity (Banker and Rhodes, 2002). It was necessary to confirm 
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whether there were any differences in viscosity for both the formulations with and without 
brominated cholesterol (Table 3.4). The results confirmed that there was no significant difference 
in viscosity of MLV formulations not containing brominated cholesterol and a brominated 
formulations of (DPPC:Chol:BrChol 16:4:12 μMol), both of which were similar to the viscosity of 
water which is 1.0019 (Martin, 2003). 
Table 3.4 Viscosity of DPPC:Chol:BrChol 16:4:12 μMol and DPPC:CHOL 16:16 μMol liposome 
suspensions. Results represent mean ± SD of n =3 batches. 
 
As no significant difference were previously observed in the vesicle size between the non-
brominated and brominated samples (Figure 3.14), it can be concluded that the initial increase in 
sedimentation observed, according to Stokes’ law (Equation 3.3), can only be accounted for by the 
increased density of the liposomes.  
 
 3.3.3 BSA-FITC assay optimisation; spectral scans to establish optimal wavelengths 
Initially scans were carried out at the literature stated wavelengths of 492 nm for excitation as 
shown in Figure 3.19 (a) and 519 nm for the emission wavelength as shown in Figure 3.19 (b) 
(Chandaroy, 2001). The results showed a small wavelength difference between the two scans and 
by using a wavelength of 492 nm for excitation there would be a large overlap between excitation 
and emission. Therefore, to determine a more appropriate excitation wavelength to use in order to 
obtain a purer signal, a more precise spectral scan was carried out (Figure 3.20 a) from 450 nm to 
500 nm in increments of 5 nm.  
Lipid Composition Ratio of Lipids  
(μMol) 
Dynamic Viscosity 
(mPas) 
Kinetic Viscosity 
(mm
2
/s) 
DPPC:Chol 16:16 1.03 ± 0.03 0.94 ± 0.04 
DPPC:Chol :Brchol 16:4:12 1.07 ± 0.04 0.97 ± 0.05 
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Figure 3.19 Spectral scans for excitation and emission wavelengths for BSA-FITC; (a) The excitation wavelength spectra 
at 520nm (b) The emission wavelength spectra at 490nm. 
 
a 
b 
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Figure 3.20 Spectral scans for (a) excitation wavelengths from 470nm to 570nm and the (b) emission wavelength 
scanned from 470nm to 570nm, the lower line depicted is of PBS. 
 
 
a 
b 
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A wavelength was required which was lower than 492 nm, yet still high enough to be able to 
provide an appropriate signal for the assay (emission was fixed at 520 nm). Based on these scans, 
the selected excitation wavelength was 470 nm and confirmation was obtained of a clear emission 
signal through the final spectral scan (Figure 3.20 b).There are a number of factors which can affect 
the accuracy of fluorescent measurements and these can include instrumental variations (Birdsall et 
al., 1983).  
The difference between the excitation and emission wavelength is referred to as Stokes’ shift, if the 
shift is large there is less interference in the assay from incident light and the assay is more 
sensitive (Wild, 2001). Optimisation of the spectral scans is thus an essential aspect of the 
development of an assay and the spectral analysis has resulted in an appropriate excitation and 
emission wavelength (480 nm and 520 nm) respectively.  
 
3.3.3.1 Endpoint fluorescence assay to confirm chosen wavelength 
The concentration of the BSA-FITC to be used within the liposome preparations for entrapment 
was prepared at 5 µg/mL. A calibration curve was constructed from a serial dilution of the stock 
solution, the data points were plotted as a linear regression curve, and a trend line added (Figure 
3.21). The R
2 
value indicated the validity of the concentration curve. The calibration curve (Figure 
3.21) represents the average of three separate calibration graphs. The results show the 
demonstration of linearity by dilution of a standard stock solution. Visual inspection of the graph 
confirms this to be a linear relationship as a function of analyte concentration (Figure 3.21) and 
was further evaluated by calculation of a regression line and by the method of least squares as 
recommended by ICH guidelines (ICH, 2005).  
According to ICH guidelines (ICH, 2005) on the validation of analytical procedures demonstration 
of linearity, accuracy, precision, and reproducibility are required. Accuracy is defined as the 
closeness of agreement between the values, which is accepted either as a true value or from a 
reference value; the precision is the closeness of agreement between a series of obtained 
measurements. For a calibration curve the test results should be directly proportional to the 
concentration of an analyte. The guidelines specify that for the establishment of linearity a 
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minimum of 5 concentrations is recommended. For this study, 8 concentrations have been used 
(Figure 3.21). An appropriate range was used for the concentration curve as the maximum amount 
used of BSA-FITC per liposome formulation was 10 μg. The value of 1 for R2 indicates a perfectly 
linear relationship thus the obtained value of 0.99 indicates a good statistical fit (Freund et al., 
2006). Repeatability of the assay has also been shown as a minimum of 9 determinations covering 
the specified range; three replicates were run for the three assays. According to ICH guidelines 
(ICH, 2006) other aspects of the assay that should be validated include the limits of 
detection/quantification and the specificity of the assay.  
 
 
Figure 3.21 Calibration curve for BSA-FITC. Results represent mean ± SD of triplicate assays. 
 
3.3.3.2 Limits of detection and quantification 
The limit of detection is the lowest amount of analyte detected but not quantified and the limit of 
quantification is the lowest amount of analyte, which can be quantitatively determined. The limit of 
the detection calculated, from triplicate samples from three separate assays was 0.929 ± 0.05 
µg/mL and the limit of quantification was 2.015 ± 0.06 µg/mL.  
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3.3.3.3 Speed, time and frequency of centrifugation 
Subsequent to the production of the liposome formulations, it was essential for the precision of the 
assay to remove all unencapsulated material. The results obtained (Figure 3.22) confirmed that one 
centrifugation step at 29,771 g was sufficient to remove the fluorescent molecules. The remaining 
concentration after one centrifugation step was 0.74 ± 0.21 µg/mL, which was below the limits of 
quantification, specified previously (section 3.3.4.2). Subsequent centrifugation showed no further 
decrease in the levels of fluorescence, with no statistical difference between the levels of 
fluorescence after 30, 60 or 90 minutes of centrifugation (Figure 3.22). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Concentration of  BSA-FITC remaining in the supernatant subsequent to three steps of 
30 minutes of centrifugation for up to 90 minutes. Results represent mean ± SD of n =3 assays. 
 
The removal of unencapsulated material especially in the formulation of multilamellar vesicles was 
an essential part of establishing a methodology for analysis of encapsulated material. Previously 
used methods include separation by a gel filtration column as shown by Daleke et al., (1990) or 
dialysis and ultracentrifugation (Szoka et al., 1980). The results in Figure 3.22 show that effective 
removal of unencapsulated BSA-FITC was feasible. 
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3.3.3.4 Effects of lysis chemicals on the BSA-FITC concentration curve 
A lysis agent was required for the disruption of the liposomal vesicles in order to measure the 
amount of entrapped material and thus it was necessary to establish how the presence of the agent 
would interfere with any readings from the assay. Of the two lysis agents tested (isopropanol and 
Triton X; Figure 3.23), isopropanol was shown to significantly increase the measured fluorescence 
activity (p<0.05) whilst the presence of Triton X made no significant difference even at the higher 
concentrations of 5 μg/mL and 10 μg/mL. A good linearity of the assay was shown even in the 
presence of isopropanol and Triton X with R
2 
values similar to the normal calibration (0.9886, 
0.9991, and 0.9998 respectively).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 The effect of isopropanol and Triton X on the BSA-FITC fluorescence assay. Results 
represent the mean ± SD of triplicate assays. 
 
Based on the results obtained Triton X was chosen as a disruption agent for liposomes as it 
interfered the least with the assay as according to ICH guidelines the specificity is defined as the 
ability to assess unequivocally the analyte in the presence of components which maybe present 
upon analysis with Triton X this is possible (ICH, 2006). In addition, this non-ionic surfactant has 
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been used extensively for the purposes of liposome disruption (Urbaneja et al., 1988, Ruderman 
and Grigera, 1986, de la Maza and Parra, 1996).  
 
3.3.3.5 Determination of BSA-FITC release from liposomes 
Having optimised the various parameters of the assay, it was necessary to establish if BSA-FITC 
could be encapsulated within the liposomal formulations of DPPC:Chol 16:16 μMol and 
DPPC:Chol:BrChol 16:4:12 μMol and thus quantify the amount entrapped.  
 
 
 
 
 
 
 
 
 
 
Figure 3.24 The total recovery and entrapment of BSA-FITC (%) of DPPC:Chol 16:16 μMol and 
DPPC:Chol:Brchol 16:4:12 μMol preparations. Mean particle size of liposome formulations of 
DPPC:Chol 13.4 ± 5.26 µm and DPPC:Chol:Brchol 11.8 ± 3.1 µm. Results represent mean ± SD of 
n =3 batches. 
  
Protein entrapment for DPPC:Chol and DPPC:Chol:BrChol formulations were not significantly 
different (22.6 ± 2.25 % and 32.64 ± 1.91 % respectively; Figure 3.24) with total recovery of the 
protein being above 70 % in both cases. Studies by McWilliam and Stewart, (1989) using neutral 
liposomes (PC) for the encapsulation of protein have shown entrapment levels of up to 29 %, 
similar to levels observed in the results in Figure 3.24. However in the studies conducted by 
McAllister et al., (1999) the dehydration-rehydration method was used, which involves freeze 
drying empty liposomes and resuspending them with the protein in buffer, entrapment levels of up 
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to 45 % were observed. This method promotes higher entrapment due to morphological changes, 
which occur during the process of freezing and thawing of the liposomes and can result in 
increased aqueous volumes (Mayer et al., 1996). There is a wide array of methods available for the 
formulation of liposomes; the two aforementioned techniques are the dry film lipid hydration 
method and the dehydration-rehydration vesicles method. Other techniques include the reverse 
phase evaporation method in which liposomes are formed from water-in-oil emulsions using 
buffers and excess organic phase this is carried out under reduced pressure and have been found to 
have 4 times higher entrapment efficiencies as large unilamellar vesicles are formed (Szoka and 
Papahadjopoulos, 1978). The methods used for the formation of liposomes can impact upon the 
entrapment efficencies as generally MLV have low entrapment efficiencies which is thought to be 
due to the bilayers reducing the internal aqueous space (Szoka and Papahadjopoulos, 1978).  
 
In terms of the specific entrapment of rIFNγ there are also variations observed in literature in 
regards to entrapment effciencies. In a study by Slooten et al., (2001) neutral liposomes of PC 
prepared by the dry film hydration method and upon assessment for the entrapment of a cytokine 
showed very low entrapment efficiency at 5 %. Within these studies, the authors also observed that 
using liposomes with a more negative surface potential dramatically increased the entrapment 
efficiency. For instance for DPPC:DPPG which had a surface potential of -36 ± 6 mV showed 
entrapment efficiencies of 89 ± 1 %. In addition the higher observed entrapment by Slooten et al., 
(2001) of negatively charged liposomes was not observed in the results shown in this study (Figure 
3.24); even though the negative surface potential for the DPPC:Chol:BrChol was similar. The 
higher entrapment noted by Slooten et al., (2001) in their anionic liposomes may be a result of 
electrostatic interactions, if the protein was slightly cationic in nature. In addition to electrostatic 
interactions, higher entrapment efficiencies have been attributed to the inclusion of cholesterol 
within liposome formulations. For example, Panico et al., (1997) noted that tighter packing effects, 
promoted by cholesterol induced high (30-65 % depending on the protein) immunomodulatory 
protein entrapment in MLV composed of 10 mg lipid for DPPC and DPPC:Chol at 9:1 mg. In the 
results shown in this, study (Figure 3.24) there was no significant difference in the amount 
entrapped even with the inclusion of cholesterol. In another study using liposomes for the 
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entrapment of rIFNγ with the dry film hydration method, observed entrapment levels were 11 % 
but using a freeze-thaw method the IFNγ encapsulation increased to 29 % (Goldbach et al., 1999.)  
 
 3.3.3.6 Confocal Microscopy  
An important aspect of this study was to use light microscopy in order to confirm developments in 
vesicle formation, size and morphology. The inclusion of a fluorescent probe in the bilayer can aid 
visual observation of vesicles and highlight the upper limits of the size distribution (Szoka and 
Papahadjopoulos, 1980). It was evident from the images (Figure 3.25 a) that the liposome vesicles 
from a formulation of DPPC:Cholesterol 16:16 μMol were well-formed vesicles with generally, a 
spherical morphology (Figure 3.25 a). Furthermore, BSA-FITC can be seen entrapped within the 
internal aqueous core of the vesicles (Figure 3.25 b and c), with rhodamine being used as a bilayer 
marker. Liposome formulations of DPPC:Chol:BrChol at 16:4:12 μMol were made using BSA-
FITC at 5 µg/mL.  
To visualise the internal aqueous compartment and the bilayer simultaneously, an additional 
fluorescent marker (dilC at 0.2 mol % at probe:lipid molar ratio) was added to the lipids prior to 
rotary evaporation and observed on a Leica multiphoton confocal microscope using an 63 X oil 
objective (Fig 3.25 d - i). The images show BSA-FITC entrapped within well formed vesicles and 
the aqueous compartment.The use of fluorescence microscopy further enhances the information 
which was obtained from the more basic light microscopy images. Using mulitiple probes within 
the vesicles allows them to be distributed in the bilayer and, in this case BSA-FITC was shown to 
be within the aqueous phase apartment as would be expected and previously reported (Bouvrais et 
al., 2010).  
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Figure 3.25 Confocal microscopy pictures of DPPC:Chol:BrChol at 16:4:12 μMol liposomes (a-i) taken with a multiphoton Confocal Microscope using a 40 X 
objective. The lipid bilayer is shown by the red colour, and the internal aqueous compartment by the green fluorescent marker. A Zeiss Axiovert A1 and a 40 X 
objective were used for image (a) and a Leica confocal microscope for subsequent images. The green fluorescent marker shown is BSA-FITC and the red marker is 
the dye dilC for all images except (c) where Rhodamine was used.  
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Figure 3.26 (a)The construction of a 3D visualisation of a liposome using confocal microscopy of DPPC:Chol liposomes with the fluorescent marker Dilc added at 
0.2 mol %. Representative slices used for the construction of the 3D image are also shown (b – m). Aleica confocal microscope was used under a 40 X objective. 
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Figure 3.25 e and f show the full vesicle structure; this was carried out using confocal microscopy 
by taking numerous images; thus, a three-dimensional image can be built up of the vesicle. Image 
software can show each ‘slice’ from the vesicle and allow the rendered 3D projection to be 
visualised at 360 °C angles. An example of how this was achieved is shown in Figure 3.26, the 3D 
construction (Figure 3.26 a) of DPPC:Chol (16:16 μMol) liposomes was made using a number of z-
stacks taken of the liposome vesicles (Figure 3.26 b – m). This has been shown recently (Vequil- 
Suplicy et al., 2010) where giant unilamellar vesicles made of 1,2-dioleoyl-s-3-phosphn-glycero-
[1-rac-glycerol] sodium salt, egg sphingomyelin and cholesterol were observed using 3D 
projections and the fluorescent dye DilC18. Through microscopy the formation of lipid rafts was 
shown and how these are reduced when charged lipids are used. The images for the purposes of this 
study demonstrate the defined morphology and the successful encapsulation of protein marker 
within the liposomes for both neutral liposomes and the liposomes containing synthesised 
dibromocholesterol.  
 
3.3.4. Stability assessment of liposome formulations 
Subsequent to the synthesis of dibromocholesterol it was important to assess the stability of the 
liposome formulations thus a stability study was carried out assessing formulations of  DPPC 32 
μMol, DPPC:Chol 16:16 μMol and DPPC:Chol:BrChol 16:4:12 μMol. In this way the effects of 
placing the aqueous dispersions at 4 °C, 25 °C and 40 °C was observed by assessing the three 
physicochemical parameters of size, zeta potential and the size distribution of the vesicles (span). 
 
3.3.4.1 Stability of saturated lipids in liposome formulations 
In order to assess the impact of the presence of the dibromocholesterol formulations made up of the 
individual components were assessed thus in this instance DPPC formulations of 32 μMol. The 
study of stability at the three temperatures of 4 °C, 25 °C and 40 °C was carried out over 28 days. 
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Figure 3.27 Stability assessment of saturated phospholipids (DPPC 32 μMol) over 28 days at 4 °C, 
25 °C and 40 °C. Measurements were taken of (a) Size (μm) and (b) zeta potential (mV) and (c) 
span measurements at Day 0, 1, 4, 7, 14 and 28. Results represent mean ± SD of n =3 batches. 
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In this study, DPPC 32 μMol formulations were assessed for variations in size, zeta potential and 
span (Figure 3.27 a-c), there was no statistical significance across the assessed parameters over the 
28 days even at 40
o
C. DPPC is a commonly used phospholipid  and is known to exhibit greater 
stability and less leakage over a range of temperatures due to the relatively higher transition 
temperature (Tc) of the synthetic phospholipid of 41°C (Chen et al., 2010). DPPC is a saturated 
phospholipid and is thus more stable than the unsaturated counterparts, which are more susceptible 
to oxidation (which take place via a free radical chain mechanism) (Grit and Crommelin, 1993).  
As the storage conditions assessed were not above the transition temperature of the lipid, the 
liposomes were stable over the 28 day study although neutral liposomes normally have a tendency 
to aggregate this was not observed in the results obtained (Casals et al., 2003). The results observed 
(Figure 3.27) highlight that the single lipid component of DPPC 32 μMol forms stable liposomes 
and even in conditions of accelerated stability testing at 40 °C were able to remain stable as 
indicated by the physicochemical characterisation results.  
 
3.3.4.2 Stability of saturated lipids with the inclusion of cholesterol 
Stability assessments of aqueous liposome formulations of DPPC were previously assessed and 
shown to be stable, however the inclusion of cholesterol for the stability of the vesicles was 
necessary. Similarly, assessments were made of size, surface potential and size distribution over 28 
days at defined time points. DPPC:Chol (16:16 μMol) formulations exhibited stability in regards to 
size and zeta potential over the 28 day period of the study (Figure 3.28 a and Figure 3.28 b) and 
there was no significant difference observed at any stage. In terms of the size distribution, the span 
was lower at day 7 for 40 °C and thus when compared to the other time points had a significant 
difference (p<0.01) although when comparing the span from day 0 to 28 there was no significant 
difference for any of the temperatures assessed in the study (Figure 3.28 c). The observed stability 
assessment (Figure 3.28) that combined an unsaturated lipid (DPPC) with cholesterol in equimolar 
ratio exhibited stability over the 28 day study.  
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Figure 3.27 (a) Size (μm) and  (b)zeta potential (mV) and (c) Span measurements for DPPC:Chol 16 
μMol: 16 µMol 
Figure 3.28 Stability assessment of saturated phospholipids with cholesterol (DPPC:Chol 16:16 
μMol) over 28 days at 4 °C, 25 °C and 40 °C. Measurements were taken of  (a) Size (μm) and  (b) 
zeta potential (mV) and (c) span measurements at Day 0, 1, 4, 7, 14 and 28. Results represent mean 
± SD of n =3 batches. 
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This data concurs with the findings found within literature on the stability of liposomal membranes 
with the inclusion of cholesterol; an amount of 33 % mole ratio is sufficient to eliminate the 
transition temperature (Szoka and Papahadjopoulos, 1980). Cholesterol alters the fluidic nature of 
the membrane and its behaviour in the liposome membrane is dependent upon the temperature of 
the surrounding environment (Chen et al., 2010). Below the Tm it is thought to contribute to the 
disorder of the gel state however above the Tm it is able to enhance the stability of the liquid state 
and thus reduce membrane permeability (Chen et al., 2010). Other studies have shown that 
phosphatidylcholine liposomes containing high concentrations of cholesterol were stable at 4 °C 
for several days and even by 53 days their stability had only declined moderately (Kirby et al., 
1980). Sulkowski et al., (2005) found using NMR 
31
P analysis that when cholesterol is present the 
structural changes in the bilayer decrease with increasing temperature whereas higher membrane 
fluidity is observed for formulations of DPPC alone. Although in the observed results in this study 
liposome formulations of DPPC were as stable as those containing cholesterol. In relation to 
producing stable reference standards in can be seen that the inclusion of cholesterol and lipids with 
transition temperatures above 40 °C allow enhanced stability of liposomal formulations; however 
the challenge lies in balancing the need for effective release and stability upon storage.  
 
3.3.4.3 Stability of formulations containing the synthesised brominated cholesterol   
Subsequent to the synthesis of brominated cholesterol and inclusion within liposomal bilayer many 
parameters were assessed including: physicochemical characterisation of size and zeta potential, 
vesicle morphology through microscopy techniques, sedimentation efficiency and the ability to 
encapsulate a protein marker. The studies thus far had shown that DPPC formulations with lipid 
alone and those formulations containing cholesterol were stable at 4 °C, 25 °C and 40 °C. It was 
important to assess the impact of the inclusion of dibromocholesterol under the same conditions.  
Therfore liposome formulations of  DPPC:Chol:BrChol 16:4:12 μMol were placed at 4 °C, 25 °C 
and 40 °C in stability cabinets over 28 days. 
In terms of vesicle size (Figure 3.29 a ), at 4 °C and 25 °C there was no significant difference in 
size when comparing the formulations from day 0 to day 28 although there were some fluctuations 
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over the time points, the general trend suggests liposomes were stable over the 28 day period 
(Figure 3.29 a). However, at 40 °C there was a significant (p<0.05) increase in the size of the 
formulation after only 1 day with vesicle size increasing from (10.95 ± 0.64 µm) to (13.3 ± 0.93 
µm) respectively. At this elevated temperature, on storage the vesicle size continued to increase by 
day 7 to 18.37 ± 1.06 µm (Figure 3.29 a). This instability of vesicles at higher temperature storage 
was also noted by light microscopy (Figure 3.29). By day 7 that there were instances of complete 
vesicle disintegration and fusion, thus any stability data would have been inaccurate and the study 
at this temperature was terminated at this point for size, span and zeta potential although light 
microscopy images were taken until the termination point at day 28 of the study.   
In terms of zeta potential (Figure 3.29 b) by the first day there was no significant difference in 
surface charge under any of the storage conditions. The surface potential was significantly different 
(p<0.05) by day 4 and 7 when compared to day 0 at 40 °C changing from -51.27 ± 7.14 mV to        
-76.37 ± 1.06 mV. At 4 °C and 28 °C there were no significant differences observed over the 28 
days. There were also no significant changes to the span over the 28 day study. The light 
microscopy images confirmed the pattern in stability which was observed from the particle size 
data  (Figure 3.30) with vesicles at 4°C retaining shape and morphology and at 25 °C some 
morphological changes became apparent (at the day 14 timepoint). At 40 °C evidence of 
degradation was visible (Figure 3.30).  
Electron microscopy images of the formulations were also shown comparing the formulation at day 
0 to the formulations at 4°C, 25°C and 40°C at day 18 (Figure 3.31). The multilamellar nature of 
the bilayer was clearly evident from the formulation at day 0 and the fractured planes clearly show 
the individual bilayers (Figure 3.31 a - c). However an assessment of the formulations at day 18 
indicates that bilayer fusion at 25 °C and 40 °C, although the vesicle itself seems to have 
maintained shape in some instances (Figure 3.31 h), there seems to be a lack of an internal aqueous 
compartments suggesting collapse of the bilayers (Figure 3.31 j - l).  
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Figure 3.29 Stability assessment of liposome formulations containing brominated cholesterol 
(DPPC:Chol:BrChol 16:4:12 μMol ) over 28 days at 4 °C, 25 °C and 40 °C. Measurements were 
taken of (a) Size (μm) and (b) zeta potential (mV) and (c) span measurements at Day 0, 1, 4, 7, 14 
and 28. Results represent mean ± SD of n =3 batches. 
 
Particle size variation, chemical stability, and leakage have proven to present problems during the 
long-term storage of liposomes (Crommelin and Brommel, 1984). The formulations tested of 
DPPC:Chol:BrChol 16:4:12 μMol had a strong negative zeta potential, and this is normally 
associated with increased stability of colloidal particles as they can remain dispersed. The zeta 
-110
-90
-70
-50
-30
-10
10
30
50
0 5 10 15 20 25 30
Time (Days) 
4°C Size (μm) 
25°C Size (μm) 
40°C Size (μm) 
0
0.5
1
1.5
2
2.5
3
3.5
4
0 5 10 15 20 25 30
Sp
an
 
Time (Days) 
4°C Span
25°C Span
40°C Span
a 
b 
c 
153 
 
potential of the formulations was -50 mV at day 0 and became more negative over the duration of 
the study, thus by this definition is considered to depict good stability (Plessis et al., 1996). The 
variations observed in size of the aqueous formulations compares to those observed in literature 
wherein increases in the mean volume diameter have been observed at 4 °C and 25 °C of neutral 
and charged liposomes, and similarly instability is enhanced at higher storage temperatures (Plessis 
et al., 1996). These observations are confirmed by Pahadjopoulos and Szoka, (1980), who 
comment that the retention of encapsulated material in terms of the storage of liposomes was 
optimal at 4 °C, and then 25 °C and 40 °C.  
 Such observations compare well to the results obtained in this study, which show that at 4 °C the 
changes to the physicochemical parameters assessed were reduced, and showed that storage was 
possible at 4 °C for a limited time (Figure 3.27, 3.28 and 3.29). At the higher temperatures, there 
was qualitative evidence of the impact of increased temperature on the changing morphology of the 
vesicles from light microscopy. Such effects can be attributed to the acyl lipid chains as they are 
susceptible to oxidation and more so in the presence of other factors (such as trace amounts of 
transition metal ions or radiation) and can lead to changes in the bilayer and also hydrolysis of the 
phospholipids catalysed by acids and bases (Mohammed et al., 2006). The formulations containing 
DPPC alone or DPPC with equimolar cholesterol were stable although the inclusion of the 
dibromocholesterol did affect the stability of the liposomes at the higher temperature of 40 °C 
(Figure 3.29). 
This was particularly evident through both the light and electron microscopy images (Figure 3.30 
and Figure 3.31). The electron freeze-fracture technique can elucidate the effects that are occurring 
at a bilayer level and have shown the fusion of the bilayers for the vesicles at the higher storage 
temperatures (Meyer, 2001). The stability study was terminated at day 7 for those formulations at 
40°C, as the physicochemical characterisation data of size and zeta potential in conjunction with 
the microscopy showed that aggregation and collapse of the vesicles had occurred.  
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Figure 3.30 Representative light microscopy images taken throughout the duration of the stability study from formulations containing brominated cholesterol 
(DPPC:Chol:BrChol 16:4:12 μMol). Images were taken of formulations at 4 °C, 25 °C and 40 °C at Day 0, 1, 4, 7,  14 and 28.  
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Figure 3.31 Freeze fracture electron micrographs of DPPC:Chol:BrChol 16:4:12 μMol at day 0 
with formulations from day 18 at 4 °C at 25 °C  and 40 °C. 
 
Thus, overall the results have confirmed that liposomes as a carrier are stable with neutral lipids 
such as DPPC and with the inclusion of cholesterol, although the formulations of 
DPPC:Chol:Brchol were not as stable at the higher temperature of 40 °C. How stability impacts on 
the effectiveness of these formulations within the ELISPOT assay is not necessarily evident from 
this data, as a formulation is required that will rapidly sediment then release the cytokine 
entrapped, thus whilst it may seem a negative characteristic for the formulations to be unstable this 
may not be the case for this application. Protein retention was not assessed as a part of this study as 
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a wide range of liposomal compositions need to be tested within the ELISPOT assay to confirm 
which formulations are best suited in terms of release characteristics. For instance DPPC:Chol 
liposomes may have the ability to retain the protein well due to their stable nature; however this 
may not translate into effective spot formation, as the kinetics of release is an important factor 
within the assay (Lehmann, 2005). It is also of note that the formulations are placed directly on the 
ELISPOT assay overnight once hydrated, thus long-term stability of the aqueous formulations may 
not be necessary. The long-term storage of liposomes would require lyophilisation (freeze-drying) 
and the presence of cryoprotectants (Mohammed et al., 2006).  
 
3.3.5 Size Separation of liposome formulations using centrifugation, density gradients, and 
filtration 
Previous work carried out has included the assessment of the sedimentation of liposome 
formulations subsequent to the incorporation of synthesised dibromocholesterol to increase the 
density of vesicles. However, the thin-film hydration method (Bangham et al., 1969) used in the 
protocol because it one of the simplest methods, produces a heterogenous population of 
multilamellar vesicles whose size range can vary widely (Sharma et al., 1997). Thus, various 
methods including; centrifugation, density gradients, and filtration techniques were investigated in 
order to remove some of the smaller vesicles that may lead to increased background with an 
ELISPOT assay if they are unable to settle to the bottom of the well and produce spots. 
 
3.3.5.1 Variation of centrifugation speed and time  
For the purposes of the removal of smaller vesicles, the basic technique of centrifugation was 
investigated. Formulations of DPPC:Chol:BrChol 16:4:12 μMol were subjected to five and ten 
minutes of centrifugation at speeds of 51 g, 115 g and 205 g (Figure 3.32 and Figure 3.33). After 
removal of the supernatant, the pellets were re-suspended in PBS. Formulations were characterised 
for size and span prior to and subsequent to centrifugation. The cumulative size distribution curves 
were also assessed to elucidate any shift of the curve subsequent to centrifugation (Figure 3.32 b, c, 
d and Figure 3.33 b, c, d).  
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At the centrifugation speed of 51 g, there was a significant (p<0.001) increase in the size of the 
formulation after centrifugation for both five (Figure 3.31) and ten minutes (Figure 3.33). The 
initial size of the formulations prior to centrifugation at five and ten minutes were 10.64 ± 0.30 µm 
and 7.91 ± 0.41 µm respectively and subsequent to 5 and 10 minutes centrifugation at 51 g this 
increased to 16.14  ± 0.51 µm and 11.44 ± 0.65 µm respectively (Figure 3.32 a and Figure 3.33. At 
the higher speeds of 115 g, again after five minutes there was a significant (p<0.05) increase in size 
when compared to the formulation prior to centrifugation (from 10.64 ± 0.30 µm to 12.78 ± 0.67; 
Figure 3.32). However, this was not the case for centrifugation after 10 minutes at 51 g, when 
comparing the size of the formulation prior to centrifugation no significant difference was 
observed. At 205 g there were no significant changes in the size observed at either five of ten 
minutes of centrifugation, similarly there were no other significant changes to the span (Figure 3.32 
c and Figure 3.33 c).  
The heterogeneity of the liposomal formulation significantly (p<0.01) decreased at the slowest 
centrifugation speed of 51 g at 5 minutes with an observed change in span value of the formulation 
prior to centrifugation at 1.74 ± 0.04, which decreased to 1.44 ± 0.04. This change is also visible 
from the overlaid cumulative distribution curves shown in Figure 3.32 b. At the higher 
centrifugation speed of 115 g and 205 g there was no significant difference in the span from the 
formulation prior to centrifugation. At ten minutes of centrifugation at 51 g, 115 g and 205 g there 
was no significant changes in the span data. The results indicate that the use of slower speeds does 
result in the pelleting of larger vesicles hence the observed increase in size however as the 
centrifugal pressure is increase on the formulation more of the smaller vesicles also become 
pelleted. The data obtained for centrifugation at five minutes (Figure 3.32) supports this in terms of 
particle size and span data however when centrifuging for  the slightly longer time of ten minutes a 
significant increase in size was observed at the slower speed although  this was not evident from 
the span data.  
There have been various techniques previously investigated for the very purpose of size separation 
of liposomes, one such technique was size exclusion chromatography in particular the use of 
sepharose chromatography for the separation of MLV from SUV liposomes (Lundahl et al., 1999).  
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Figure 3.32 (a) Size and span data for formulations for formulations of DPPC:Chol:BrChol (16:4:12 μMol) after five minutes of centrifugation at with 
cumulative size distribution curves for n=3 for the corresponding speeds (b) 51 g, (c) 155 g and (d) 205 g overlaid with formulations prior to 
centrifugation. Results represent mean ± SD of n =3 batches. 
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Figure 3.33 (a) Size and span for formulations for formulations of DPPC:Chol:BrChol (16:4:12 μMol) after ten minutes of centrifugation with 
cumulative size distribution curves for the corresponding speeds (b) 51 g, (c) 155 g and (d) 205 g overlaid with formulations prior to centrifugation. 
Results represent mean ± SD of n =3 batches. 
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However, one of the major disadvantages observed with such chromatographic techniques was the 
loss of formulation through the process itself, which in some studies has been as high as 40 %; with 
losses attributed to adsorption of liposomes to the gel matrices and physical blocking of the gel 
pores (Huang, 1969, Szoka and Papahadjopoulos, 1980). For the purposes of this project, the 
liposomes are essentially artificial cells and thus techniques focused upon were those ordinarily 
applicable for cell-based work, such as centrifugation (Alberts et al., 2008). The use of 
centrifugation for the isolation of a size population from a polydisperse batch is a technique that 
can be carried out with relative ease (Gaumet et al., 2007). In addition, the separation of MLV from 
SUV liposomes has been previously demonstrated using centrifugation at speeds of 100,000 g and 
159,000 g as discussed by Szoka and Papahadjopoulos, (1980). If such high speeds are able to 
remove smaller vesicles then the protocol in place for the removal of unentrapped BSA-FITC used 
previously (section 3.3.4.3) would to some extent already be removing some of the smaller 
particles. The results from this centrifugation study indicated that it was possible to further enhance 
the removal of smaller vesicles and utilise centrifugation for the separation of smaller particles in 
the formulation; however, this required a short centrifugation time and a slow speed for the effect 
to be evident in particle size data. 
 
3.3.5.2 Sucrose density gradients in conjunction with centrifugation  
Subsequent to the use of centrifugation as a means to separate liposome formulations, an 
assessment was made of the use of sucrose density gradients in conjunction with centrifugation. 
Thus, initially a range of sucrose density gradients were assessed 10% w/v, 20% w/v, 40% w/v, 
60% w/v an 80% w/v at 2660 g for 30 minutes (Figure 3.34). Then the combination of a heavy and 
light sucrose density gradient made up from 20% w/v and 80% w/v were also assessed at the 
centrifugation speed of 2660 g for 30 minutes (Figure 3.35). Three liposome formulations of 
DPPC:Chol:Brchol were produced 16:4:12 μMol and were initially characterised for size (µm) and 
zeta potential (mV). The average size of the formulations (n=3) was 9.1 ± 0.32 µm and the average 
zeta potential was -37.5 ± 3.9 mV. For the initial investigations a wide range of concentrations of 
sucrose were used at 2660 g in order to fractionate them into bands of various sizes; however, it 
was found that only two distinct bands formed. 
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Removed liposomes from each band underwent analysis for particle size and size distribution 
(Figure 3.34). There was no significant difference in the mean particle size of the two populations 
observed. There was however, a significant difference (p<0.05) in the span when comparing the 
formulations prior to centrifugation with those obtained in the upper and lower layer (this was 2.19 
± 0.17 to 1.71 ± 0.20 and 1.69 ± 0.08 respectively). Thus, there was an impact upon the 
heterogeneity of the formulation but not upon the particle size (Figure 3.34). In the separation of 
individual cell types from whole blood density gradients are ubiquitously used in particular two 
density gradients (Histopaque 1077 and Histopaque 1119); when the whole blood is layered on to 
the top of the two density gradients, and subjected to centrifugation cells will separate into different 
bands (Slifkin and Cumbie, 1992). As this work inherently involves viewing the liposomes as cells 
the same principle was applied to the liposome formulations and a 20% w/v and 80% w/v solution 
of sucrose was used (Figure 3.34). However, upon assessment of particle size and span, there was 
no significant difference in the liposomes obtained in the two obtained bands (Figure 3.35).  
The investigative work on density gradients was not successful for the size separation of liposomal 
vesicles. One of the reasons for this difficulty was the lack of density difference between the 
liposome vesicles. For density gradients to be successful, the particles must separate due to the 
differences in sedimentation rate, determined by size, shape, and density (Sanchez-Lopez et al., 
2009). The fractionation of small unilamellar vesicles has been shown previously using glycerol 
density gradients at 19% v/v and 22% v/v by centrifugation at 45,000 rpm for 14 hours 
(Goormaghtigh and Scarborough, 1986). It was not practical to have a method, which would 
involve this duration of centrifugation as this could affect the stability of the entrapped cytokine. In 
addition, such a precise level of separation of very small vesicles was not required. The use of 
reduced viscosities of sucrose may aid the fractionation process (Goormaghtigh and Scarborough, 
1986). According to Stokes law sedimentation rate is affected by viscosity, settling is reduced by 
the increase in viscosity (Troy, 2006). Thus in the subsequent investigations reduced concentrations 
of sucrose were used and assessed at a short and longer time points. 
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Figure 3.34 Size (µm) and span data for liposome 
formulations fractionated using sucrose density gradients at 
10, 20, 40, 60 and 80% (w/v) sucrose. Results represent 
mean ± SD of n =3 batches. 
.  
 
Figure 3.35 Size (µm) and span data for liposome 
formulations fractionated using sucrose density gradients at 20 
% and   80% (w/v) sucrose. Results represent mean ± SD of n 
=3 batches. 
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3.3.5.3 The use of low viscosity, sucrose density gradients for the size separation of liposomes 
To assess the effect of lower viscosity density gradients for the size separation of liposomal 
formulations with centrifugation, density gradients were prepared at 5, 15, 25 and 35% w/v with 
sucrose and centrifuged at 1) 2660 g at 30 minutes and 2) 434,902 g for 3 hours. 
The formulations of DPPC:Chol:Brchol were produced 16:4:12 μMol were characterised for size 
and size distribution. When the lower viscosity density gradients were centrifuged with the 
liposomal formulations at 2660 g for thirty minutes (Figure 3.36),  there was a significant 
difference in the span (p<0.05) and a significant difference in the size (p<0.01). When comparing 
the formulations prior to centrifugation to the upper layer separated band after centrifugation; the 
size increased from 9.20 ± 0.24 µm to 12.91 ± 0.29 µm and the span from 2.10  ± 0.14 to 1.65 ± 
0.13 (Figure 3.36). There was no significant difference in size observed when the original 
formulation was compared to the particles in the lower band. The shift in the cumulative size 
distribution curves elucidates the change in size and span qualitatively (Figure 3.36 b). The 
cumulative size distribution curves of the lower band showed very little difference compared to the 
formulation prior to centrifugation (Figure 3.36 c). The effect of increased centrifugation time to 3 
hours using the same density gradients (Figure 3.37) resulted in no significant difference in size by 
increasing the speed to 434, 902 g. In fact the band separation was not as clear. 
These results (Figure 3.36) indicate that it is possible to significantly change the particle size and 
size distribution of a heterogeneous formulation by the removal of smaller vesicles using density 
gradient centrifugation through the optimisation of the speed, time and selection of density 
gradients. Although the upper band had the larger particle size, this was contradictory to that which 
is normally expected. An explanation could be due to the complexity of sedimentation of charged 
colloidal particles in viscous solutions. Chiu et al., (2012) comments that the effect of the electrical 
double layer surrounding each charged particle can distort the ﬂuid ﬂow relative to the particle and 
this causes the induction of a sedimentation/migration potential. Thus, the anionic nature of the 
vesicles (Figure 3.14) may have affected the sedimentation velocity of the liposome vesicles.  
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Figure 3.36 The characterisation of liposome formulations for size from obtained fractions 
subsequent to centrifugation  (2660 g for 30 minutes) with density gradients at 5, 15, 25 and 35%  
sucrose (w/v). Results are shown for (a) mean particle size (µm) and span (b) Cumulative size 
distribution curves for the upper and (c) lower band. Results represent mean ± SD of n =3 batches. 
 
 
 
 
 
a 
b c 
165 
 
.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37 Size measurements for obtained fractions of liposome formulations subsequent to 
centrifugation  (2660 g for 3 hours) with density gradients at 5, 15, 25 and 35% w/v. Results are 
shown for (a) mean particle size (µm) and span  (b) Cumulative size distribution curves for the 
upper and (c) lower band. Results represent mean ± SD of n =3 batches. 
 
By using sucrose density gradients in conjunction with centrifugation similarly to chromatographic 
techniques of separation there is contact of the vesicles with the matrix which was sucrose in this 
case, Stokes’ law of sedimentation does not take into consideration any potential interactions or 
affinity of the vesicles with the dispersion medium (Banker and Rhodes, 2002). Thus the anionic 
nature of the vesicles with the presence of the sucrose brings additional parameters that effect the 
sedimentation rate. An additional aspect not considered within this study was actual recovery. In 
future work consideration of quantification of recovered formulations would be required. The 
recovery would affect the overall effectiveness of such techniques for the production of reference 
standards on an industrial scale. In addition, unlike centrifugation without density gradients, there 
are additional preparative steps that need to be carried out prior to and subsequent to centrifugation. 
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3.3.5.4. Use of a biosieve filter for the size separation of liposomes 
Subsequent to investigation of centrifugation and density gradients, another technique assessed was 
filtration and whether it could be used for basic size separation of liposomes. Three batches of 
DPPC:Chol:BrChol were produced (16:4:12 μMol) of an average size of 10.6 ± 0.3 µm and the 
average zeta potential was -28.8 ± 2.1 mV (data not shown). The formulations were placed through 
the top of a filtration system using a mild vacuum and were subsequently collected from both above 
and below the filter. The change in size from the original liposome formulation (Figure 3.38) to 
those liposomes recovered from the top of the filter was significant (p <0.05) changing from 10.94 ± 
0.75 µm to 14.17 ± 1.55 µm and the decrease in the span from 1.94 ± 0.66 to 1.27 ± 0.14 was highly 
significant (p<0.001).  
The microscopy pictures (Figure 3.38 a-c) of the formulations collected above and below the filter 
show the presence of a few vesicles in the upper filtrate this suggests that the pore size was maybe 
slightly too large. However, if this was the case more would have been expected in the lower filtrate 
this suggested that the recovery from the filter is ineffective. 
Filtration techniques have been previously used with aim of the removal of larger particles from 
liposomal formulations or for extrusion purposes to produce a more homogenous population of 
smaller vesicles (Szoka and Papahadjopoulos, 1980, Vemuri and Rhodes, 1995). Such techniques 
have also been used within the field of cellular work, although perhaps not as ubiquitously as 
centrifugation for the removal of cellular debris (Allegraza, 2008). Membrane microﬁltration is used 
within the biological processing industry for the separation of particles in the size range of 0.1–
10µm (Cláudia Sousa et al., 2002). Thus, the application of filtration systems were considered for 
heterogenous liposome formulations and although it proved promising in the ability to produce a 
significant chance in the particle size; the inefficiency to actually keep all particles above this size 
on top of the filter is a significant drawback. The significant increase in size and the decrease in span 
although promising would need to be offset with a good recovery otherwise would not be cost 
effective especially for industry-based production of a reference standard. 
 
167 
 
 
0
1
2
3
4
0
2
4
6
8
10
12
14
16
18
Prior to filtration Below filter Above Filter
Sp
an
 
Si
ze
 µ
m
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38 The effects on morphology and particle size of filtration on liposomes using a biosieve. 
Microscope pictures of original formulations (a) and upper (b) and bottom filtrate (c), with span and 
size data for formulations prior to and subsequent to filtration with a biosieve and (e) Cumulative 
size distribution curves. Results represent mean ± SD n=3 batches. 
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The problem of adsorption of vesicles to the membranes of the filters themselves has also been 
previously observed (Szoka and Papahadjopoulos, 1980). Such results highlight the importance of 
recovery and how this was highlighted through light microscopy, thus there would need to be 
careful consideration of the effectiveness and efficiency of techniques.  
 
3.3.5.5 Filtration using polycarbonate filters of 3μm and 1.2 μm pore size for the size separation of 
liposomal formulations 
As previously three liposome batches of DPPC:Chol:BrChol were produced 16:4:12 μMol these 
were initially characterised for size (µm) and zeta potential (mV). The average size of the 
formulations (n=3) was 8.25 ± 0.5 µm and the average zeta potential was -32.0 ± 7.8 mV (results 
not shown). Although the light microscope images suggested that the liposomal formulations 
filtered through the polycarbonate filters of 3 µm and 1.2 µm had become smaller (Figure 3.39 a – 
c and Figure 3.40 a –c) after the filtration process there was no statistically significant difference 
either in the particle size data nor the size distribution (Figure 3.39 d and Figure 3.40 d). 
 Polycarbonate filters are generally used for the process of producing a homogenous population of 
smaller vesicles when they are pushed through such filters under pressure using an extruder 
(Endruschat and Henschke, 2000; Vemuri and Rhodes, 1995); the results suggest that the aim of 
retaining the larger particles above the filter was not achieved. One of the reasons why size 
separation was not achieved is that liposomes are not solid particles but are made from flexible 
lipid membranes that can be easily deformed upon passing through narrow pores or can be 
excluded from larger ones (Lundahl et al., 1999). The results suggest that polycarbonate filters 
would perhaps be more suitable for obtaining smaller size populations as shown through the 
previous studies in which they have been used.      
Overall, the techniques assessed for the size separation of liposomes have highlighted how such 
simple vesicles in terms of structure are in fact quite difficult to separate in terms of size. This is 
due to the many factors that can impact on the effectiveness of such techniques especially as 
liposomal interaction with membranes or matrix can affect recovery, thus perhaps the use of 
centrifugation is the most practical technique for the purposes of this work. 
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Figure 3.39 The effects on morphology and particle size of filtration 
using a 3 µm polycarbonate filter on DPPC:Chol:Brchol formulations. 
Bright field microscopy images (a) prior to centrifugation (b) liposomes 
below the filter and (c) above the filter. Size (µm) and Span (d) data prior 
to and subsequent to filtration. Results represent mean ± SD of n =3. 
batches. 
 
 
Figure 3.40 The effects on morphology and particle size of filtration 
using a 1.2 µm polycarbonate filter on DPPC:Chol:Brchol formulations . 
Bright field microscopy images (a) prior to centrifugation (b) liposomes 
below the filter and (c) above the filter. Size (µm) and Span data (d) 
prior to and subsequent to filtration. Results represent mean ± SD of n =3 
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3.4 Conclusion  
 
Although fluorescence assays are well established it was important to validate the various aspects 
of the assay and method to be used for the measurement of entrapment and release from liposomes. 
Thus, the protocol developed offers a good basic screening assay for liposome formulations 
developed to measure release characteristics. Brominated cholesterol was synthesised and 
characterised thoroughly to reveal the modification had taken place, this was carried out through a 
wide variety of techniques including; TLC, 
13
C NMR, 
1
H NMR and  IR spectroscopy. Stability 
testing on brominated cholesterol stored for six months established that it remained stable and there 
was no degradation. The sedimentation studies have elucidated the behaviour of liposomes in terms 
of their ability to settle; the results have shown that the presence of small vesicles in an SUV 
formulation tend not to settle. Thus, the size of the vesicles was shown to be related to their density 
and attempts made to increase the overall density by the addition of brominated cholesterol were 
complicated by the negative zeta potential of the formulations. Therefore the formulation 
containing a lower ratio of brominated cholesterol (DPPC:Chol:BrChol 16:4:12 μMol) of the total 
cholesterol content may provide more optimal sedimentation characteristics for future work. 
However, the microscopy images have elucidated that vesicles with or without the modified 
cholesterol are successfully able to encapsulate a marker and should therefore theoretically entrap 
the cytokine. 
The results for size separation have clearly elucidated the difficulties in the separation of liposomes 
of different sizes. A mixture of cells such as whole blood can be quite effectively separated using 
centrifugation and density gradients because of the difference in density of the individual 
components. However, although the liposome formulations have a wide range in size from less 
than 1μm to greater than 10 µm the actual difference in density between each vesicle is much 
smaller. The results from the filtration in general suggest that if any of the techniques have shown 
promise for further optimisation it is filtration with the biosieve; however, the size of the pore is 5 
µm and this is the minimum attainable for this type of filter. At this stage the inefficiency of 
keeping all the particles above this size on top of the filter is another drawback. This initial 
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screening is useful because at this stage it may be sufficient to use centrifugation for short time 
periods and low speeds; as a means of removing many of the smaller vesicles. The use of density 
gradients had some promising results with lower viscosities of sucrose. The density gradients at 5, 
15, 25 and 35 % w/v sucrose show a greater level of separation of the small and larger particles 
than the sucrose density gradients of higher viscosities. It remains a relatively simple technique 
with minimal effect on the vesicles thus there is further scope for optimisation.  
 The overall aim of such preliminary investigations was to circumvent issues, which may arise as a 
result of the structural differences between liposomes and cells; as the ideal scenario for the 
reference standards is for them to rest at the bottom of the plate and then release. The size of the 
spots are on average between 30 µm to 150 µm  (Janetzki et al., 2004)  and yet the liposome 
vesicles as MLVs will be on average approximately 10 µm however they will solely contain the 
cytokine. The real challenge of this project will be fine tuning the kinetics of release, if the release 
is too rapid it can produce ‘large, fuzzy spots’ and if it is too slow and steady it will result in 
‘smaller, denser spots’ (Lehman, 2005). 
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Interferon γ containing liposomes in conjunction with trigger 
release mechanisms for use within an ELISPOT assay 
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4.1 Introduction 
Interferon γ is a cytokine that displays immunomodulatory, antiviral, and antiproliferative effects 
(Goldbach et al., 1995). It plays an important role in the destruction of invading microorganisms 
and has thus in many previous studies thought to be an effective therapeutic agent which could be 
encapsulated within liposomes to protect it from in vivo degradation (Christian and Hunter, 2012).  
 
4.1.1 The challenges of using Interferon γ in liposomes 
The challenge of this study was not only incorporating the cytokine within the liposomes, but also 
in retaining sufficient activity to produce a robust reference standard for use within an in vitro 
immunoassay. In previous studies, the rIFNγ used within liposomes was in the recombinant form 
(Anderson et al., 1981). There are important differences in the IFNγ in its natural form and that of 
the recombinant form which is isolated from E.Coli cells (Curling et al., 1990). Human interferon γ 
(Figure 4.1) contains only one tryptophan amino acid, consisting of 143 amino acids in total 
including two n-glycosylation sites and 28 lysine and arginine residues whereas the E.Coli derived 
rIFNγ is not glycosylated and contains an extra methionine residue (Farrar and Schreiber, 1993, 
Döbeli et al., 1988).  
 
 
 
 
 
Figure 4.1  Computer model of  human IFN γ. 
The recombinant interferon is less stable in solution and has the tendency to aggregate (Christova 
et al., 2003). rIFNγ is an unstable protein demonstrated by previous studies in which inactivation 
occurred through the formulation process of the liposomes (Ishihara et al., 1990). The absorption of 
174 
 
the protein can also occur at liquid-solid interfaces and thus there are many challenges to ensure the 
effective encapsulation of the cytokine into the liposomes (Goldbach et al., 1995). However, 
successful formulations of liposomes containing rIFNγ, even with single lipid components such as 
DMPC for in vitro or in vivo purposes have previously been demonstrated (Anderson et al., 1994). 
Thus establishing the effects of the formulation process on the cytokine is an important aspect in 
the assessment of the feasibility of using the cytokine within liposomes in the ELISPOT assay. 
 
4.1.2 Controlling the release from liposomal formulations 
It is well established that liposomes can release their contents in a gradual and sustained manner, 
(Saravolac et al., 1996). The challenge of this study lies with optimising a release pattern so that it 
is similar to that of the cells and the way in which they secrete cytokines. The stability of the 
liposomal membrane in terms of the mechanical strength and its ability to act as a permeable 
barrier relies upon the constituent lipids and sterols used in the formulation. Such liposomal 
membranes exhibit well-ordered gel phases below the lipid phase transition (Tm) and disordered 
liquid phase transitions above this temperature; as the Tm varies on the length of the lipid chain and 
the level of saturation it is a means by which membrane permeability can be controlled (Maurer et 
al., 2001). The presence of cholesterol can have a significant impact too, as lower concentrations 
can increase permeability and higher concentrations (> 30 mol %) can eliminate the transition 
temperature and dramatically increase the stability (Szoka and Papahadjopoulos, 1980). Thus a 
wide variety of formulations of varying transition temperatures, with and without the presence of 
cholesterol require investigation as the correct release pattern cannot be predicted for the novel 
application of the liposomes within the ELISPOT assay. 
 
4.1.3 Triggered release from liposomal formulations 
To produce a liposomal reference standard, which can release cytokine in a similar way to cells 
various mechanisms, need to be investigated including thermosensitive release of liposomal 
contents through the manipulation of liposomal composition; however, this alone may not achieve 
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the desired release characteristics and thus an external trigger may be required. The use of trigger 
release mechanisms such as enzymatic, photo-triggered, pH and ultrasound for the release of 
liposomal contents has been widely exploited for in vivo purposes (Elegbede et al., 2008, Sarkar et 
al., 2008, Connor and Huang, 1985, Burke et al., 2011, Shum et al., 2001). However, some trigger 
release options are not feasible within the ELISPOT assay, including pH-triggered release and light 
triggered release as the protein itself is susceptible at a pH below 4.8 or above 9.5. Therefore, there 
is a risk that designing a pH dependant system brings an additional element of possible structural 
degradation of the cytokine (Christova, 2003). Use of light triggered mechanisms would require 
changing the basic ELISPOT protocol, as an additional step for the application of the light would 
be required. Movement of the plate once the cells have been placed in the wells is detrimental to 
the quality of the spots formed and should be avoided (Weiss, 2005). Suitable triggered release 
options include the use of a surfactant such as Triton X to cause the breakdown of the liposomal 
bilayer; such techniques are ubiquitously used to lyse liposomes and if rapid release is required 
would be very effective (Urbaneja et al., 1988). Enzymatically triggered release also seems a 
favourable option to investigate as both the enzymes PLC and PLA2 work at an optimal 
temperature of 37 °C (Op den Kamp et al., 1972) which is the incubation temperature for the assay. 
 
4.2 Aims and Objectives 
The overall aim of this work was to establish the ‘proof of principle’ as to whether liposomes can 
encapsulate rIFNγ  and are subsequently able to produce spots within an ELISPOT assay. 
Furthermore whether spot formation can occur with thermosensitive release or whether additional 
triggered release elements such as enzymes or detergents are necessary for enhanced spot 
formation.  
The objectives for this study were: 
 The characterisation of liposomes formulated from lipids of varying transition temperatures 
and the inclusion or absence of cholesterol to be used within the study as potential 
reference standards.  
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 To use an IFNγ ELISA assay for the optimisation of the concentration of the recombinant 
cytokine which would be sufficient to produce spots on the ELISPOT assay. 
 To use an IFNγ ELISA to show encapsulation and recovery of the cytokine subsequent to 
the formulaton process for a range of liposome compositions. 
 To carry out and optimise an ELISPOT assay and assess  ‘proof of principle’ and whether 
the formation of spots from encapsulated recombinant cytokine is feasible. 
 To assess the physical effects of the formulation process on the integrity of the rIFNγ  with 
assessment of parameters such as temperature, centrifugation and vortexing. 
 To carry out ELISPOT assays for the quantitative assessment of thermosensitive, 
enzymatic and detergent triggered release mechanisms in terms of spot number and 
qualitative assessments of the background for the wells. 
 To optimise enzyme concentrations and buffers for the dilution of PLA2 and PLC. 
 In addition examine the effects of different pre-wetting volumes of ethanol across different 
formulations in order to establish iptimal parameters for the ELISPOT assay. 
 
4.3 Results and discussion 
4.3.1 Optimisation of cytokine concentration, validation and assessment of entrapped 
cytokine using an IFNγ ELISA assay 
The ELISA assay and the ELISPOT assay are two similar immune-enzymatic assays based 
generally on the same principles however there are some fundamental differences. The ELISA 
assay is for quantification purposes; exactly ‘how much’ is secreted whereas the ELISPOT assay 
enumerates the number of cytokine secreting cells (Kalyuzhny, 2005). It was an important initial 
step to optimise the amount of cytokine, which would be sufficient to allow spot formation to occur 
from the artificial reference standards, thus the ELISA and ELISPOT kits that have been chosen are 
coated using the same antibody at the same concentration (Mabtech). There were also other 
important factors which needed to be assessed including the various steps of the formulation 
process on the integrity of the cytokine.  
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4.3.1.1 Validation of the ELISA assay for rIFNγ measurement 
 In order to establish the protocol for an IFNγ ELISA assay and subsequently demonstrate the  
reproducibility of the plate coating and the protocol, three calibration curves were made using the 
kit standards and  ran on three different days on three plates. The overlay from the three curves was 
highly reproducible, with low standard deviations for each calibrator (<1)  and the R
2
 value of 0.99 
and therefore confirmed the accuracy, precision and robustness of this assay for quantitative 
analysis of the recombinant Interferon γ used for encapsulation (Figure 4.2). The limits of detection 
were 1 pg/mL which was the lowest concentration which could be detected but not necessarily 
quantified. The limit of quantification was 3.16 pg/ mL and the standard range was 3.16 pg/mL to 
1000 pg/mL. The inter and intra assay variation measured by the coefficient of variation was 4.2 % 
and 2.7 % respectively.      
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Sigmoidal dose-response curves for IFNγ calibration curves repeated in triplicate using 
standards with ELISA kit. The bottom and the top of the curve defined as 0.04 and 3.16 OD, Log 
EC50 2.323, Hill slope 1.387. The R
2
 value calculated was 0.99. Results shown are for the mean ± 
SD triplicate assays. 
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As the assay components were purchased as a complete kit (Mabtech, Sweden), it was in fact 
validated, comprehensively QC tested and complied with European Regulations ISO 13485 and 
90001 (ISO, 2003) and (ISO, 2008) respectively. Therefore, it was not necessary to validate the kit 
itself but it was appropriate to confirm that reproducibility, precision and accuracy were achievable 
through the operator. According to ICH guidelines (ICH, 2005) in the validation of analytical 
procedures linearity, accuracy, precision, and reproducibility need to be shown. Accuracy is 
defined as the closeness of agreement between the value, which is accepted either as a true value or 
from a reference value; the precision is the closeness of agreement between a series of obtained 
measurements. For a calibration curve, the test results should be directly proportional to the 
concentration of an analyte. The guidelines specify that for the establishment of linearity a 
minimum of 5 concentrations are recommended. For this study, 7 concentrations were provided 
(Figure 4.2). The value of 1 for R
2
 indicates a perfectly linear relationship thus the obtained value 
of 0.99 indicates a good statistical fit (Freund et al., 2006). 
 
4.3.1.2 Titration of the recombinant cytokine 
A titration of the human recombinant interferon γ purchased (Sigma) was necessary in order to 
obtain an approximate concentration strong enough to produce spots on the ELISPOT assay thus a 
high optical density on the ELISA assay was required. Using the kit standard curve (Figure 4.3) to 
extrapolate concentrations, dilutions of recombinant IFNγ cytokine (Sigma) of 1000 pg/mL, 500 
pg/ mL    and 100 pg/mL were tested to examine their suitability for encapsulation purposes. The 
lyophilised cytokine (1 mg in amount) was diluted in phosphate buffered saline with 0.5% bovine 
serum albumin. Three titres initially tested were in duplicate and the optical densities obtained 
shown in Table 4.1. 
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Figure 4.3 Dose-response curves for IFNγ with the ELISA kit standards for the extrapolation of 
dilutions of stock recombinant Interferon γ.  
 
Table 4.1 Optical density of tested dilutions of rIFNγ and extrapolated concentrations carried out 
in duplicate. 
 
The concentration in the first column of Table 4.1 derived from the dilution of the purchased 
recombinant cytokine was used within the ELISA assay to determine their actual concentration. 
The coating antibody used in the ELISA assay is the same as the one used for the ELISPOT assay 
and therefore an indicator for the necessary concentration of the purchased IFNγ required for the 
liposome formulations. As observed in Table 4.1 the concentration of the purchased cytokine and 
the extrapolated concentrations were very different; for instance at 1000 pg/mL of the purchased 
cytokine on the ELISA assay provided an extrapolated concentration of 1.078 pg/mL. 
The values obtained for the optical density were within the limits of detection (1.0 pg/mL); 
however, they were well below the limits of quantification (3.75 pg/mL) for the assay (Table 4.1). 
The results suggest that the concentration in mass defined by the kit standards was not directly 
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Concentration (pg/mL) Optical Density Extrapolated value (pg/mL) 
1000 0.0325 1.078 
500 0.0205 1.048 
100 0.0555 1.136 
Sigmoidal dose-response 
(variable slope); 
Bottom: 0.0787 
TOP:  3.144 
LOGEC50: 2.146 
HILLSLOPE: 1.887 
EC50:  140  
 R²  0.9989 
 Absolute Sum of Squares
 0.01545 
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comparable to the stock rIFNγ for encapsulation within the liposomes. Thus, the titration was 
repeated at stronger concentrations with the aim of obtaining a concentration as close to the upper 
end of the optical density of the assay as possible (Figure 4.4). 
The result from the repeat titration confirmed that a much stronger concentration was required to 
obtain higher optical densities than predicted (Figure 4.4 and Table 4.2). Even with the highest 
concentration tested at 5000 ng/mL of the recombinant cytokine, the optical density was 2.697 
(Table 4.2) whereas it was evident from the curve that saturation was at an optical density of 3.1 
before the curve begins to plateau (Figure 4.4). This was used as a basis to make the stock solution 
at a much stronger concentration, which was 10,000 ng/mL (10 µg/mL). Due to the lack of 
comparability between the kit standards and the stock solution of cytokine, it was necessary in 
further work to use the stock solution to construct a calibration curve to allow for the calculation of 
entrapment. 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.4 Extrapolation of dilutions of titrated concentrations of rIFNγ, for encapsulation within 
liposomes. Results represent mean ± SD of triplicate assays. 
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Table 4.2 Results for the mean optical density of extrapolated concentrations of specified dilutions 
of rIFNγ. 
 
In the preliminary titration, there was an assumption that the concentration of the standard curve 
and the rIFNγ dilutions tested were directly comparable, however the results indicated that this was 
not the case. An explanation for this substantial difference in the activity as explained within 
literature is due to the variability observed during the production of recombinant interferon gamma, 
especially in glycosylation of the polypeptide chains; as this variability can result in reduced 
activity (Curling et al., 1990). Various methods can be used to produce recombinant cytokines 
including E. Coli, yeast and Chinese hamster ovary cells (CHO) however, production of cytokine 
even using the same method can lead to different forms (Mire-Sluis et al., 1999). The rIFNγ used 
within this study was E.Coli derived and produced in bacterial plasmids thus the variability found 
in the expression levels using this method is common and serves as an on-going challenge in the 
biotechnology industry (Sharma et al., 2011). Therefore, it was not unexpected for there to be such 
discrepancy between the kit interferon (Mabtech, Sweden) and the purchased rIFNγ (Sigma, UK). 
In fact according to Mire-Sluis et al., (1999) the biological potency of one amount from a 
manufacturer such as 1 mg of can have a very different activity to that from another.  
However, the purpose of this study was to obtain a concentration for the cytokine that would be 
suitable for the formulation of the liposomes for the production of spots within an ELISPOT assay. 
The concentration of 10 µg/mL also equates to 2.5 x 10
5
 U/mL in terms of the specific activity of 
the cytokine. Although it was simpler to initially work with the stock concentration in terms of 
amount, for the purposes of calculating encapsulation of cytokine within liposomes. In terms of the 
validation work for the ELISPOT assay subsequently, it was necessary to work in specific activity 
because to quantify the biological activity of different cytokine preparations biological activity has 
Concentration (ng/mL) Optical Density Extrapolated value (pg/mL) 
5000 2.69 716.9 
2500 2.093 350.7 
1250 0.558 78.3 
625 0.345 49.2 
312.5 0.193 23.6 
156.25 0.171 18.9 
78.125 0.137 9.1 
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to be expressed and not mass units. This is calculated from a bioassay and allows for more 
comparability between different laboratories (Mire-Sluis et al., 1999). 
 
4.3.1.3 Examining the effects of Triton X on the coating antibody and rIFN gamma 
As the kit standards were no longer to be used, it was necessary to confirm that a reproducible 
curve could be obtained with a serial dilution of the rIFNγ stock solution at 10 µg/mL. It was also 
important to establish that liposome lysis with 10% v/v Triton X for the measurement of 
encapsulated protein would not affect the optical density of the calibration curve by interference 
with the assay.  
The results showed (Figure 4.5) that there was no significant difference between the two curves 
when various parameters of the graph including the bottom, top, Log EC50 and hill slope were 
compared. The R
2
 value for the normal calibration vs. Triton X was 0.996 and 0.995 respectively. 
The results from the overlay show the calibration curve produced from the stock 10 µg/mL solution 
of recombinant cytokine produced a highly reproducible curve. Furthermore, the Triton X did not 
affect reproducibility. This was thus a suitable lysis agent for both the ELISA assay for the 
determination of percentage encapsulation and within the ELISPOT assay as a means to show 
complete release. 
If Triton X caused interference within the assay then it would not be an acceptable lysis agent, as 
the specificity of the assay would be affected; according to ICH guidelines, the specificity is the 
ability to assess explicitly the analyte in the presence of other components that maybe present 
(ICH, 2006). However, the results have shown that there was no interference with the use of Triton 
X and this was a suitable non-ionic surfactant for the lysis of liposomal membranes. Its suitability 
further confirmed through literature, showed its extensive use for the purposes of liposome 
disruption, and was therefore used for subsequent studies. (Urbaneja et al., 1988, Ruderman and 
Grigera, 1986, De la Maza and Parra, 1996). 
 
 
183 
 
 
 
 
 
 
 
 
 
. 
Figure 4.5 The effect of Triton X on the rIFNγ calibration curve. Results represent mean ± SD of n 
=3 assays.  
 
4.3.2 Determining the effects of the physical stresses of the formulation process 
An assessment of the effects of the formulation process on the cytokine was necessary to establish 
the impact on activity of the protein. It was important to determine the effects of temperature, 
centrifugation and/or vortexing on the rIFNγ and consequently on the ability of the protein to bind 
to the coating antibody. During the formulation process, the temperature was required to be above 
the transition temperature for the lipids for liposomes to form, with encapsulated rIFNγ (Anderson 
and Omri, 2004). Thus dependent upon the lipid used the temperature can range from room 
temperature to 60 °C. 
 
4.3.2.1 Determining the effect of temperature on rIFNγ  
To assess which formulations were suitable for the encapsulation; 500 µL of the rIFNγ (10 µg/mL) 
was placed in a dry heat block for either 30 minutes or 1 hour (Figure 4.6). It was found that as the 
temperature increased there was a significant (p<0.05) change in the optical density from 40 °C to 
50 °C, from 2.89 at 40 °C the optical density decreased at 50 °C for 30 minutes and 1 hour to 2.53 
and 2.47 respectively. Thereafter the decrease for both incubation times remained highly significant 
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(p<0.001) compared to the optical density at 40 °C. When comparing the difference between the 
two incubation times at each temperature there was no significant difference observed at 40 °C or 
50 °C; however, subsequently at 60°C and 70 °C the difference in optical density was highly 
significant  (p<0.001). At 60 °C, the optical density at 30 minutes incubation and 1 hour incubation 
was 2.73 ± 0.14 and 1.71 ± 0.21 respectively. At 80 °C the difference in optical density was not 
significant and at 90 °C was significant (p<0.05) again, by which point the optical density was at 
0.61 ± 0.12 and 0.22 ± 0.02 (Figure 4.6). These results show that even small changes in 
temperature can have a significant impact on the activity of the rIFNγ, thereby limiting working 
temperatures that could be used for the manufacture and application of the liposome systems. 
In previous studies, liposome encapsulation of rIFNγ has been successful using the dry film 
hydration method. Various formulations including lipids such as PC, EPG (1,2-diacyl-sn-glycero-
3-[phospho-rac-(1-glycerol)] , DPPC and DPPG (1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-
glycerol) which have a range of transition temperatures (<20°C to 41°C) above which the 
formulation process occurs (Van Slooten et al., 2001). Furthermore, assessment of the bioactivity 
of the rIFNγ through a TNFα bioassay found that the activity was unaffected by the formulation 
process (Van Slooten et al., 2001). In fact other studies have shown that at at 50 °C the infrared 
spectrum of the rIFNγ exhibited minor changes; however, above this temperature it was observed 
that with increasing exposure to higher temperatures there were irreversible changes to the 
secondary structure (Goossens et al., 2003). Such results agree with the observations from this 
study which suggest that although there was an observed decrease in the optical density using the 
rIFNγ ELISA assay at 50 °C the actual level of activity remaining would be acceptable for the 
formulation of liposomes using the dry film lipid hydration method. However, formulations above 
this temperature may result in irreversible damage to the cytokine. 
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Figure 4.6 Effect of increased temperature on 10 µg/mL recombinant IFNγ for 30 minutes and 1 
hour. Results are the mean of triplicate samples tested ± SD.  
 
4.3.2.2 Determining the effect of centrifugation on rIFNγ 
Three serial dilutions were made and divided into two; one set was centrifuged at 29, 771 g for 30 
minutes and the other was not. These were then tested on the ELISA IFNγ assay (Figure 4.7). From 
the results (Figure 4.7) it can be seen that the curves do not overlay precisely; however a statistical 
analysis for the two curves using the similarity factor F2 test which is a logarithmic transformation 
of the sum-squared error of differences at all the calibrator dilutions was calculated to be 52. This 
represents the closeness of the two curves as acceptable values are 50 – 100 according to FDA 
guidelines for dissolution curves (Yuksel et al., 2009). This suggests that although centrifugation 
has some effect on the optical densities although overall the curves were simlar and thus 
centrifugation was a suitable technique within the formulation process which was compatible with 
the rIFNγ. 
The differences observed in the curves maybe due to the calibrators for the centrifuged curve being 
transferred to plastic tubes sealed and then centrifuged, some protein may have been lost due to it 
being adsorbed at interfaces such as the tube. This is a result of electrostatic interactions between a 
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charged adsorbent material and oppositely charged amino acid chains on the protein (Hlady et al., 
1999). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7  The effects of centrifugation at 29, 771 g for 30 minutes on the optical density of the 
calibration curve on an ELISA IFNγ assay vs. a normal calibration. Results are the mean of 
triplicate samples tested ± SD.   
 
Furthermore, the adsorption process can result in protein denaturation. Other studies have shown 
that recombinant IFNγ can be susceptible to a loss of activity when subjected to mechanical 
stresses, such as shearing forces and increased surface tension (Tsanev et al., 2007). In terms of the 
formulation process, the centrifugation of the protein is for the purposes of removing the free IFNγ 
so any loss observed should not affect the encapsulated rIFNγ. 
 
4.3.3.3 Determining the effect of vortexing on rIFNγ 
Vortexing the dry lipid film is an important step subsequent to hydration of the film, thus the stock 
solution was vortexed for various time points ranging from 30 seconds to 15 minutes and analysed 
for biological activity on the ELISA assay. 
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Figure 4.8 The effect of vortexing on the recombinant interferon cytokine. Results show are the 
mean ± SD for triplicate assays. 
 
The results in Figure 4.8 show that rIFNγ was sensitive to vortexing, after only 30 seconds a 
significant (p<0.05) reduction in protein activity was noted from 2.0 ± 0.02 to 1.77 ± 0.04 (optical 
density). However, continued vortexing for up to 15 minutes did not have any further significant 
effects on the optical density (Figure 4.8). Mechanical stresses such as increased pressure, 
temperature, and shearing has been shown to affect the biological activity of rIFNγ (Goossens et 
al., 2003). During the encapsulation process, the exposure of proteins to mechanical stress can lead 
to the denaturation of sensitive proteins (Hwang et al., 2000). The formulation process for this 
study would not require such prolonged periods of vortexing and would be limited. In addition, 
previous studies have shown that it has been possible to formulate liposomes with rIFNγ and thus 
confirm that although the protein can show instability it is still feasible to form liposomes (Van 
Slooten et al., 2001, Anderson et al., 1981, Eppstein and Stewart, 1982). 
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4.3.4 Physicochemical characterisation and entrapment  of rIFNγ with varying liposome 
compositions 
Having established the feasibility of using an ELISA IFNγ assay to establish encapsulation 
efficiency (section 4.3.1), prior to liposome formulations being placed in an ELISPOT assay it was 
important to assess a wide range of lipids with varying transition temperatures. Once liposomes 
were formulated they were characterised for size and zeta potentials and subsequently establish 
ecapsulation efficiency. 
 
4.3.4.1 Characterisation of liposome formulations 
The purpose of this study was to assess a wide range of liposome formulations which were 
composed of either 16 μMol for formulations without cholesterol and 8:8 μMol for those with 
cholesterol (Table 4.3). ‘Empty’ and rIFNγ encapsulated formulations were made for each 
corresponding composition (Figure 4.9).  For the formulations containing rIFNγ there was no 
notable differences or trends in the various liposome formulations. The PC 16 μMol ‘empty’ 
liposome formulation was significantly smaller (P<0.05) when compared to other formulations 
such as PC:Chol , DPPC:Chol, DMPC, DMPC:Chol and DOPC, although there was no significant 
difference between empty PC formulations and the size of PC rIFNγ encapsulated formulations. In 
terms of zeta potential, the formulations exhibited no signicant difference when compared between 
formulations other than DPPC:Chol:BrChol 8:4:4 μMol which showed either a signicant difference 
(p<0.05) or a highly significant difference (p<0.001) with remaining formulations. This is due to 
the anionic nature of the formulations which have a zeta potential -21.9 ± 6.9 mV whereas the other 
formulations are more neutral, for instance PC has a surface potential of -6.8 ± 3.9 mV. 
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Table 4.3 Liposomal formulations for empty and rIFNγ containing liposomes for characterisation 
and the entrapment of rIFNγ. 
Formulation  Lipid                 
composition                     
(μMol) 
Formulation  Lipid             
composition 
(μMol) 
1.  PC empty 16 10. DPPC:Chol:BrChol IFNγ 8: 2: 6 
2. PC IFNγ 16 11. DMPC empty 16 
3. PC:Chol empty 8: 8 12. DMPC IFNγ 16 
4. PC:Chol IFNγ 8: 8 13. DMPC:Chol empty 8: 8 
5. DPPC empty 16 14. DMPC:Chol IFNγ 8: 8 
6. DPPC IFNγ 16 15. DOPC empty 16 
7. DPPC:Chol empty 8: 8 16. DOPC IFNγ 16 
8. DPPC:Chol IFNγ 8: 8 17. DOPC:Chol empty 8: 8 
9. DPPC:Chol:BrChol empty 8: 2: 6  18. DOPC:Chol IFNγ 8: 8 
 
For the purposes of producing a reference standard for the ELISPOT assay, it was difficult to 
predict which formulation would provide optimal characteristics for the effective entrapment of 
rIFNγ and consequently effective spot formation within the ELISPOT assay. Thus, it was necessary 
to characterise a wide range of formulations. A range of lipids were chosen and in addition 
cholesterol was added at an equimolar ratio, the inclusion of cholesterol can decrease the 
permeability of the membrane (Kirby and Gregoriadis, 1983, Kirby et al., 1980). The lipids chosen 
were PC, DMPC, DPPC, and DOPC and these have transition temperatures of  <20 °C, 23 °C, 41 
°C, -22 °C respectively (Vemuri and Rhodes, 1995). The characterisation of the liposomes 
generally showed no significant difference across the formulations. Some variability was due to 
producing the formulations on three separate occasions, the dry film hydration method produces a 
heterogenous mixture of liposomes and this is where the variation is introduced not only in terms of 
size but also lamerallity and is one of the major drawbacks for this method (Wagner and Vorauer-
Uhl, 2011, Szoka and Papahadjopoulos, 1980). The statistical significance observed in size 
between the empty PC formulations when compared to other formulations was not deemed to be 
important for the purposes of assessment of formulations on the assay as no spots would be 
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expected. The effect of any variation would become more significant subsequent to an assessment 
of encapsulation.  
 
 
 
 
 
 
 
 
 
 
Figure 4.9  Physicochemical characterisation of size (µm) and zeta potential (mV) for both empty 
and rIFNγ containing liposmes with and without cholesterol and brominated cholesterol. Liposome 
formulations were made using 16 μMol total lipid amount. Results represent mean ± SD for n=3 
batches. 
 
4.3.4.2  Encapsulation of rIFNγ in varying liposome compositions 
The results from the ELISA assays (Figure 4.9) showed that encapsulation of the rIFNγ was 
feasible, with the percentage encapsulation ranging from 13 ± 9% for DOPC  to 25 ± 4.4 % for 
DPPC:Chol, with no statistical significance between the encapsulation efficiency for the 
formulations. Results obtained for the total recovery of protein were more variable (Figure 4.10); 
Statistical analysis revealed the p value across the groups was significant (p<0.05). The recovery 
ranged from 57 ± 7.6 % for DPPC:Chol: to 83 ± 8 % for DMPC. All formulations were 
significantly different from DPPC:Chol:Brchol (p<0.05) in terms of recovered protein and there 
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was also a significant difference (p<0.05) between DPPC vs. DMPC:Chol 40 ±  6.5 % and 91 ± 4.7 
%  (Figure 4.10).  
 
Figure 4.10 Encapsulation and recovery (%) for rIFNγ containing liposmes using ELISA assays. 
Liposome formulations were made using 16 μMol total lipid with cholesterol containing liposomes 
at 8:8 μMol. Results represent mean ± SD for n=3 batches. 
 
Previously reported entrapment efficiencies for rIFNγ containing liposomes for topical delivery 
include 10-20 % using the dehydration rehydration method (Weiner et al., 1989). Other studies 
have shown the successful entrapment of cytokine in positive and negative liposomes with the 
inclusion or absence of cholesterol, with entrapment levels for REVs at 10-20 % and 4-5 % for 
MLVs (Eppstein and Stewart, 1982). Furthermore, the authors observe that the inclusion of 
cholesterol in the phosphatidylserine containing liposomes was necessary for stable association of 
the rIFNγ for more than 2 days at 4 °C and for 24 hours at 37 °C (Eppstein and Stewart, 1982). 
This was an interesting observation, as although there was no statistically significant difference 
between the formulations in terms of entrapment in this study (Figure 4.10), the mean entrapment 
suggest a trend of higher entrapment for the formulations containing cholesterol (with the 
exception of liposomes containing dibromocholesterol). When PC and PC:Chol formulations were 
compared, for instance, the entrapment values were 14 ± 4 % and 20 ± 4.4 % respectively. The 
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trends found in the data (Figure 4.10) agree with Eppstein et al., (1982). The studies mentioned 
from literature do not include values for the assessment of total protein recovery however as 
previously discussed the variability in the amount recovered could be due to the mechanical stress 
of the formulation process as the free interferon is exposed (Hwang et al., 2000). 
 
4.3.5 Determining the activity of phospholipase C and phospholipase A2 
Given that a range of formulations were shown to encapsulate rIFNγ, the next stage was to consider 
release mechanisms for the system. Release from liposome formulations can be enhanced using 
various methods of trigger release for the purposes of controlled release (Allen and Cullis, 2013). 
The purpose of the study was to assess the effectiveness of enzymatic triggered release particularly 
of PLC and PLA2 activity of purchased enzymes for their ultimate use within the ELISPOT assay 
to assess their impact on spot number. Prior to the incorporation of enzymes within the assay an 
activity assessment was carried out both qualitatively and quantitatively to show that the enzyme 
was active and able to degrade the liposomes. Three aqueous dispersions of pure lipids were tested; 
PC, DOPC and DPPC and the breakdown of the lipids measured using absorbance values, which, 
were converted to enzyme activity using a phosphate standard curve (Figure 4.11). 
The assay was a quality control check to ensure that there was activity of the enzyme, prior to the 
assessment of triggered release work within the ELISPOT assay. The observed results suggested 
that the observed activity of the enzyme varied dependent upon the lipid. Phosphatidylcholine 
seemed to show the greatest level of enzymatic activity and was significantly higher (P<0.001) than 
DOPC and DPPC with measured activity at 0.97 U/mL, 0.63 U/mL and 0.24 U/mL respectively. 
Previously PLC has been used within an immune based assay for the release of entrapped 
fluorescent marker (Kim and Park, 1994). The purpose of this study was to incorporate the enzyme 
for more effective release from liposomal formulations within the ELISPOT assay. Initially it was 
necessary to confirm the activity of the enzyme itself. The quality control assay (Figure 4.11) 
showed that there was enzyme activity and that this varied with the different lipid compositions 
assessed. Both PLA2 and PLC work by catalysing the hydrolysis of the phospholipids to produce 
phosphocholine and diacylglycerol (Liao et al., 2010). 
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Figure 4.11 Quality control asssesment of the activity of PLC carried out with aqueous dispersions 
of PC, DOPC and DPPC. Results shown are mean ± SD for n=3 preparations.  
 
The results observed concurred with findings by Van et al., (1961), where differences in the 
hydrolysis of lipids by PLC were thought to be due to the variation in the length of the acyl chain 
with longer chains leading to a decrease in the rate of hydrolysis. Although other research has 
pointed to the level of saturation of the chain as an important determinate for the rate of hydrolysis; 
with saturated chains being more resistant (Long and Maguire, 1954). The results confirm that the 
enzyme activity was greatest with the unsaturated PC and then for DOPC which has an 18 carbon 
chain length and 1 double bond. Least activity was exhibited for DPPC, which has a 16 carbon 
chain length however, has no double bonds (Chen et al., 2010). For further confirmation of enzyme 
activity using microscopy, PC and PC:Chol (16 μMol and 8:8 μMol respectively)  without rIFNγ 
were placed into microslides with specified concentrations of PLA2 and PLC (Table 4.4). 
Microscope images were obtained on the Zeiss Axioscope A1 light microscope at the time points 
of 0, 1 hour and after an overnight incubation at 37 °C; subsequently the microscope slides were 
assessed for changes in morphology of the vesicles. 
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Table 4.4 Lipids and enzyme concentrations assessed for PLA2 and PLC activity using PC 16 
μMol and PC:Chol 8:8 μMol (of mean particle size 8.68 ± 0.02 µm and 11.09 ± 0.03 µm 
respectively) for the light microscopy study. 
Microslide 
number 
Liposome 
formulation 
  PLA 2 
added 
  U/ mL 
Microslide 
number 
Liposome 
formulation 
PLC  added 
U/ mL 
   1. PC 0    1. PC 0 
2.   PC 1 2.   PC 1 
3.   PC     5 3.   PC     5 
4.          PC              10 4.          PC 10 
5. PC:Chol 0 5. PC:Chol  0 
6.         PC:Chol 1 6.         PC:Chol  1 
7.  PC:Chol 5 7. PC:Chol  5 
8.         PC:Chol  10 8.        PC:Chol   10 
 
The microscopy results show that there is enzymatic action and this is most visible with overnight 
incubations, at concentrations between 1 U/mL and 5 U/mL (Figure 4.12 - 4.13). From the 
qualitative assessments of the images, the effect of the PLC was evident for both the formulations 
of PC (Figure 4.12 a) and PC:Chol (Figure 4.12 b). There was visible evidence of the breakdown of 
liposomes but larger liposomes showed some level of aggregation. Similar results were observed 
for the PLA2 enzyme (Figure 4.13 a and b) with breakdown of liposomes into smaller particles and 
aggregation of larger liposomes. Previous studies have shown similar effects were observed when 
PLC was added to PC liposomes and examined using cryo-electron microscopy, which allows 
much further insight into the changes in the bilayer (Basanez et al., 1997). In a study by Basanez et 
al., (1997), the action of the enzyme induced vesicle fusion by initially entering an intermediate 
stage where the vesicles became aggregated and closely packed before then fusing into larger 
vesicles. There was no evidence observed of larger vesicles formed although there was observed 
aggregation. It was not possible to conclude conclusively from the images, the optimal 
concentration of the enzyme for the assay and thus a variety of enzyme concentrations would need 
assessment within the ELISPOT assay. 
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Figure 4.12 a; Light microscope images of a PC 16 µMol 
formulation (8.6 ± 0.02 µm mean particle size) incubated with or 
without various concentrations of  PLC enzymes. 
 
Figure 4.12 b; Light microscope images of a PC:Chol 8:8 
µMol formulation (11.09 ± 0.03 µm mean particle size), 
incubated with or without various concentrations of PLC 
enzymes. 
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Figure 4.13 a Light microscope images taken of a PC 16 µMol 
formulation (8.6 ± 0.02 µm mean particle size) incubated with or 
without various concentrations of PLA 2 enzymes. 
 
 
Figure 4.13 b Light microscope images of a PC:Chol formulation 
8:8 µMol (11.09 ± 0.03 µm mean particle size) incubated with or 
without various concentrations of PLA2 enzymes. 
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4.3.6 An assessment of pre-wetting volume for the optimisation of the ELISPOT protocol for 
the use of liposomal reference standards  
The ELISPOT protocol ordinarily has a pre-wetting step with 70% v/v ethanol and is a 
recommended aspect of the protocol due to the hydrophobic nature of the membrane; however, this 
can vary from protocol to protocol in terms of the amounts used and the length of time in the well 
(Janetzki et al., 2005). As this is a step left to the discretion of the user and as the application of 
liposomes in the assay was a novel concept, it was important to assess whether variation of the 
volume of ethanol used for this pre-wetting step would have any impact on the liposomes prior to 
establishing the coating procedure.   
 
 
 
 
 
 
 
Figure 4.14 The effect of variation of the pre-wetting volume of 70 % ethanol on spot numbers 
generated for PC:Chol (8:8 μMol) formulations with an average size of 12.28 ± 2.4 µm. Results 
represent mean ± SD of n=3 batches.  
 
The results observed (Figure 4.14) indicate that there was no significant difference in the spot 
number generated upon variation of the pre-wetting volume. The assay also served as ‘proof of 
principle’ that in fact liposomes were able to produce spots on the ELISPOT assay (Figure 4.15). 
The spots were visible under the stereomicroscope and showed that the encapsulation, release, and 
binding of the recombinant IFNγ to the well membrane was achieved. 
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Figure 4.15 Photographic Images obtained with 2.8 X magnification using the Leica stereomicroscope with spots counted with various pre-wetting volume 
of 70% Ethanol. Images shown are representative and are of the n=1 PC:Chol formulation and were obtained using a Kodak camera over the eyepiece. 
No ethanol for pre-wetting 15µL ethanol for pre-wetting 25µl ethanol for pre-wetting 50µl ethanol for pre-wetting 
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Figure 4.16 The effect of changing the pre-wetting volume on empty PC liposomes and rIFNγ 
containing liposomes of PC, PC:Chol, DPPC, DPPC:Chol, DMPC, DMPC; Chol, DOPC and 
DOPC:Chol. Total lipid amounts were 16 μMol. Results represent mean ± SD of n =3 batches. 
 
An assessment was made of the pre-wetting volumes of 25 µL and 50 µL across liposomal 
formulations made from various lipids with and without equimolar cholesterol (Figure 4.16). When 
comparing the effects of using 25 µL and 50 µL of ethanol there was no significant difference 
shown for PC, PC:Chol, DPPC, DMPC, DOPC or DOPC:Chol liposome formulations. However, 
there was a significant (p<0.001) difference for the formulations of DPPC:Chol and DMPC. It was 
interesting to observe that the formulations of PC 16 μMol gave a significantly higher (p<0.001) 
spot number compared to all the other formulations other than DOPC at 25 µL pre-wetting volume. 
These results show no significant variation in spot number across the formulations at 50 µL        
pre-wetting volume and the formulation that gave the highest spot number was for the formulation 
of PC 16 μMol. The results from this assessment for the pre-wetting volume with all the 
formulations served to confirm that 50 µL of 70 % ethanol would be used for subsequent work.  
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Previous studies have shown with cells that the absence of a pre-wetting step prior to antibody 
coating of the wells can result in reduced spot number and can affect background, with results 
showing up to a 30 %  reduction in spot number (Weiss, 2005). From the results observed it was 
also evident that different liposomal compositions are affecting spot number; it has become well 
established that different liposomal compositions will have very different properties in terms of 
release characteristics (Maurer et al., 2001). This is based on whether lipids are saturated or 
unsaturated, the length of the alkyl chain and the inclusion of cholesterol (Vemuri and Rhodes, 
1995). Higher transition temperature lipids such as DPPC were less leaky at 37 °C and seven at the 
50 µL pre-wetting volume had the least mean spot number compared to other lipids in the absence 
of cholesterol (46 ± 9 spots). The effect of using cholesterol within the formulations was most 
prominent when comparing the PC 16 μMol formulations to the formulation containing cholesterol 
8:8 μMol where the mean spot number was observed to be 62 ± 6 and 28 ± 5 respectively. 
Although DOPC has the lowest transition temperature it did not have the highest spot number, this 
may be due to the increased levels of background observed. The formulation process retained the 
activity of the encapsulated rIFNγ for all of the formulations assessed; thus, the ‘proof of principle’ 
was established for a range of liposomal formulations. 
 
4.3.7 Establishing the buffer to be used for enzyme dilutions and a preliminary trigger release 
assessment 
The four different variables that were to be examined for each formulation were; 
(a) thermo-triggered release ie the effects of placing the liposome formulations in the ELISPOT 
well and placing them at 37 °C which is an essential step of the ELISPOT assay (it is 
the’incubation period’ for the cells ordinarily used for this assay).  
(b) Enzymatic triggered release, i.e. this will initially be assessed using phospholipase C to promote 
the release of cytokine through the breakdown of the bilayer. 
(c) Triggered release using a detergent, in this case Triton X at 10% v/v concentration. Prior to 
examining the trigger release options on a range of formulations it was important to ensure the 
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conditions for enzyme were optimal, this included examining the buffer and the concentration of 
the enzyme to be used.  
 
 
 
 
 
 
 
 
 
 
Figure 4.17; ELISPOT spot number obtained for the assessment of PLC triggered release 
mechanisms in PBS and Tris and Triton X release from PC:Chol formulations with an average size 
of 12.11 ± 0.9 µm and the zeta potential of -10.23 ± 5.31 mV (data not shown). Results represent 
mean ± SD of n =3 batches. 
 
Statistical analysis of the results (Figure 4.17) has shown that when comparing the control to the 
PLC in PBS the results are significantly different (p<0.05). However, there was a greater statistical 
significance between the control and the PLC in Tris buffer (p<0.001) with 18 ± 6 spots and 90 ± 
28 spots respectively. There was no statistical significance between the results of the control 
formulation and Triton X triggered release. The results showed that the most suitable buffer for the 
dilution of PLC, which maintained the activity of the enzyme was the Tris based buffer, (Tris 
10Mm, 150mM NaCl and 10mM Calcium Chloride). Triton X was also added to the liposome 
formulation and had a significantly decreased (p<0.001) spot number compared to the trigger 
release mechanism (PC:Chol + PLC in Tris) 16.4 ± 5 and 90 ± 28 spots respectively. 
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It was important to ensure that prior to making assessment of release of liposomal formulations in 
the presence of external triggers that smaller assays were carried out to optimise parameters; 
ensuring the correct buffer was used for the enzymes was an essential pre-requisite for the assay to 
establish optimal conditions. The results (Figure 4.17) indicate that the Tris based buffer-containing 
CaCl2 allowed the enzyme to work more effectively in the hydrolysis of the liposomal membranes. 
These results (Figure 4.17) concur with previous studies which have highlighted the catalytic 
properties of PLC enzymes was dependant on calcium as a cofactor and increases with rising 
calcium concentration (Ellis et al., 1998). Other studies that have isolated PLC from Bacillus 
Cereus, used a Tris based buffer with the addition of 2 μMol CaCl2 in the assessment of activity 
(Kleiman and Lands, 1969). Even with the PBS there was an increase in activity observed 
compared to the control formulation with the presence of the PLC. This agrees with previous 
studies (Holopainen et al., 2002) that have shown that PLC successfully hydrolysed giant 
unilamellar liposomes and the authors comment that the vesicle size and curvature plays significant 
role in the outcome of the enzymatic reactions taking place on the lipid membrane.  
Triton X is a well-established non-ionic surfactant used for the lysis and degradation of liposomal 
membranes and was therefore assessed for the purposes of method optimisation (Urbaneja et al., 
1988). The lack of an increase in spot number was thus, not expected (Figure 4.17). In the 
qualitative assessment of the well it was observed that the control formulation in the absence of any 
triggers (Figure 4.18 a), showed defined spots with reduced background whereas the wells in which 
enzymatic triggers are used (Figure 4.18 b and d). These spots seemed less defined, possibly 
smaller and yet greater in number. In Figure 4.18 c, in which the Triton X was added to the settled 
liposomes, the background was high and spot number reduced. This can be attributed to the highly 
viscous nature of the surfactant, which is perhaps disturbing the layer of liposomes on the wells and 
causing release, whilst reducing contact of the vesicles with the membrane (Spicer et al., 1986). 
Alternatively, the kinetics of release was too abrupt as this is thought to reflect upon spot 
morphology, density and general shape (Lehmann, 2005). 
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Figure 4.18 Selected images of ELISPOT wells for the effects of triggered release; (a) PC:Chol 
with no trigger (b) PC:Chol with PLC in PBS buffer, (c) PC:Chol with Triton X (d) PC:Chol with 
Tris images viewed under a stereomicroscope. 
 
4.3.8 Establishing the effect of varying enzymatic concentration on spot number 
Further to establishing that Tris was the optimal buffer for the assay, the next stage was to assess 
the effect of increased enzymatic concentration on spot number within the ELISPOT assay.  
 
 
 
A. Control: PC:Chol (No Trigger) 
 
B. PC:Chol (PLC with PBS) 
 
C.  PC:Chol with Triton X. 
 
d. PC:Chol (PLC with Tris) 
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Figure 4.19 ELISPOT numbers generated for PC:Chol (8:8 μMol) formulations with PLC 
concentrations of 1, 4 and 16 U/mL and Triton X 10% v/v. Controls of ‘empty’ PC:Chol 
formulations and neat enzyme solutions were also assessed. Results represent mean ± SD of n =3 
batches. 
 
The PC:Chol formulations were measured for size and empty formulations were 10.3 ± 0.6 µm and 
IFNγ containing PC:Chol formulations had a mean particle size of 11.2 ± 1.3 µm (data not shown).  
The results show (Figure 4.19) that there was no significant difference between each of the 
variables when comparing the release to the control PC:Chol. As previously observed, the mean 
spot number for the detergent triggered release produced the least number of mean spots 16 ± 5 and 
the highest mean spot number was 41.5 ± 4.1 produced, when the liposomes were in the presence 
of PLC at 1 U/mL. Based on the observed results, even at the lowest concentration, activity of the 
PLC was evident. The enzyme solutions, which were ran as controls showed no spots thus 
confirming that the enzyme concentrations did not interfere with the membrane. Empty liposome 
formulations also did not promote spot formation. The ELISPOT images from all three assays in 
Figure 4.19, similarly confirmed high background levels for the Triton X, and enhanced levels for 
those wells where enzymatic triggers were used.  
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 Figure 4.20  ELISPOT images for establishing the effective concentration of  PLC with PC:Chol 
formulations. PLC concentrations assessed were 1 U/mL, 4 U/mL and 16 U/mL and Triton X 10% 
(v/v) were added to PC:Chol formulations. 
 
There are two types of staining problems previously associated with the use of cells and these 
include specific and non-specific background; the first of which arises because of the secreted 
molecule diffusing away from the cell and the latter due to the adsorption of detecting components 
of the assay to the membrane (Kalyuzhny, 2005). The images suggest that with triggered release 
mechanisms and the Triton X  the combination of enhanced release is resulting in such non-specific 
background staining although the presence of the liposomal membranes are not interfering with 
assays as the empty liposomes shown very clear wells. 
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As further confirmation, three different concentrations (1 U/mL, 5 U/mL and 10 U/mL) of PLA2 
were assessed. In Figure 4.21 results for the control and PLA2 triggered release are shown. 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 ELISPOT results to determine the phospholipase A2 concentration for the triggered 
release of liposome formulations. Results represent mean ± SD of n =3 batches. 
 
Size characterisation for PC:Chol formulations was carried out; empty formulations had a mean 
particle size 10.12 ± 0.04 µm and rIFNγ formulations had a mean particle size of 8.16 ± 0.33 µm 
(data not shown). It was necessary to confirm a suitable concentration of PLA2, which for use in 
further studies. Concentrations assessed were 1 U/mL, 5 U/mL and 10 U/mL. The results (Figure 
4.21) show there was a significant increase (p<0.05) in the number of spots when comparing the 
control to the concentration of PLA2 at 1 U/mL (28 ± 5 vs. 68.8 ±13.7 respectively). There was also 
a significant difference (p<0.05) between the control and the PLA2 at 10 U/mL (28 ± 5 vs. 67.6 ± 
18.3 respectively). There was however no significant difference between the three concentrations. 
The results (Figure 4.21) confirm that a final concentration of 1 U/mL was sufficient for the 
triggered release of liposomes. It was interesting to observe that increasing concentrations of PLA2 
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did not result in a linear increase in spot number. This pattern was also observed previously with 
PLC and suggests that manipulating the release to have the correct kinetics is perhaps more 
important than complete disintegration of liposomal membranes. As liposomes have not been used 
within the ELISPOT assay previously, the increased speed of release can perhaps be compared to 
the presence of having too many cells within a well. Zhang et al., (2009) observed that increasing 
the number of cells did show a linear increase in spot number, until a critical point after which 
elevated levels of background and spot confluence resulted in a loss of this linear relationship. 
Whilst higher concentrations may actually be more effective in liposomal breakdown, ‘overload’ of 
the well with free cytokine is also a concern; thus 1 U/mL was deemed a suitable concentration for 
further studies.      
 
4.3.9 ELISPOT results for thermo-triggered, PLC and Triton X triggered release 
Having optimised and established activity of the enzyme and confirmed the actual methods for 
addition of trigger release vehicles a range of formulations were assessed to establish the optimal 
formulations to further progress the study and these were; 
- PC and PC:Chol 
- DMPC and DMPC:Chol 
- DPPC and DPPC:Chol 
- DPPC:Chol:BrChol 
- DOPC and DOPC:Chol. 
As previously particle size characterisation was carried out for all the formulations in this study; 
PC (9.8 ± 1.3 µm), PC: Chol (11.4 ± 2.1 µm), DPPC (10.3 ± 1.1 µm), DPPC: Chol (12.1 ± 1.4 µm), 
DMPC (8.94 ± 0.9 µm), DMPC: Chol (11.7 ± 2.1 µm), DOPC (7.8 ± 1.1 µm), DOPC: Chol (11.2 ± 
0.8 µm) and DPPC:Chol:BrChol (8.5 ± 2.1 µm) and there were no significant differences observed 
(data not shown). 
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Figure 4.22 Assessment of enzymatic (PLC) and Triton X trigger release mechanisms using the ELISPOT assay for liposome formulations of  PC, 
PC:Chol, DPPC, DPPC:Chol, DMPC, DMPC:Chol, DOPC, DOPC:Chol (16 μMol without cholesterol and 8:8 μMol with cholesterol) and 
DPPC:Chol:Brchol (16:4:12 μMol). Results represent mean ± SD of n =3 batches. 
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The formulations were assessed (Figure 4.22) for thermo-triggered release, promoted due to the assay 
being placed in the incubator at 37 °C overnight, Triton X for surfactant-based release, and enzymatic 
release with PLA2 and PLC at a concentration of 1 U/mL with Tris based buffer containing calcium. 
Results were analysed for each aspect of release across the different liposomal formulations. From 
Figure 4.22 it can be seen that for thermo-triggered release, which relies on no external trigger, the 
optimal formulation in terms of spot number was PC which was significantly higher (p<0.001)  than 
all formulations other than DOPC with 75 ± 1.6 spots and 56 ± 8.0 spots respectively. Although the 
background, levels observed were higher for DOPC formulations. The least spot number was 
observed for formulations containing the synthesised dibromocholesterol with few spots present. Even 
with additional trigger release mechanism present, such as PLC and Triton X, there was no further 
significant increase in spot number. In the analysis of enzymatic triggered release using PLC it was 
observed that a significant increase in spot number upon addition of the enzyme when compared to 
the control, only occurred for three formulations; PC:Chol (p<0.001), DOPC (p<0.001), and 
DOPC:Chol (p<0.01) with spot numbers counted to be 90 ± 28, 114 ± 36 and 62.9 ± 21.8 
respectively. There was no significant difference in the formulations for Triton X triggered release 
when compared to thermo-triggered release other than for PC (P<0.001) where spot number In fact 
decreased upon addition of the detergent. 
Enzymatic triggered release of PLA2 was similarly assessed (Figure 4.23).These results show that 
only two formulations (PC:Chol and DMPC) demonstrated a significant (p<0.001) increase in spot 
number compared to the formulations in the absence of PLA2. The spot numbers for PC:Chol 
formulations increased 2-fold from 28 ± 5 to 69 ± 16 with the presence of the PLA2 similarly for 
DMPC there was over a 2-fold increase from 64 ± 4 spots for the control to 146 ± 7.8 for PLA2 
triggered release, thus the greatest increase in spot number was for DMPC. Although the enzymatic 
triggered release from PLA2 gives an increased spot number, this simultaneously increases overall 
background level and an increased level of very small spots that are extremely difficult to discern 
from background on some occasions (Figure 4.24). Overall, from Figure 4.23 and 4.24 it can be seen 
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that the PC:Chol control formulations have consistently given well-defined spots and a reduced level 
of background without the need of a trigger.  
Another important aspect of reference standards was to be able to have a negative control and there 
was not any evidence of spots observed in the wells for the empty formulations (Figure 4.23). Empty 
liposomes would be robust negative reference standards thus any observance of spots in such wells 
would indicate a problem within the assay.  
.  
 
 
 
 
 
Figure 4.23 The effects of PLA2 on spot number for liposome formulations of varying lipid 
compositions including PC, PC:Chol, DPPC, DPPC:Chol, DMPC, DMPC:Chol, DOPC and 
DOPC:Chol placed in the ELISPOT assay. Results represent mean ± SD of n =3 batches. 
 
  
 
 
 
 
Figure 4.24 Representative ELISPOT wells of PC:Chol 8:8 μMol enlarged to compare the effects of 
trigger release mechanisms. 
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Figure 4.25 ELISPOT wells of control formulations of liposomes without rIFNγ. 
The results observed for thermo-triggered release can be explained in terms of two factors; the 
transition temperature of the lipid and the inclusion of cholesterol. Figure 4.20 showed that with the 
formulations containing solely lipid, enhanced release was observed generally in accordance to the Tm 
of the lipid thus PC and DOPC had the greatest spot numbers and they have a Tm of  -15 °C and -20 
°C (Szoka and Papahadjopoulos, 1980). Spot numbers for thermo-triggered release were the least for 
DPPC, which is a saturated phospholipid with a Tm of 41 °C, thus the bilayers remained in the ordered 
gel state at the incubation temperature of 37 °C. Therefore, DPPC formulations retained the 
encapsulated rIFNγ more effectively, than for instance DMPC, which has a transition temperature of 
23 °C (Maurer et al., 2001). Leakage is thought to be maximal at the Tm of the lipid due to the 
existence of the two phases; the gel state and the liquid crystalline state, which causes bilayer defects 
(Lasic, 1998). However, with the inclusion of cholesterol as is well established within literature there 
was an altered the pattern of release observed. The presence of cholesterol at 1:1 equimolar ratio for 
all of the lipid formulations (other than DPPC:Chol:Brchol) resulted in a decrease in spot number. 
The presence of cholesterol changes the nature of the bilayer through improved stability of the bilayer 
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by reducing the fluidity of the bilayer and thus the movement of molecules through the membrane 
(Kirby et al., 1980, Gregoriadis and Davis, 1979).  
Triton X is an effective detergent used for lysis of cells and liposomes; however, it is known that its 
presence can lead to interference in some immunoassays (Lepage et al., 1993). The Triton X wells 
(Figure 4.19) have increased background and reduced spot number. This may be due to the complete 
release of the rIFNγ from the liposomes or some level of interaction with the well itself or a 
combination of both. The results indicate the use of Triton X to enhance release for this study was 
ineffective. However, the results observed for PLC triggered release was promising for selected 
formulations such as PC:Chol. Increased spot numbers were also observed for PLA2 with PC:Chol 
and DMPC; however, enzymatic release did also increase the level of background. For the purposes of 
in in vivo targeted delivery, areas of elevated enzymatic levels in disease state are often sought for 
rapid and effective release (Davidsen et al., 2001, Kaasgaard et al., 2009). However the suggestion 
from the data and images obtained was that use of triggered mechanisms alters the kinetics of rIFNγ 
release from liposomes and the resultant increase in release may be too rapid, as even when increased 
release rate occurs with cells on the ELISPOT plate the spots are larger and less defined (Lehmann, 
2005). Furthermore elevated background levels with cells used in an ELISPOT assay can be as a 
direct result of increased secretory activity (Lehmann, 2005) 
The use of the liposomal formulations containing the synthesised dibromocholesterol proved 
ineffective for spot formation within the ELISPOT assay, perhaps due to the high negative surface 
charge of the formulation, which may be detrimental for settling of the liposomes onto the PVDF 
membrane. The process of sedimentation of colloidal particles is somewhat complicated, there is 
literature that supports theories of how sedimentation velocity can be influenced by the size of the 
container, much remains unknown about the fundamental properties of the long-range nature of 
hydrodynamic interactions between particles (Guazzelli, 2006). Even though the initial aim was to 
produce vesicles, which were higher in density, how the synthesised dibromocholesterol inserted into 
the liposomal bilayer and consequently its interaction with the encapsulating material and the 
surrounding hydrodynamic environment was uncertain. However, its application within the ELISPOT 
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assay proved unfeasible and was not suitable for further development as a reference standard within 
the ELISPOT assay. The formulations of PC, PC:Chol and DMPC have shown effective spot 
formation without any elevated levels of background and promising formulations for further 
development and optimisation. 
 
4.4 Conclusion 
Establishing an ELISA assay initially was essential to demonstrate quantitatively the level of 
encapsulation with liposomes as well as the effect on activity of the cytokine that other factors such as 
temperature or the presence of Triton X may have. The assay was both reproducible and accurate for 
the purposes of this study. Encapsulation of the recombinant IFNγ was been achieved with a wide 
variety of formulations of varying lipid and/or cholesterol composition. The results from the ELISA 
assay suggest that the cytokine was able to withstand a variety of temperatures up to 55 °C for up to 
30 minutes, which are sufficient for formulation purposes using a range of lipids. This allows us to 
investigate lipids with a range of transition temperatures for both thermo-triggered release and 
enzymatic release. A protocol for carrying out the ELISPOT assay was established, with an 
assessment of the pre-coating stage by using different volumes of 70 % ethanol. There seems to be no 
significant difference between spot numbers between the wells on variation of this parameter but the 
pre-wetting volumes of ethanol has shown that it can affect spot number and will thus be an integrated 
part of the protocol. 
More significantly, there are clear defined spots on the ELISPOT plate, which demonstrate that, the 
principle that liposome vesicles can release rIFNγ encapsulated onto the PVDF membrane of the plate 
to produce spots in a similar way to cells. Although the ‘proof of principle’ has been established; it 
has been found that the optimised formulation containing brominated cholesterol was not effective at 
producing spots on the wells and thus can be eliminated as a formulation to be optimised. Triton X 
triggered release has also shown to be ineffective; as there are high levels of background associated 
with its use in the wells. Such levels of background would be detrimental to producing a robust 
214 
 
reference standard furthermore the viscosity of the Triton X solution also meant that upon being 
pipetted into the well sedimented liposomes were moved back upwards, this disturbance of the settled 
liposomes would result in release occurring but not whilst the vesicles were in direct contact with the 
PVDF membrane. This study proves that it has no benefit as a trigger release mechanism in an 
ELISPOT assay and there was not used for further studies. From the control formulation where there 
are no external trigger release systems other than the heat at 37 °C from incubation there is reduced 
background and a better level of defined spots. Such formulations are less susceptible to changes in 
the pre-wetting volume although the issue of very small spots still emerges but this is less so than 
having additional trigger release mechanism present. The formulations of PC and PC with cholesterol 
(1:1) have consistently showed low levels of background, well-defined spots and good reproducibility 
even when the pre-wetting volume was changed. From the work thus far completed with no attempt at 
optimisation of background or size of vesicles, they seem like promising formulations candidates to 
take forward for thermo-triggered release. 
The enzymatic release studies so far indicate that the enzyme is working to degrade the vesicles for 
selective formulations such as PC:Chol and DMPC, however, for the majority of formulations at 
present this release is not translating in to an increased number of well-defined spots. Background 
levels when using the enzymes in the wells tends to be high, including diffuse spots and an increased 
number of very small spots. From the ELISPOT results, it is difficult to make decisive conclusions 
about the effectiveness of enzymes with formulations because they may be very effective at 
degradation and release of contents such as the Triton X, but this effectiveness may not be translating 
directly into an increase into spot number. The increase in number of smaller spots could also be 
counteractive when attempting to produce robust reference standards. Thus although ‘proof of 
principle’ has been established, further optimisation of the reference standards was required to ensure 
that they are robust and background levels are low and as such all parameters which could further 
enhance the reliability of the artificial reference standards was further investigated. Va 
n e 
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Chapter 5 
The optimisation of liposome formulations  
as artificial reference standards for the ELISPOT assay 
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5.1 Introduction 
The need for reference standards for immunological assays has become more apparent over the past 
decade, particularly for the ELISPOT assay, as concerns regarding variability of assays have grown 
(Smith et al., 2009, Janetzki et al., 2009). It has been found that immunoassays have been particularly 
problematic with regard to achieving the aim of standardisation (Wadhwa and Thorpe, 1998). The 
proof of concept for a novel artificial reference standard using liposomes within the ELISPOT assay 
was previously shown (chapter 4). However, further parameters required investigation, including 
optimisation of the protocol and establishing how such a novel reference can fulfil the criteria 
required of established reference standards. 
 
5.1.1 Reducing background levels when using liposomes in the ELISPOT assay  
The ELISPOT assay is established for the use of cells, and even for this purpose, the importance of 
reducing or eliminating background staining is an important consideration (Grant et al., 2005, 
Janetzki et al., 2005, Kalyuzhny, 2005). The assay is able to detect low-level cytokine secreting cells 
and this has resulted in its widespread use within vaccine clinical trials (Moodie et al., 2006). 
However, non-specific staining can give high background levels, leading to challenges in spot 
detection and quantification (Grant et al., 2005). 
In the previous work (chapter 4), liposomes were formulated in PBS. However, many ELISPOT assay 
protocols use cells placed in either media, or media supplemented with 10-20 % fetal bovine serum 
(Janetzki et al., 2005). More recently, the cancer vaccine consortium (CVC-CRI) has identified the 
choice of serum in ELISPOT assays as one of the leading causes for variability within assays and 
found that serum free medium performs as well as qualified medium/serum combinations (Janetzki et 
al., 2010). Therefore, it was necessary to assess the feasibility of using alternative resuspending 
medium to PBS that was previously used; especially as cell medium RPMI with or without 10 % FCS 
may help to reduce the inconsistencies observed with background variability. 
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Spot enumeration is normally conducted using a stereomicroscope, there are also automated processes 
available, but in both cases background levels need to be low to ensure accuracy (Janetzki et al., 
2004). In addition, there are difficulties associated with the use of manual counting techniques such as 
the difficulty in counting high spot numbers, limited resolution making it difficult to recognise and 
exclude artefacts, and the counting of small and faint spots (Janetzki et al., 2004). Thus, the 
importance of introducing an artificial standard with low levels of background and high levels of spot 
clarity are essential.  
 
5.1.2 Investigating the feasibility of calibration curves and enhancing spot number 
Generally, for the production of reference standards there has been a rule of ‘like versus like’ where 
the standard should mimic as closely as possible the test sample. However, there are an increasing 
number of exceptions to this rule, and according to the World Health Organisation (WHO) guidelines, 
no longer considered essential with some reference standards having qualitative rather than quantitave 
purposes (WHO, 2006). Reference materials are generally for the purpose of assay calibration, and 
invariably used in the form of a dose response curve, although they can also be used comparatively 
for comparing the performance of various assays and their ability to detect similar analytes (Thorpe, 
1998). Based on this, it was important to investigate the feasibility to produce calibration curves from 
a serial dilution of the highest control.   
Other parameters, which also required investigation, were the possibility of increasing spot number to 
produce a control. Optimisation of the control, which assesses whether the optimal lipid or cytokine 
concentration have been achieved are important parameters that require assessment. Examining the 
impact of changing these parameters on spot number will determine the limits for the reference 
standard in terms of maximum spot number achievable.  
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5.2 Aims and Objectives 
Therefore, the aim of the work was to optimise the formulation process so as to reducing background 
and enhancing spot number. Based on this, the objectives were as follows: 
 To assess the effect of resuspending liposome formulations with cell medium, in particular 
RPMI or RPMI with 10 % FCS and their compatibility within the assay. 
 To assess the feasibility of a calibration curve for the assay, using a serial dilution from the 
main reference standard. 
 To examine a range of lipid concentrations and subsequently assess the impact upon spot 
numbers. 
 To assess whether increased cytokine concentration can improve spot number and/or clarity 
of the spots obtained in the assay. 
 To compare spots produced from liposomes and those from live cells and automated reading 
of the ELISPOT assay and manual counting. 
 
5.3 Results and Discussion 
5.3.1 Assessment of optimised liposome formulations for triggered release 
Three liposomes formulations 1) PC, 2) PC:Chol and 3) DMPC were further investigated for triggered 
release within the ELISPOT assay, based on results from Chapter 4. There was no significant 
difference in the size or zeta potential across the formulations (Table 5.1). In the assessment of trigger 
release using either thermo-triggered or enzymatic-triggered release with PLA2 and PLC, it was found 
that the background levels for the assays were high from qualitative assessments (Figure 5.1). The 
representative wells of the thermo-triggered release control formulations shown with individual spots 
marked (Figure 5.1); this indicates the challenge of discerning the spots from the image alone 
(although when viewing directly under the stereomicroscope there was slightly greater clarity). 
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The overall results (Figure 5.2) indicate that in terms of thermo-triggered release there was no 
significant difference in observed spot numbers between the three liposome formulations (PC, 
PC:Chol and DMPC; Figure 5.2). Generally, the use of the enzymatic triggers PLA2 or PLC did not 
increase in spot numbers (Figure 5.2). However, only very low levels (1.3 ± 1) were detectable for the 
PC:Chol formulation in the presence PLC and spot numbers produced by the PC formulation in the 
presence of PLC were also significantly lower (two-fold; p<0.05) than those produced by the DMPC 
formulation.  
Table 5.1 Characterisation data for the formulations of PC, PC:Chol and DMPC used within the 
ELISPOT assay. Results represent mean ± SD for n=3 batches. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Representative ELISPOT wells for wells containing (a) ‘empty’ liposomes for PC, 
PC:Chol and DMPC and (b) control formulations containing rIFNγ without external triggers.   
 
Formulation Lipid composition        
( μMol) 
Size                         
(µm) 
Zeta Potential (mV) 
PC empty 16     7.98 ± 0.09 -9.72 ± 6.80 
PC:Chol empty 8:8           10.99 ± 0.20 -5.70 ± 5.70 
DMPC empty 16    8.11 ± 0.23 -8.88 ± 9.36 
PC rIFNγ 16     8.39 ± 0.06 -6.08 ± 6.32 
PC:Chol  rIFNγ 8:8     9.08 ± 0.01         -6.30  ± 7.80 
DMPC  rIFNγ 16  10.06 ± 0.05         -5.17  ± 7.85 
 PC: Chol empty 
DMPC with rIFNγ PC: Chol with rIFNγ PC with rIFNγ 
PC empty DMPC empty 
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 AND 
 
 
 
 
 
 
 
Figure 5.2 ELISPOT numbers for PC 16 μMol, PC:Chol 8:8 μMol and DMPC 16 μMol liposome 
formulations with thermo-triggered release (control) and enzymatic triggered release using PLA2 and 
PLC. Results represent mean ± SD for n=3 batches. 
 
Overall, these results show that using PLA2 and PLC as enzymatic triggers for release offers no 
benefit in terms of spot number (Figure 5.2). Previous results have confirmed that the enzymes can 
disrupt liposomes and promote triggered release (chapter 3), and there are numerous examples (e.g. 
Meers, 2001) where such enzymes, in particular PLA2, have effectively promoted release of liposomal 
contents. Thus the degradation of the liposomal membranes and subsequent protein release are most 
likely occurring; however, it maybe that the kinetics of release was not beneficial for spot formation. 
Indeed degradation of the liposomes may be too rapid and occurring prior to sedimentation of the 
liposomes and increase background levels. When cells are used within these assays to promote spot 
formation, the relationship between spot size is based on various parameters including cytokine 
secretion rate, net amount produced, binding and lateral diffusion of the cytokine (Karulin and 
Lehmann, 2012). A rapid secretion is thought to produce large spots which are not well defined 
(Lehmann, 2005).  
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In terms of thermo-triggered release, the lack of discernible differences between the three 
formulations of PC, PC:Chol and DMPC, these control formulations had no external trigger release 
mechanisms; the release of the encapsulated rIFNγ was a result of the permeability changes to the 
membrane occurring at the incubation temperature of 37 °C (Szoka and Papahadjopoulos, 1980). In a 
study by Anderson and Omri, (2010) the effect of different liposomal compositions were assessed for 
in vitro stability at 37 °C using DSPC, DPPC and DMPC liposomes prepared by sonication. It was 
found that DSPC formulations (which had the highest transition temperature of 55 °C) gave the 
highest retention (85 ± 10 %) of radiolabelled inulin at 37 °C and the lowest retention was observed 
for DMPC liposomes at 53 ± 5.3%. Whilst this may suggest that PC liposomes would give the highest 
spot number when used in the ELISPOT assay, the accuracy of this assay is dependent upon a good 
contrast between the background and spot formation. In the presence of high background levels spots 
become masked, compromising quantification (Kalyuzhny and Stark, 2001) thus enhanced release 
rates of rIFNγ within the assay may not translate into localised release of the protein when liposomes 
sediment in the well of the ELISPOT assay, which is required for effective spot formation with low 
background levels.  
 
5.3.2 Identifying the appropriate suspension media for liposomal reference standards for 
greater compatibility within the ELISPOT assay  
To further enhance the compatibility of the artificial liposome reference standards (PC 16 μMol and 
PC:Chol 8:8 μMol) within the ELISPOT assay, the liposomes were  re-suspended in either 1) PBS, 2) 
RPMI or 3) RPMI with 10 % FCS. When comparing the choice of suspension buffer (Figure 5.3), 
there was no significant difference in the spot numbers produced by either PC and PC:Chol liposome 
formulations in PBS or RPMI. However, when suspended in RPMI with 10 % FCS spot numbers 
were significantly reduced (p<0.05 and p<0.01 for PC and PC:Chol formulations respectively; Figure 
5.3). Indeed there was a two-fold reduction in the generation of spot number (Figure 5.3) for PC (from 
97.11 ± 21 in PBS to 45 ± 17 in RPMI with 10% FCS) and with the PC:Chol formulations over a five-
fold reduction in spot number (from 85 ± 21in PBS to 15 ± 7.7 in RPMI with 10 % FCS). As 
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previously noted there was no significant difference between the formulations in the same buffers 
(Figure 5.3).  
 
 
 
 
 
 
 
 
Figure 5.3 Spot numbers generated for formulations of PC 16 μMol and PC:Chol 8:8 μMol 
subsequent to two centrifugation steps and the effects of different resuspending medium. (Size: 11.92 
± 0.24 µm and 12.01 ± 2.4 µm respectively, data not shown). Results represent mean ± SD for n=3 
batches.  
 
The results showed that RPMI can be used as the re-suspending buffer instead of PBS allowing the 
reference standards to be in the same media as the rest of the samples placed within the assay thus 
making it more compatible (Hempel, 2004). Cells used in the ELISPOT assay are ordinarily in RPMI 
as it contains all the necessary carbohydrates, amino acids, vitamins and inorganic salts required for 
the cells and it is often necessary to add animal or human derived serum (Ng and Schantz, 2010). 
However, the additional presence of serum in the re-suspension media resulted in the reduction in spot 
number, and this may be due to serum induced liposome instability. A recent study (Hossann et al., 
2012) investigating the effect of serum on thermosensitive release of liposomes found the liposomes 
were influenced by serum components and the constitutive proteins can adsorb to liposomes and 
affect the integrity of the membrane bilayer through partial penetration promoting leakage of the 
entrapped material. However, previous studies by Gregoriadis and Senior (1980) have shown that 
P<0.05 
P<0.01 
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through the inclusion of 50 mole % of cholesterol in liposomes prepared from PC, DPPC or DMPC 
had enhanced stability, and in vivo permeability was significantly reduced through a reduction in 
opsonisation. For instance, the leakage of carboxyfluorescein from liposomes prepared from DSPC 
was reduced from 86.5 % to 32.4 %, and for PC liposomes retention increased from 0 to 86.3 %. 
Even when cells are used in assays, there is a general increase in the use of cell free medium (Ng and 
Schantz, 2010). The addition of the serum is thought to interfere with cell culture and subsequent 
analysis and disadvantages include lot–to-lot variation and the presence of inhibitors or toxins, which 
cause unwanted reactions or interference (Ng and Schantz, 2010). Within ELISPOT assays, the pre-
testing of serum batches is recommended to ensure low background reactivity and optimal antigen 
specific spot reduction. Furthermore, it has been reported by the Assay Working Group of the Cancer 
Vaccine Consortium (CVC-CRI) that the choice of serum to be the leading cause for variability and 
suboptimal performance in large international ELISPOT proficiency panels (Mander et al., 2010, 
Janetzki et al., 2010, Smith et al., 2009). To overcome the variability in the effect of batches received, 
and changes in serum properties over time, a large-scale harmonisation trial reported by Mander et al., 
(2010) (organised through The Cancer Immunotherapy Immunoguiding program) showed a direct 
comparison of serum and serum free medium on the ELISPOT assay. The recommendation was put 
forward that serum supplemented media could be eliminated, as detection rates and background were 
similar. A similar large-scale trial further confirms this recommendation, which has shown that one 
type of serum free medium showed increased spot number (Janetzki et al., 2010).  
Whilst it was most likely that the use of serum in this study resulted in decreased spot number with 
liposomes possibly due to a destabilising effect, changes in the viscosity of the resuspending buffer 
was also tested (as according to Stokes’ law, viscosity difference can affect sedimentation behaviour 
(Banker and Rhodes, 2002)). The results in Table 5.3 confirmed that there was no significant 
difference in the viscosities between the formulations. 
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Table 5.2 PC (16 μMol) formulations assessed for differences in viscosity between 1) PBS, 2) RPMI 
and 3) RPMI with 10 % FCS. Results represent mean ± SD for n=3 batches. 
 Dynamic Viscosity[mPa.s] Kinetic Viscosity[mm2/s] 
PBS  1.07 ± 0.11 1.07 ± 0.11 
RPMI 0.98 ± 0.00 0.98 ± 0.11 
RPMI with 10% FCS 0.97 ± 0.00 0.97 ± 0.00 
 
5.3.3 Reducing background in ELISPOT wells by modification of centrifugation steps for the 
removal of non-incorporated rIFNγ 
The basic protocol established for the removal of unentrapped protein subsequent to formulation was 
one centrifugation step at 29,771 g for 30 minutes at 4°C (chapter 4). However, the results observed 
(section 5.3.1) have shown that background levels are varying between assays. The effects of 
modifying the protocol, to include an additional centrifugation step of 29,771 g for 30 minutes at 4 °C 
was assessed with liposome formulations composed of 1) PC, 2) PC:Chol or 3) DMPC (total 16 
μMol) were assessed. The results for the physicochemical characterisation (Table 5.3) show that there 
was no significant difference in the physicochemical attributes of the formulations in terms of their 
vesicle size or zeta potential, as previously noted. 
 
Table 5.3 Characterisation data for liposomes composed of PC, PC:Chol or DMPC. Results represent 
mean ± SD for n=3 batches. 
In terms of their efficacy as ELISPOT standards (Figure 5.4), there was a significant (p<0.001) 
increase in detectable spot number from the pre-centrifuged liposome formulations to the spots 
counted after the first centrifugation step. For liposomes prepared with PC and DMPC there was over 
a three-fold increase in mean spot number, and for PC:Chol liposomes there was over a five- fold 
Formulation Lipid composition     
( μMol)                      
Size (µm) Zeta Potential (mV) 
PC 16  10.4 ± 1.27 -13.0 ± 7.94 
PC: Chol 8: 8 8.99 ± 1.09 -5.96 ± 6.82 
DMPC 16 7.83 ± 0.81 -6.88 ± 6.95 
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increase in spot number (Figure 5.4). However, the addition of a second centrifugation step, made no 
significant difference in spot number for any of the formulations and there was no significant 
difference between the three formulations for spot number at each stage (Figure 5.4). In terms of a 
qualitative assessment of the wells the impact of an additional centrifugation step did not make a 
notable difference to the background of the wells, although the intensity of the individual spots was 
slightly improved from the first centrifugation step (Figure 5.4 b) and subsequent to the second 
centrifugation step (Figure 5.4 c).  
The increased spot number noted in the assay after removal of unentrapped rIFNγ from the liposome 
preparations, can be attributed to the presence of the free cytokine diffusing across the well prior to 
centrifugation, leading to high background levels and lower spot definition (Chambers et al., 2010). 
This excess cytokine is detrimental to the specificity and sensitivity of the assay and can be related to 
other immunological assays such as ELISA assays. High protein binding plates are used to enhance 
detection in ELISA assays, but can result in high background levels and samples are either titrated to 
reduce the concentration plated or lower binding plates are used (Chiswick et al., 2012).  
Given that there was no significant difference in results after one or two centrifugation steps, this 
suggests that one centrifugation step can sufficiently remove free rIFNγ to an appropriate level. A 
two-step centrifugation protocol has previously been used for the effective removal of unentrapped 
protein, for vaccine containing formulations (Gregoriadis et al., 1999). In this study, the liposome 
formulations were centrifuged at 40,000 g for 60 minutes at 4 °C and then the process was repeated 
again to ensure the effective removal of free vaccine. Thus, although an additional centrifugation step 
may be beneficial to ensure the removal of residual protein in this instance this did not translate into 
increased spot numbers, although background levels were improved slightly.  
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Figure 5.4 The spot numbers generated for PC, PC:Chol and DMPC liposome formulations (16 μMol total for each), shown pre-centrifugation and post 
centrifugation at 29, 771 g for 30 minutes and after the second centrifugation at 29, 771 g for 30 minutes. Representative ELISPOT images are also shown (a) 
pre-centrifugation (b) post- centrifugation 1 and (c) post -centrifugation 2 for each liposome formulation. Results represent mean ± SD for n=3 batches.
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5.3.3.1 Reducing background of ELISPOT wells by removal of smaller liposomal vesicles 
Previous results have shown that the addition of a slower centrifugation step for a short duration can 
aid the retention of larger liposomes and the removal of smaller liposomes (chapter 3). The inclusion 
of a slow speed and short duration step was included within the current protocol for the assessment on 
spot numbers. The protocol for the formulation and removal of unencapsulated rIFNγ included the 
following stages: 
1. Centrifuge the formulations at 29, 771 g for 30 minutes at 4 °C. 
2. Remove supernatant and re-suspend pellet in 3.9 mL of PBS. 
3. Centrifuge the formulations at 29, 771 g for 30 minutes at 4 °C. 
4. Remove the supernatant and re-suspend the pellet in 5 mL of PBS. 
5. Centrifuge the formulations at 205 g for 10 minutes at 4 °C. 
6. Resuspend formulations in 2 mL of RPMI. 
The results in Figure 5.5 show that PC and PC:Chol formulations (16 μMol total) assessed using the 
optimised protocol showed no significant increase in spot numbers counted. However, there were 
improvements in background levels and spot clarity (Figure 5.6) especially when compared to the 
background of wells from the previous protocols such as Figure 5.4. The aim of adding the additional 
centrifugation step (205 g for 10 minutes at 4 °C) was to assess the effects of removing some of the 
smaller vesicles. The MLV formulations produced are heterogenous in nature (Figure 5.7) and thus 
there will be particles less than a micron in size, for such particles to pellet centrifugation speeds of 
100,000 g are required (Gregoriadis and Senior, 1980). Differential centrifugation has been used 
extensively within the cellular field as an established method for the speration of cellular components 
and depends upon the fact that such components differ in size and density and will therefore sediment 
at different rates (Suckling and Suckling, 1980). Larger and denser particles will centrifuge more 
rapidly, so in terms of cell work small proteins and free lipid will remain in the supernatant (Suckling 
and Suckling, 1980). Based on such principles, and the previously observed effects of reducing the 
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number of smaller vesicles in the formulation (Chapter 2), such a step should form a part of an 
optimised protocol.  
 
 
 
 
 
 
 
 
 
Figure 5.5 ELISPOT spot numbers to show liposome formulations of PC and PC:Chol (16 μMol total 
lipid) pre and post centrifugation (size 8.2µm ±0.24 and 9.5 µm ±1.19 respectively). Results represent 
mean ± SD for n=3 batches. 
 
 
 
 
 
 
 
 
Figure 5.6 Representative images from ELISPOT wells of PC (16 μMol) wells pre and post removal 
of SUV liposomes. 
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Figure 5.7 Cumulative size distribution curve shown for a PC:Chol liposome formulation with a 
mean particle diameter of 8.29 ± 0.06 µm. 
 
5.3.3.2 Adaptation of the protocol to meet the needs of scale-up requirements 
Although a protocol with low levels of background and high levels of spot clarity had been achieved 
(section 5.3.4), it was time consuming both in terms of the overall process time for the formulation 
procedure and in terms of the different preparative steps for the operator. In terms of biological 
material, it is important that the manufacturing process in place can be scaled up from the small 
amounts required in the laboratory, to large commercial needs (Evans, 2007). In terms of producing a 
reference standard, at a certain stage in development a larger batch size that can be used for routine 
testing, calibration and validation will be required (Raut and Hubbard, 2010). At this stage, the 
protocol consisted of two 30-minute centrifugation steps using the ultra-centrifuge, which involved 
pipetting into specialised 3.9 mL tubes without an air bubble and then heat sealing prior to each 
centrifugation. The centrifuge then required time for the vacuum to be at the correct level, which adds 
another ten minute for each run. Subsequent to each centrifugation step, it was necessary to re-
disperse the pelleted liposomes.  
Thus, the manufacturing process was quite long even for a small batch. This was not only a logistical 
issue but can also effect the protein as discussed in Chapter 4; the process of centrifugation and 
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vortexing could impact on the protein integrity, thus a protracted formulation process should be 
avoided (Christova et al., 2003). Therefore the protocol for preparation of the liposome formulations 
was further modified (outlined below), with the ultra-centrifuge steps removed. Instead, there was an 
additional slower centrifugation step incorporated into the protocol using a lab centrifuge for the 
reduction of the background by simultaneously removing free rIFNγ and smaller liposomal vesicles. 
The modified protocol consisted of: 
1. The 2 mL formulations made up to 5 mL with PBS in a 10 mL tube. 
2. Centrifuge for 15 minutes at 2660 g at 4 °C. 
3. Re-suspend liposomal pellet in 5 mL of RPMI. 
4. Centrifuge at 206 g for 10 minutes at 4 °C.  
5. Re-suspend liposomal pellet in 1 mL in RPMI. 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 ELISPOT spot numbers for the formulations of PC 16 μMol and PC:Chol 8:8 μMol for a 
modified protocol to meet scale-up requirements (Size of formulations: 9.5 ± 1.24 µm and 11.5 ± 1.25 
µm respectively). Results represent mean ± SD for n=3 batches.  
(p <0.05) 
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Through the re-suspension of the final pellet in 1 mL as opposed to the normal 2 mL, there was an 
observed increase in spot number compared to previous assays (Figure 5.8 vs. Figure 5.5). In terms of 
spot number, there was a significant difference (p<0.05) in the mean between liposomal formulations 
for PC and PC:Chol with spot numbers of 198 ± 34 and 115 ± 17 respectively (Figure 5.8). 
Qualitative assessment of the wells showed that the background was low and the spots counted 
without any difficulty, as they were distinctive from the background (Figure 5.9). In terms of 
production of formulations, this was a more user friendly and quicker protocol. For this study, the 
initial concentrations of the formulations were 9 mg/mL but during centrifugation, the increase in 
volume results in a concentration of 1.8 mg/mL. Thus, larger volumes of RPMI could be used to 
ensure effective removal of unentrapped cytokine. It is perhaps this reduction in the observed 
background levels (Figure 5.9), the removal of smaller vesicles, and changing the re-suspending 
volume, which has allowed effective spot formation.  
 
 
 
 
 
 
 
 
 
Figure 5.9 ELISPOT wells for formulations of PC a 16 μMol and PC:Chol 8:8 μMol formulations 
from a modified protocol to meet scale-up requirements. Total spot numbers evaluated by manual 
counting for the liposomal formulations of PC and PC:Chol were 198 ± 34 and 115 ± 17 respectively.  
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In numerous protocols where centrifugation has been used as a means to remove unentrapped 
material, centrifugation speeds used are generally high (Szoka and Papahadjopoulos, 1980). This is 
often necessary to enhance recovery of the liposomes particularly with small unilamellar vesicles 
(Gregoriadis and Senior, 1980). However, in a study by Dey-Hazra et al., (2010) examining the 
detection of circulating platelet derived micro-particles, different centrifugation protocols were 
investigated for their extraction from plasma. It was found that at slower centrifugation speeds at 1500 
g, the amount of microparticles were 10 to 15 fold higher compared with protocols using 
centrifugation speeds of 5000 g (p<0.001). This confirms that the careful selection of centrifugation 
protocols can result in the separation of smaller particles. 
 
5.3.4 Testing the feasibility of a calibration curve and inter batch variation 
Previous work has shown that liposome encapsulated rIFNγ can be used within ELISPOT assays to 
produce an artificial reference standard. It was important to assess the feasibility of using this control 
and carrying out a serial dilution to produce a calibration curve. Liposomal formulations of PC and 
PC:Chol (16 μMol total) were characterised for size and zeta potential (Table 5.4). There was no 
significant difference observed in the size or zeta potential of the formulations. The serial dilution of 
the neat standard controls were carried out in RPMI at a 1:1 ratio with the initial 1 mL control 
produced from the formulation protocol.  
The results observed for both PC and PC:Chol liposome reference standards (Figure 5.10 and 5.11 
respectively) indicated that the calibration curves were not linear. However, these fit an exponential 
trend line (or for logarithmic conversion the power trend line). The R
2
 value for the PC liposome 
formulation was 0.998 and the R
2
 value for PC:Chol formulation was 0.986. The images show that 
spots were well defined and the background decreases by the dilution of the formulations in RPMI 
(Figure 5.12). 
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Table 5.4 Characterisation data for PC:Chol and PC liposome formulations (16 μMol total). Results 
represent mean ± SD for n=3 batches. 
 
ICH guidelines recognise that immunoassays in particular, do not always demonstrate a linear 
relationship, as observed from the results of this study. Therefore, the analytical response was 
described by an appropriate function of the concentration (ICH, 2006). Although the R
2
 values 
indicated a good fit, there was a high standard deviation for each dilution. The coefficient of variation 
is a statistical term, which can be used to express the variability of a set of data and is defined as the 
ratio of the standard deviation to the mean (Jones, 2002). It is typically used within immune assays to 
show the variance, a CV % of 20 is normally used to define the limits (Shah et al., 1992). The 
coefficient of variation across the three formulations for the PC liposome formulation at each 
calibration dilution ranged from 38.5 % to 61 %, and for PC:Chol liposomes from 22.8 % to 94 %.  
Other ELISPOT studies have shown coefficient of variations for inter- and intra- assay to be 21.9 % 
and 24.7 % respectively (Kumar et al., 2001). Furthermore, a study examining IFNγ release from 
PBMCs in cancer patients have shown the inter- assay variation to be 15 % (Asai et al., 2000), 
suggesting that the variability from using the liposomes as standards remains higher than required. 
However, in terms of a reference standard this is acceptable, because for production purposes there is 
production of a single, validated batch. For instance, when cytokine standards are produced for the 
WHO ordinarily a batch of 3500 ampoules maybe produced and validated; thus the variability within 
the batch would be expected to fall within defined limits (R. Mire-Sluis et al., 1998). 
 
Formulation Lipid composition     
( μMol )                      
Size (µm)                       Zeta Potential (mV) 
PC rIFNγ 16   7.21 ± 0.33 -6.56 ± 9.22 
PC:Chol  rIFNγ 8: 8  10.22 ± 3.37 -13.2 ± 10.1 
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Figure 5.10 Serial dilutions of PC liposomes (16 
µMol) with rIFNγ. Results are shown with an 
exponential trend line. Results are mean ± SD for 
n=3 assays. 
 
 
Figure 5.11 Serial dilutions of PC:Chol (8:8 
µMol) liposomes with rIFNγ. Results are 
shown with an exponential trend line. Results 
are mean ± SD for n=3 assays.  
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Figure 5.12 A representative 
assay for PC 16 µMol 
formulations with single wells 
shown for increasing 
concentrations. 
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5.3.4.1 Reproducibility assessment of a single batch of reference standard to assess intra batch 
variation 
Subsequent to the formulation of a single batch of PC 16 μMol liposomes with rIFNγ (particle size 
9.79 ± 0.3 µm; results not shown), assessment of batch reproducibility was required. From the stock 
preparation, a 1:1 serial dilution in RPMI was carried out three times and ran across three plates and 
the results for the individual replicates are shown in Figure 5.13, with the average shown in Figure 
5.14. The results for each serial dilution, per well, are also shown (Figure 5.15). The three calibration 
curves similarly followed an exponential trend line and demonstrated a good fit as shown by the R
2
 
values of 0.995, 0.99 and 0.99 for n=3 assays (Figure 5.13). Similarly, for the average of the three-
combined curves (Figure 5.14), the R
2
 value was 0.99 and the points for each dilution followed the 
exponential trend line closely. The standard deviations on each dilution show a reduced variation 
compared to those in Figure 5.8 and Figure 5.9. The results for the values for each well (Figure 5.15) 
further highlight the reproducibility across the three assays. 
The coefficient of variation was < 15 % for calibrator 1, 2, 3 which were the three strongest dilutions 
then for the lower part of the curve it was <30 %. Thus, the average coefficient of variation for the 
serial dilution was 23.6 %, which shows an acceptable level of reproducibility at this stage of 
optimisation. In some studies using the ELISPOT assay, an acceptable coefficient of variation was 
defined as ≤ 20 %, although in the study of responses from ten participants that observed variation 
was actually 25 – 36 % (Comin-Anduix et al., 2006). 
The results for the assessment of reproducibility were promising because although the batch-to-batch 
variability was high in previous results, this study has shown that one batch can produce good 
reproducible results. Within immunoassays variability between different batches can occur with many 
showing large assay errors (Deshpande, 1996). The overall shape of the curve also followed a non-
linear pattern, but most immunoassays exhibit a non-linear relationship between the response and the 
analyte (Deshpande, 1996).  
 
236 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R² = 0.9947 
R² = 0.9958 
R² = 0.9947 
0
50
100
150
200
250
300
0.1 1 10
Sp
o
t 
n
u
m
b
e
r 
Log concentration (mg/mL) 
Replicate 1
Replicate 2
Replicate 3
R² = 0.9993 
0
50
100
150
200
250
300
0.1 1 10
Sp
o
t 
n
u
m
b
e
r 
Log concentration (mg/mL) 
0
50
100
150
200
250
300
350
0.37 0.75 1.50 3.00 6.00 12.00
Sp
o
t 
N
u
m
b
e
r 
Concentration mg/mL 
Replicate 1a
Replicate 1b
Replicate 1c
Replicate 2a
Replicate 2b
Replicate 2c
Replicate 3a
Replicate 3b
Replicate 3c
Figure 5.13 Three replicate curves from one batch of PC 16 
µMol formulation on three separate assays with R
2
 values. 
 
Figure 5.14 The mean of three replicate curves from one 
liposomal batch of PC 16 µMol with R
2
 values. Results 
represent mean ± SD, n =3. 
 
Figure 5.15 Individual results for spot numbers for each replicate for the 
triplicate assays of PC 16 µMol.  
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In a study by Janetzki et al., (2006) 200,000 cells per well were plated with subsequent dilutions at 
100,000, 50,000 and 25,000 cells per wells and the number of spots were counted with and without 
stimulation from a peptide pool. Similarly, triplicate wells were tested for each condition. The shape 
of the curves obtained are comparable with R
2
 values in the experiment for stimulated versus non-
stimulated at >0.9 and >0.84 respectively. Within the scope of ELISPOT literature, a calibration curve 
has not previously shown for a reference standard. Ordinarily reference standards for the ELISPOT 
assay rely on stimulating cells to produce high levels of IFNγ. There are three main types of existing 
controls mitogens, ionophores and peptide pools (Currier et al., 2002). Mitogens which include; 
Phytohaemagglutin (PHA), Concavalin A (ConA), Lipopolyscaccharide (LPS) induce proliferation in 
a variety of cell types particularly T-lymphocytes and ionophores such as phorbol myristate acetate 
(PMA) mimic early signal transduction pathways and activate human T-lymphocytes to secrete 
cytokines (Moreland, 2004, Chopra et al., 1989). The disadvantages of such controls such as PHA is 
that patches can occur in the wells, spots can vary widely in size, intensity and shape and loss of 
activity during storage (Currier et al., 2002). In this study an artificial reference standards has been 
shown to produce a reproducible calibration curve, thus the ‘proof of concept’ has been extended and 
this study shows that artificial vesicle with encapsulated cytokine are able to mimic the actions of the 
cell on the ELISPOT assay. 
 
5.3.5 Quantitative comparison of automated and manual reading. 
Although much of the work for this study had, thus far used manual ELISPOT counting, normally 
automated procedures are used to reduce reader bias (Cox et al., 2006). Therefore, it was important to 
assess how the automated reading of a calibration curve with the reference standards would perform 
when compared to the manual reading using a stereomicroscope. With three batches of PC 16 μMol 
liposome formulations containing rIFNγ, serial dilutions using 1:1 RPMI were carried out with each 
dilution placed on two separate plates. Results were analysed by manual counting using a 
stereomicroscope and automated counting at NIBSC.  
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The observed results (Figure 5.16 a) confirm that previous assays using the manual counting method 
were comparable to the assays read using automated reading. In addition, it showed that the spots 
produced by the reference standards were of a suitable size, morphology and counted effectively 
through the automated procedure (Figure 5.16 b and c). The curve used was the fit spline curve and 
statistical analysis of the curves using F2 similarity factor resulted in an obtained value of 50.5 values 
between 50 – 100 are acceptable according to the FDA regulations (Yuksel et al., 2000). Thus, the 
two curves are considered similar and results obtained thus confirm that for the purposes of this study, 
spot-counting using a manual method was comparable to the automated method.  
The use of automated reading is recommended as a means for standardisation of protocols and it is 
thought to reduce the variability observed by manual counting (Janetzki et al., 2005). In a study by 
Almeida et al., (2009), automated and manual protocols for spot enumeration were compared for 
PBMCs from six healthy individuals (fresh) and with cryopreserved cells. It was found that similar 
cells counts were obtained for both methods; with the median manual count at 66.18 spots and a range 
from 22 to 128.21 spots generated compared with automated at a median cell count of 69 and a range 
of 22 to 128.1 spots generated for fresh cells (Almeida et al., 2009). Similar comparable results were 
observed with cryopreserved cells, and indicate that automated and manual spot enumeration 
techniques can provide similar results. 
Manual counting procedures are carried out using a stereomicroscope, which typically consists of a 4 
X objective lens and further 10 X magnification through the eyepiece (Kaluzhny, 2005). This 
technique relies solely on the operator to assess the spot number. Although time consuming and 
tedious, it is thought to have a higher sensitivity in identifying faint spots of smaller sizes although no 
significant differences were observed at the weaker concentrations in this study, the mean spot 
numbers counted were higher for the manual count (Hagen, 2012). The use of automated procedures 
within the field of ELISPOT is advised on many levels including harmonisation of results between 
different laboratories, automated counting offers many advantages including the reading of multiple 
plates, reduction in bias and increased accuracy (Cox et al., 2006).  
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Figure 5.16 A quantitative and qualitative comparison of manual and automated reading procedures for the ELISPOT assay.(a) A fit spline curve comparison 
between automated and manual counting of ELISPOT wells of three batches of PC 16 μMol with an average size of 7.96 µm ± 1.41 and average zeta 
potential of -7.51 ± 4.65 mV. Results shown are for n=3 assays ± SD. (b) Images for ELISPOT wells using automated reading (c) Images for spots counted 
manually using a stereomicroscope. 
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Figure 5.17 ELISPOT images for automated reading and the final protocol. Artificial reference 
standards are shown for two assays with automated reading (a) and (b) highlighting high levels of 
background in wells in comparison to (c) live cells. The final protocol when applied to automated 
reading is shown (d). The protocol (e) for the removal of free rIFNγ used for the assay (Table 2.4; 
protocol 4). 
 
The final protocol should be adaptable for all situations as required by the user; this is a part of having 
a robust reference standard (ICH, 2006). However when assays were assessed using automated 
counting procedures, qualitative assessments revealed higher background levels (Figure 5.16 b and 
5.17 a and b). This was particularly notable when compared to the cells normally plated in the assay 
(Figure 5.17 c). To address this, an additional step was brought back into the protocol of 2660 g for 15 
minutes at 4 °C. This resulted in more acceptable levels of background (Figure 5.17 d). Thus, the final 
protocol (Figure 5.17 e) meets end user requirements in that it offers potential for scale up to larger 
batches and robust enough to achieve low levels of background was established (Figure 5.17 e). 
Unless the formulation procedure for the formulation of reference standards was robust then this will 
a 
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2 mL Liposome 
formulation 
Make up to 5 mL with RPMI 
and centrifuge at 4 °C for 15 
minutes at 2660 g. 
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Remove supernatant 
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centrifuge for 206 g for 10 min. 
e 
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limit the potential of transfer from smaller batch production to larger scale requirements (Wagner, 
2011).  
5.3.6 A qualitative assessment of live cells vs. artificial reference standards 
It was necessary to make a qualitative assessment of how spots produced from live cells compared to 
those produced from the formulated artificial liposome reference standards. This was an important 
issue as the reference standard needed to mimic the actions of live cells and produce spots. In 
addition, the wells needed to have comparable background levels. Thus, live cells were used to 
produce spots (Figure 5.18) and images taken using a stereomicroscope to compare the wells directly 
to the wells that have liposome reference standards. The images of the live cells (Figure 5.18) 
highlight the spot definition against the low levels of background observed.   
Figure 5.19 a, shows a representative image for the artificial liposomal reference standard and Figure 
5.19 b shows an ELISPOT well produced from cells. From qualitative observations the liposome-
induced spots do not diffuse out the way the cell forming spots do; the live cells seem to produce 
larger spots. The T-cells ordinarily placed into the wells are spherical with a diameter of 10-15 µm 
and are thus physically a similar average size to the liposomes used (Weiss, 2012). 
Spot sizes within cells can vary due to different cell types within the mixed populations that are 
placed onto the wells. For instance, macrophage derived spots for IL-10 cytokine are much smaller 
than T-cell antigen induced spots (Lehmann, 2005). It is also thought that reduced cytokine activity 
from a cell results in the formation of smaller spots (Lehmann, 2005). This suggests that the levels of 
entrapped cytokine are not equivalent to the amount of cytokine released by the live cells. Although 
the images (Figure 5.19) have shown productions of spots from an artificial reference standard are not 
exactly the same, the similarity is close enough to make it difficult (without prior knowledge) to 
discern the two. 
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Figure 5.18 ELISPOT plate sent from NIBSC of peripheral blood mononuclear cells stimulated with 
phorbol 12-myristate 13-acetate (PMA), and purified protein derivative (PPD). PMA stimulated cells 
are shown in the top row and PPD stimulated cells shown in the lower row. 
 
 
Figure 5.19 A direct comparison of a well from an ELISPOT assay of cells and an artificial reference 
standard. (a) A well from an ELISPOT plate of a PC (16 μMol) liposome formulation with rIFNγ and 
(b) A well from an ELISPOT of PBMCs stimulated with PMA (phorbol 12-myristate 13-acetate). 
 
Immunoassays’ can be particularly problematic from a standardisation view-point because of their 
ability to bind selectively to different molecular species of an analyte (Thorpe, 1998). In terms of the 
ELISPOT assay, the challenge for finding a robust reference standard is due to the nature of the assay, 
which is ex vivo and cells (generally peripheral blood mononuclear cells (PBMCs) or other subsets 
from the blood) are used directly on the assay. There are currently no reference standards used 
consistently from laboratory to laboratory and in conjunction with variations in protocol this has 
100μm 
a b 
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greatly affected standardisation (Janetzki and Britten, 2012). Liposomes have not been used within the 
assay previously, but as shown in Figure 5.19 they can be directly comparable. It is not necessary for 
reference standard production to be the same as the components of the assay and according to WHO 
guidelines; reference standards may differ from the formulation or matrices of the examined 
substances (WHO, 2006). 
 
5.3.7 Assessing the effects of spot number on increasing lipid concentration 
For the purposes of producing a reference standard, a high positive control maybe needed, thus with 
the aim of increasing the spot number, the effect of increased lipid concentration was investigated. 
The formulations assessed were for PC at 16, 32 or 64 μMol and PC:Chol (1:1 ratio) at the same total 
molar concentrations (Table 5.5). Also assessed were pooled formulations consisting of two smaller 
concentrations, such as 16 μMol and 16 μMol, to make up the larger concentration of 32 μMol of total 
lipid. The formulations were characterised for size (Table 5.5). There was no significant difference in 
size observed for the formulations including the pooled batches, thus any affects seen in the ELISPOT 
data are a direct result of increased lipid concentration. 
The results observed (Figure 5.20) indicated that as the lipid concentration increased there was no 
increase in spot number. In fact for liposome formulations of PC 16, 32 or 64 μMol, there is a trend of 
decreasing mean spot number with significant differences (p<0.05) observed for PC formulations of 
16 μMol and 32 μMol, when compared with 64 μMol formulations (Figure 5.20). Spot numbers 
reduced from 62 ± 15 spots to 18 ± 8 (PC 16 μMol vs. PC 64 μMol) and 53 ± 13 spots generated to 18 
± 8 (PC 32 μMol vs. PC 64 μMol) respectively. Similar results (Figure 5.20) for the PC:Chol 
formulations are shown; as the lipid concentrations increased there was a trend of decreasing spot 
number as the lipid concentrations increased from 8:8 μMol, 16:16 μMol and 32: 32 μMol (from 120 
± 25 to 85 ± 8 to 64 ± 19 respectively; Figure 5.20). There was a significant decrease (p<0.005) of 
nearly two-fold for PC:Chol formulations of 8:8 μMol when compared to PC:Chol formulations at 32: 
32 μMol lipid concentration. 
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There was an increase in spot number for the pooled batch of 16 μMol + 16 μMol for the PC liposome 
formulations, which was significantly higher than the other lipid concentrations of 16, 32 and 64 
μMol  (p<0.001; Figure 5.20). For the PC:Chol pooled liposomes batches of 8:8 μMol + 8:8 μMol 
there was over a 3-fold increase in mean spot number and it was statistically significant when 
compared to 32:32 μMol (P<0.001). Whilst the pooled batches for PC and PC:Chol formulations 
showed statistically significant increases in spot number at 8:8 + 8:8 μMol and 16+16 μMol compared 
to non-pooled batches; this trend did not continue when higher concentrations of the pooled batches 
were used. Thus PC:Chol 16:16+16:16 μMol formulations and PC 32+32 μMol formulations 
generated significantly lower spots numbers (p<0.05 and p<0.001 respectively) with almost a 3 fold 
and 9 fold decrease respectively, when compared to the lower concentration pooled batches (Figure 
5.20). 
The results observed for the effect of increasing lipid concentration were interesting as there was no 
linear increase in spot number observed with the non-pooled formulations. In a study by Zhang et al., 
(2009) a wide range of PBMC cell concentrations were tested to assess the relationship between 
ELISPOT results and increasing cell number. Thus serial dilutions used ranged from 1.6 x 10
6
 to 5.0 x 
10
5
 PBMC per well (stimulated with CMV peptide PP65). A linear relationship was observed between 
cell number and spots generated between 5.0 x 10
4
 and 4.0 x 10
5
 cells per well. However, in Figure 
5.21 a similar conclusion cannot be applied, there was no evidence of the confluence of spots 
furthermore background levels appeared to be acceptable (Figure 5.21). In the study by Zhang et al., 
(2009) spot numbers of up to 753 were observed for some of the higher cell concentrations, yet 
however the liposomal reference standards for the non-pooled formulations generated 120 spots 
(Figure 5.20). Further investigative work was carried out by similarly using a serial dilution at the 
three different concentrations of PC:Chol liposome formulations (Table 5.6).  
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Table 5.5 Size characterisation for 5 formulations of PC and PC:Chol with increasing concentrations 
of lipids or lipid and cholesterol in a 1:1 ratio. Results represent mean ± SD, n =3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 The effect of increasing lipid concentrations for PC and PC:Chol liposome formulations. 
on spot numbers generated. Results represent mean ± SD of n =3 batches. 
 
 
 
Formulation Lipid concentration  (μMol)    Size (µm)  
PC:Chol 8:8 8.72 ± 0.98 
PC:Chol 16:16 8.49 ± 1.06 
PC:Chol 32:32 9.06 ± 0.54 
PC:Chol (pooled 16:16) 8:8 + 8:8 8.91 ± 1.43 
PC:Chol (pooled 32:32) 16:16 + 16: 16 9.53 ± 0.60 
PC 16 7.13 ± 1.26 
PC 32 6.94 ± 1.27 
PC 64 7.19 ± 0.89 
PC (pooled 32) 16 + 16 7.91 ± 1.49 
PC (pooled 64) 32 + 32 8.02 ± 1.29 
P<0.05 
P<0.05 
P<0.05 
P<0.001 P<0.001 
P<0.05 
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Figure 5.21 Representative ELISPOT wells for increasing lipid concentration for liposome 
formulations of PC and PC:Chol.  
 
The results shown in Figure 5.22 were shown to have high standard deviations across the three 
different lipid amounts used for the liposomal formulations. However, there are notable differences in 
the trends between the three concentrations of the PC:Chol formulations. For the lower concentration 
(8:8 μMol; Figure 5.20), the spot number reduces from approximately 100 spots to below 20 spots per 
well with increasing concentration of liposomes as would be expected (Figure 5.22). In contrast, at 
higher concentrations (16:16 μMol and 32:32 μMol), initial spot counts are lower (approximately 80 
and 40 spots per well respectively; Figure 5.22). On dilution of these two concentrations, spot 
numbers increase to maximum spot counts of approximately 100 spots per well for the 16:16 μMol 
concentration and approximately 60 spots per well for the higher concentration (Figure 5.22). 
Subsequent further dilution of these two liposome concentrations results reduces spot number to 
similar levels as the 8:8 μMol liposome concentration (Figure 5.22). 
Thus, the results indicate that at the lower concentrations the relationship between spot number and 
liposome concentrations is very similar to that observed when PBMCs were plated out using serial 
dilutions (Zhang et al., 2009, Janetzki et al., 2006). However, the relationship between spot numbers 
at higher liposome concentrations was not observed with cells. This suggests that there is a hindrance 
to spot formation by excess liposomes being present. Although when live cells are used within the 
assay cell number optimisation is necessary, the critical parameter for spot formation to occur is the 
effective contact of the vesicles and the membrane (Dittrich and Lehmann, 2012). 
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Table 5.6 Characterisation data for the increasing lipid concentration of PC:Chol formulations of 8:8 
μMol, 16:16 μMol and 32:32 μMol . Results represent the mean ± SD of n=3 batches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22 Liposomal formulations of PC:Chol of increased lipid concentrations 8:8 μMol, 16:16 
μMol, and 32:32 μMol as serial dilutions for n=3 batches ran across three separate assays.  
 
Once this occurs then can the secreted molecule can be captured onto the antibody-coated membrane, 
this is true for cells and thus can equally be applied to liposomes. In an assessment of the quality of 
staining for live cells, it has been shown that the presence of ‘dead’ cells can cause high background 
staining or a lack of spot formation; where PBMCs have been plated out with a high numbers of dead 
cells (30 -50 %) this resulted in high background staining (Kalyuzhny, 2005). Although high levels of 
background were not observed in the liposome studies, perhaps excess liposomes cause a lack of spot 
formation due to an oversaturation of the membrane itself. Thus to further investigate the effect of 
increasing lipid concentration, fluorescent microscopy was used with entrapped model protein BSA-
FITC. 
 
Formulation Lipid composition     
( μMol) 
Size (µm) Zeta Potential (mV) 
PC:Chol  8:8  11.67 ± 0.80 -8.97 ± 7.44 
PC:Chol  16:16  10.91 ± 0.60 -10.5 ± 8.70 
PC:Chol  32:32  10.40 ± 1.16 -10.5 ± 5.77 
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5.3.8 Fluorescent microscopy study of increasing lipid concentration 
To investigate the relationship between the encapsulated biological material and the liposomes 
themselves, a confocal microscopy study was conducted with BSA-FITC as the model protein. 
Liposome formulations of 8:8 μMol, 16:16 μMol and 32:32 μMol were prepared with 5 µg/mL BSA-
FITC. Image J software was used to convert the obtained images to 3D surface plot separate the non-
fluorescent aspects of the image and the fluorescent liposomes. A qualitative assessment of the images 
(Figure 5.23) showed that as the lipid concentration increased, there was an increase in the total 
number of liposomes, but not a similar trend in liposomes containing detectable levels of fluorescently 
labelled protein. This would suggest that increasing the lipid concentration in the formulation, whilst 
increasing the number of liposomes did not increase protein-loaded liposomes, and this would result 
in reduced spot formation. The presence of the increased number of liposomes without sufficient 
protein incorporated may create a spatial hindrance to ‘spot forming’ liposomes in the well.  
In Figure 5.24, manual counting was carried out for the total number of liposomes visible per image 
and the number of fluorescent liposomes. Whilst acknowledging this is not an exact count as there 
may be liposomes there which are not visible, this method is suitable for measuring the number of 
liposomes in the size range required for the assay (Szoka and Papahadjopoulos, 1980). The 
microscopy images confirmed there was a saturation effect and although there were hundreds of 
liposomes visible in an image (Figure 5.23 and Figure 5.24), only a small proportion of these had 
enough fluorescence to be visible in the fluorescent images. From the surface plots, this was 
particularly evident (Figure 5.23), thus as the concentration of lipid increases the number of visible 
liposomes increases.  
The quantification of the results (Figure 5.25) show that for increasing concentrations of PC:Chol 
liposomes from 8:8 μMol through to 32:32 μMol, the number of BSA-FITC containing liposomes 
increased from 67 to 245 respectively (Figure 5.25). There was also a high proportion of non-
fluorescent liposomes; at the 8:8 μMol concentration there were 173 liposomes with no visible 
fluorescence, at 16:16  μMol 149 liposomes and at 32:32  μMol this had further increased to 293 
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(Figure 5.25). This work can be related back to the ELISPOT assay; if such numbers of liposomes are 
present in the well that do not have enough cytokine to form a spot, then they will hinder spot 
formation of those liposomes which do contain enough entrapped cytokine. 
A recent study carried out by Sunami et al., 2006 aimed to assess the entrapment volumes for 
individual liposomes prepared using the freeze-thaw method with the purpose of selecting out those 
liposomes with higher volume entrapments. A plasmid DNA library encoding a gene of interest was 
encapsulated into liposomes (composed of 1-Palmitoyl-2-oleoyl-sn-phosphatidylcholine (POPC), 1-
palmitoyl-2-linoleoyl-sn-phosphatidylcholine (PLPC), 1-stearoyl-2-oleoyl-sn-phosphatidylcholine 
(SOPC), and 1-stearoyl-2-linoleoyl-sn-phosphatidylcholine (SLPC), distearoyl phosphatidyl 
ethanolamine–polyethyleneglycol 5000 (DSPE–PEG5000) and cholesterol at 129:67:48:24:18:14) 
with green fluorescent protein. In the study, fluorescent activated cell sorting was applied to 
liposomes to assess the intensity of fluorescence and those exhibiting higher levels of fluorescence 
were then separated from those with lower fluorescent intensity levels (Sunami et al., 2006). It was 
interesting to observe that the differences in intensity could be as high as 10 fold between such 
liposomes. Overall, the study showed the feasibility of selectively removing liposomes with lower 
levels of entrapment to enhance protein reactions that could occur within liposomes.  
Such results confirm that in heterogenous liposomal formulations although overall entrapment is 
quantified, the individual liposomes within a population can vary in terms of the entrapped volumes. 
Thus in terms of the ELISPOT assay, if the entrapped volume of cytokine is too low, even though 
overall liposomal numbers may be higher, then it could be postulated that spot formation is hindered 
as these liposomes will still take up space on the membrane surface. In terms of liposome 
formulations, previous studies have shown that high concentrations of lipids were required to increase 
the passive entrapment of DNA into liposomes and furthermore this resulted in an increase in the 
number of ‘empty liposomes’, although entrapment did not exceed 20 % of DNA (Lee and Huang, 
1996). Ideally, a ‘high’ control would be able to reach higher spot numbers; however, the image 
analysis indicates that this may not be achievable if the proportion of ‘empty liposomes’ is high. To 
investigate this further, the effect of increased cytokine concentration was considered. 
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Figure 5.23 Confocal images of three liposomal formulations of PC:Chol with surface plots at (a) 8:8 μMol, (b) 16:16 μMol and (c) 32:32 
μMol encapsulated with BSA-FITC 5 µg/mL.
a) 8:8 µMol 
b) 16:16 µMol 
 
c) 32:32 µMol 
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Figure 5.24 Quantifying from fluorescent confocal images the visibly fluorescent and non-fluorescent 
liposomal formulations of (a) PC:Chol at 8:8 μMol, (b) 16:16 μMol and (c) 32:32 μMol encapsulated 
with BSA-FITC 5 µg/mL with gridlines added using image J software. 
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Figure 5.25 Quantification of the images for the formulations of (a) PC:Chol at 8:8 μMol, (b) 16:16 
μMol and (c) 32:32 μMol encapsulated with BSA-FITC 5 µg/mL by counting the total number of 
liposomes and visibly fluorescent liposomes. Below the histogram are representative ELISPOT wells 
for the highest lipid concentrations for each calibration curve.  
 
 
5.3.9 Assessment of increasing cytokine concentration to achieve higher spot numbers 
Subsequent to assessing the effect of increasing lipid concentration on spot number, it was also 
important to determine the effect of increasing the concentration of the encapsulated cytokine on spot 
number within the ELISPOT assay. From Figure 5.26 a trend of increased spot number for the first 
three concentrations is notable, thereafter there is a sharp decrease is spot number. The change in 
increasing concentration only had a statistical difference between 2 x 10
5
 U/mL and 4 x 10
5
 U/mL    
(p<0.05), where there was a seven fold decrease in spot number (Figure 5.26). The reduced spot 
number at high concentrations may be due to the high levels of background observed. The results 
show that the highest spot number is achieved at the concentration that has been used throughout the 
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study, which is 2 x 10
5 
U/mL. At higher concentrations, a change in protocol maybe necessary to 
ensure the removal of the higher levels of unentrapped rIFNγ. Even with cells, the presence of too 
much secreted cytokine can result in high levels of background and thus requires optimisation of the 
cell number (Chambers, 2010). Whether this would actually influence spot numbers is difficult to 
predict as the limitation could be the formulation method itself. Traditional methods for the 
preparation of MLV experience low aqueous trapped volumes and entrapment efficiencies which are 
improved by using other methods such as freeze-thaw techniques and dehydration-rehydration 
vesicles (Mayer et al., 1986).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26 Spot numbers generated for increasing cytokine concentration, representative wells 
shown from PC:Chol 8:8 μMol particle size 7.8 ±0.49 µm. Concentration of rIFNγ tested was 5 x 104, 
1 x 10
5
, 2 x 10
5
, 4 x 10
5
 and 6 x 10
5
 U/mL. Results represent mean ± SD, n =3. 
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5.4 Conclusion 
 Having established ‘proof of principle’ as shown in the previous chapter, the work in this chapter 
focused initially on optimisation of the procedure to produce high quality reference standards that 
would be user friendly. One of the principle conclusions derived was that background levels of 
unentrapped interferon can vary the quality of the ELISPOT results. However, this can be controlled 
through optimisation of the centrifugation steps. The addition of a centrifugation step made a 
significant difference to background levels. Using the ultra-centrifuge at 29,771 g RPM for 30 
minutes for two runs and an additional slow step at 205 g for 10 minutes was perhaps the optimum 
protocol in terms of just background levels; however, logistically it was very time consuming. 
Modification of the protocol ensured that background levels were acceptable using a bench centrifuge 
normally used for cell work. Using RPMI for the resuspending buffer and for the final formulation 
had a notable impact on reducing overall background, thus the final protocol at this stage was one 
centrifugation step at 2660 g for 15 minutes followed by 205 g for 10 minutes. The premise of the 
second slower step was to remove smaller, less dense particles that may find it difficult to sediment 
but would probably add to background levels of interferon. The protocol though optimised required an 
additional change when the variability of automated reading for counting spot number was 
introduced. Modification of the protocol by the re- introduction of an additional centrifugation step of 
2660 g for 15 minutes at 4 ° C was sufficient to rectify this issue. 
From establishing ‘proof of principle’ that liposomes can encapsulate rIFNγ, the studies have shown 
the feasibility that a calibration curve can be produced from the formulation, which shows an 
exponential trend line with high R
2 
values consistently obtained. There is a good level of 
reproducibility when running the same formulation batch as a calibration curve across different plates; 
however, the reproducibility of different batches can vary. The results from the calibration curves are 
promising, showing that a serial dilution can produce a standard curve. 
In terms of trigger release, relying on the phase behaviour of the lipids at 37 °C to release the cytokine 
without an additional trigger such as an enzyme, seemed to work successfully. It was also evident that 
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using liposomes as reference standards is about getting exactly the right amount of release. The 
addition of an external trigger release mechanism such as an enzyme caused background levels to 
become elevated. It can be speculated that release was increased however, it became too great for 
effective spots to form on the well, thus thermosensitive release was more successful at this stage. The 
kinetics of release and its importance is apparent even for cells Lehman, (2005), comments that a 
rapid secretion rate will produce larger, less defined spots whereas a slower, steadier release of 
cytokine results in smaller and denser spots. It terms of producing a reference standard, by relying on 
the phase behaviour of the liposomes at 37 °C the actual standard is simpler to produce and use for the 
operator. The formulations of PC and PC:Chol have shown the ‘right kinetics’ and it has become 
apparent that perhaps these are the formulations that should be taken forward for further studies. 
The assessment of achieving a ‘high’ positive control by increasing spot numbers however has proved 
more elusive. The relationship between increased lipid concentration and increased cytokine 
concentration is complex as there was no immediate increase in spot number observed. The 
microscopy work has aided in explaining why this is the case for increased lipid concentration as it 
was observed that many liposomes do not have enough encapsulated material to observe any 
fluorescence suggesting that similarly liposomes without enough cytokine would not form spots. 
Increased concentrations of cytokine did not affect spot number either but this may be due to the 
requirement of further refinements in the protocols depending upon the concentrations used. 
Overall, the spot number and morphology of the spots formed from the artificial reference standards 
appear comparable although not perfectly similar. PC and PC:Chol are promising formulations for use 
within the reference standards without additional trigger release mechanisms.  
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Feasibility of scaling up and lyophilisation of reference standards 
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6.1 Introduction 
6.1.1 Enhancing stability of liposome reference standards and consideration of production scale-
up 
Stability and long-term storage are important pre-requisites to the development of a reference standard 
and lyophilisation has enabled many reference standards to fulfil these criteria (Matejtschuk et al., 
2005). Liposomes are susceptible to chemical instabilities, such as oxidation or hydrolysis, 
particularly with lipids containing unsaturated chains (Vemuri and Rhodes, 1995; Mohammed et al., 
2006). Even when liposomes are frozen or freeze-dried, they may undergo membrane rupturing which 
can lead to the loss of encapsulated material. One way to avoid this is for the liposomes to be freeze-
dried in the presence of the lyoprotectant such as sucrose or trehalose (Bakás, 2000); however, the 
choice of cryo/lyoprotectants can play an important part (Christensen et al., 2008, van Winden and 
Crommelin, 1999).  
One theory proposed is that the sugars interact directly with the proteins or the head groups of the 
phospholipids of the bilayer membrane. The sugars replace the water molecules on the surface 
membrane, causing suppression in the bilayer transition temperature (Tm), which can cause leakage 
from the liposomes. The second theory relates to the formation of a glassy matrix around the 
liposomes upon dehydration. This matrix prevents the interaction between adjacent bilayers reducing 
mechanical stress and therefore enhancing bilayer integrity. A third theory for the protective effect of 
sugars relates to their kosmotropic effect. The charged ions present stabilise the structure of bulk 
water and reduce the amount of water at the membrane-water interface. This prevents damage by 
water during freezing and drying.  
As liposome cryo/lyoprotectants, disaccharides such as sucrose and trehalose, which are naturally 
found in plants and animals protecting them from extremely cold environments, are particularly useful 
and form an established part of the freezing protocols for many pharmaceuticals within the 
biopharmaceutical industry (Christensen et al., 2008). The advantage of using disaccharides is that 
they are small enough to interact with the phospholipid head groups whilst having a high Tg; sucrose 
and trehalose have Tg of -30 °C and -29 °C respectively (Chen et al., 2010). Other cryoprotectants 
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found to be particularly effective are the oligosaccharides inulin and dextran, with inulin being more 
effective for PEGylated liposomes (Hinrichs et al., 2005).  
Given the basic ‘proof of principle’ and further optimisation of liposomes as potential ELISPOT 
reference standards has resulted in a practical and effective formulation process (chapter 5). The 
subsequent stage involved further testing of the reference standard as a part of the initial validation 
procedure (Cox, 2004). The testing of the reference standard forms an essential part of the validation 
procedure and is a necessary pre-requisite before the introduction of the reference standard into 
widespread use (Gold et al., 2010). Many variables can affect the outcomes of an assay; the operator 
technique, equipment used, whether procedures are manual or automated thus, where possible 
evaluation of the material should be carried out under varying conditions (Janetzki et al., 2008).  
There are many available liposomal products that have achieved commercial success, including 
biological vaccines as well as drugs (Allen and Cullis, 2012). Therefore, scalable liposome techniques 
for the production and purification of liposomes on a large scale have been successful with many 
companies developing efficient procedures (Wagner et al., 2002). In terms of this project, establishing 
the feasibility of scale-up was important for the project.  
 
6.2 Aims and Objectives 
Therefore, the aim of the work in this chapter was to optimise procedures for storage of the reference 
standards and to consider operator variability and the feasibility of scale-up of the production method. 
In order to achieve this aim, the objectives of the study were as follows: 
 
 To investigate the appropriate format to facilitate storage and shipment of liposomes. 
 To assess the robustness of the reference standards, through external testing with other 
operators. 
 To assess the feasibility of making increased batch sizes that may be required for further 
validation processes. 
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6.3 Results and Discussion 
 
6.3.1 Assessing storage options for liposome reference standards 
An assessment was made of liposome formulations (PC, 32 μMol and PC:Chol, 16:16 μMol) for spot 
numbers generated pre-frozen and frozen at -70 °C (Figure 6.1). Although there was no significant 
difference observed across the formulations for PC:Chol rIFNγ reference standards pre and post 
freezing (with an average spot number generated of 120 ± 12 and 96 ± 27 respectively) there was a 
significant drop (p<0.001) in spot number for PC liposomes stored at -70 °C. There was over a two-
fold decrease in spot number (from 135 ± 6 prior to freezing to 62 ± 6 spots subsequently; Figure 6.1). 
When comparing spot numbers generated for PC and PC:Chol formulations after freezing and 
thawing there was a significant difference (p<0.05) in spot number with just over 1.5 fold higher spot 
numbers generated for PC:Chol liposome formulations.  
These results suggest that using 100 mM trehalose at -70 °C as a cryoprotectant would allow the 
liposome formulations to be stored and upon thawing, the cytokine retained enough activity for spot 
generation. As a general guideline, it is recommended to have 2 g cryoprotectant per g of 
phospholipid; within this study, the lipid to cryoprotectant ratio used was at 1:3 for the formulations 
(Mohammed et al., 2006). In this study, liposome formulations using soy bean phosphatidylcholine 
(PC) and Dicetylphosphate at a 10:1 molar ratio were assessed for leakage of CF and it was found that 
storage at -30 °C was optimal for the freezing of liposomes (85 % retention) even without 
cryoprotectant through careful manipulation of the freezing rate. Although the absence of 
cryoprotectant did result in some levels of liposome aggregation and fusion. This was stabilised by the 
addition of cryoprotectants such as glycerol 10% v/v and mannitol 10 % m/v the authors attribute this 
to cryoprotectant interaction with the bilayer, reduction of ice crystallisation and a lower eutectic 
temperature in the presence of cryoprotecant (Fransen et al., 1986). Previous studies have also shown 
that formulations of SUV containing soybean phospahtidylcholine and dicetylphosphate prepared at a 
1:10 molar concentration in the presence of trehalose at 5% v/v had over 95 % CF retention at either -
50 °C and -75 °C, with no significant variation in liposome size (Talsma et al., 1991). 
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Figure 6.1 Assessment of PC and PC:Chol liposomes (32 μMol total lipid amount) for size (μm) and 
ELISPOT number for formulations prior to and subsequent to freezing at -70 °C. Results represent 
mean ± SD for n=3 batches.  
 
6.3.2 Lyophilisation of liposome formulations encapsulating protein 
Although it was shown in Figure 6.3.1 that MLV liposomes could potentially be frozen as reference 
standards, similarly to reference standard sera used as controls for ELISA assays, the ideal format for 
a reference standard is lyophilisation (WHO, 1990). Thus, using BSA-FITC as a model protein, 
PC:Chol liposome formulations with a mean particle size of 7.7 ± 0.1 μm (data not shown) were used 
to assess the effect of lyophilisation on protein loading and liposome size. To consider the role of 
   
P<0.001 
P<0.05 
 
NS 
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lyoprotectants, the lipid to trehalose ratios assessed were (1) 1:2 (w/w), (2) 1:4 (w/w), and (3) 1:8 
(w/w) in conjunction with four aqueous media: 1) sodium bicarbonate, 2) Tris, 3) PBS and H2O 
(Figure 6.2). 
In terms of protein loading (Figure 6.2) the absence of cryoprotectant resulted in a significantly lower 
(p<0.001) protein loading (%) when compared to the pre-lyophilised formulations (4.22 ± 0.18 % vs. 
8.34 ± 0.15 % respectively). The presence of trehalose at 50 mM, 100 mM and 200 mM did not 
prevent the loss of entrapped protein due to freeze-drying, with significant (p<0.05) decreases in 
protein loading compared to pre-lyophilised formulations. However, the loading values were 
significantly higher (p<0.05) for lyoprotectants in sodium bicarbonate buffer and Tris buffer when 
compared to formulations with no cryoprotectant. When assessing the impact of changing 
lyoprotectant concentration with the four different types of aqueous media for the post-lyophilised 
formulations, no significant differences were observed (Figure 6.2).  
The impact of lyophilisation on the mean size of the liposome formulations was also investigated; 
results (Figure 6.2) showed that in the presence of the cryoprotectants (even at 50 mM) there was no 
significant difference in size when comparing pre-lyophilised formulations to lyophilised 
formulations. However, in the absence of any cryoprotectant the size was significantly higher 
(p<0.001) when compared to the pre-lyophilised formulations, increasing from 7 ± 2.16 μm to 17.68 ± 
3.31 μm. This suggested that aggregation had occurred and was further confirmed through confocal 
microscopy (Figure 6.3).   
During freeze-drying the protein is placed under a variety of stresses including low temperature stress, 
freezing stresses, the formation of ice crystals, increased ionic strength, changes in pH and drying 
stresses (Wang et al., 2000). Many studies indicate that the correct choice of buffer for the 
lyophilisation procedure is critical due to the inherent pH changes which can cause crystallisation of 
the buffering species, especially sodium phosphate buffer (Wang et al., 2000). From the results, the 
impact of the lyophilisation process was evident through the decrease in the entrapped protein and 
although the presence of the lyoprotectants reduced this loss, it was not prevented completely. 
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Figure 6.2 Protein loading (%) and size (μm) of PC:Chol liposomes entrapped with BSA-FITC (5 µg/mL) pre and post lyophilisation with trehalose at 50 
mM, 100 mM and 200 mM in Sodium bicarbonate, Tris, PBS and H20. Results represent mean ± SD for n=3 batches.                          
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Figure 6.3 Confocal microscopy images of (a) and (b) lyophilised PC: Chol liposomes and enlarged 
areas (c) and (d) showing aggregation and fusion of the vesicles. 
 
Studies by Van Winden et al (1997), examining the effect of freeze-drying of larger MLV vesicles of 
DPPC:DPPG (10:1 molar ratio) in the presence of sucrose (10% w/v), found that freeze-dried 
liposomes showed a higher (p<0.01) permeability for CF into the vesicles when compared to non-
freeze dried liposomes. Thus, the studies confirm that freeze-drying affects the bilayer properties of 
the membrane and can explain the loss of protein observed during lyophilisation. Other studies 
confirm that, despite the presence of lyoprotectants, that ‘repacking’ of the bilayer components takes 
place during and after rehydration (Zhang et al., 1997). The observed increase in size upon 
lyophilisation in the absence of cryoprotectant was shown to have occurred due to the aggregation and 
breakdown of the liposomal bilayers (Figure 6.3); such increases in size in the absence of 
cryoprotectant have also been observed in studies by Stark et al., (2010). In this study the size of 
unprotected liposomes composed of DSPE-PEG 2000, 1-stearoyl-2-hydroxy-sn-glycero-3-[phospho-
rac-1-glycerol],1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or DSPC (5:28:57 molar 
ratio) significantly increased (p<0.05) whereas those liposomes in which glucose, trehalose or lactose 
was added at a 1:10 ratio showed no significant difference in size compared to freshly prepared 
samples. Although our results indicate that even at cryoprotectant concentrations as low as 1:2 (w/w) 
lipid to carbohydrate ratio the trehalose was able to stabilise the size of the vesicles. Overall, the 
results indicate that the Tris buffer is suitable for the trehalose dilution and the presence of 
cryoprotectant is important for the retention of protein and maintaining the integrity of the liposomes. 
 
 
a b 
c 
d 
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6.3.2.1 Optimisation of lyoprotectant concentration for the liposome reference standards 
Although a general assessment of the impact of lyophilisation had been carried out (Section 6.2.2), the 
effect of lyophilisation on the rIFNγ incorporating liposomes was also required and the direct impact 
upon spot numbers to determine an optimised cryoprotectant concentration as a part of the protocol. 
Thus, formulations of PC 32 μMol were lyophilised at a range of lipid to lyoprotectant ratios, 
including 1:1.5 (w/w), 1:3 (w/w), 1:6 (w/w), and 1:9 (w/w) for both sucrose and trehalose. 
Subsequently formulations of PC:Chol (16:16 μMol) were also assessed at  1:1.5 (w/w) and 1:3 (w/w) 
lipid to lyoprotectant ratios with sucrose and trehalose.  
As shown in Figures 6.4 a and 6.4 b there was a significant decrease (p<0.001) in spot number 
observed upon lyophilisation in the absence of cryoprotectant with, for example over a 7.5 fold 
reduction in generated spot numbers produced by PC liposomes freeze-dried compared to freshly 
prepared formulations. Generally, the process of freeze-drying and rehydration in the absence of a 
lyoprotectant also resulted in an increase in vesicle size. In terms of identifying an optimum 
lyoprotectant concentration, whilst there was no discernible trend for the PC liposomes (Figure 6.4 a 
and b respectively); at 100 mM of sucrose (188 ± 31 spots; 6.62 ± 1.83 µm mean particle size) or 100 
mM trehalose (147 ± 5 spots; 8.32 ± 1.2 µm mean particle size) they gave comparable spot numbers 
and liposome size profiles to the freshly prepared PC liposomes (161 ± 62; 7.85 ± 1.26).   
Based on the results for PC formulations, PC:Chol liposomes were freeze-dried using both sucrose 
and trehalose over a concentration range of 0 to 100 mM. Similar trends were observed with the 
PC:Chol liposomes to those of PC liposomes; in the absence of cryoprotectant there was significant 
decreases in spot numbers (p<0.001) compared to freshly prepared liposome formulations (Figure 
6.5). The addition of 50 mM lyoprotectant also resulted in significantly lower spot numbers and 
overall 100 mM lyoprotectant giving more the comparable spot number and liposome size (Figure 
6.5).  
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Figure 6.4 The effect of increasing (a) sucrose and (b) 
trehalose concentration on the size (μm) and ELISPOT number 
of PC 32 μMol liposome formulations. Results represent mean 
± SD for n=3 batches. 
Figure 6.5 The effect of increasing (a) sucrose and (b) 
trehalose concentration on the size (μm) and ELISPOT number 
of PC:Chol 16:16 μMol liposome formulations. Results 
represent mean ± SD for n=3 batches. 
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Other studies assessing the impact of lyophilisation on proteins such as siRNA was carried out with 
liposomes composed of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) chloride and 
dioleoylphosphatidylethanolamine (DOPE) at a 2:1 molar ratio with a final lipid amount of 5 mg 
(Yadava et al., 2008). It was found that there was no significant differences between freshly prepared 
formulations and those lyophilised in the presence of glucose (p=0.2), sucrose (p=0.46), trehalose 
(p=0.74) and lactose (0.86) whereas lipoplexes in the absence of cryoprotectant exhibit an 88 % loss 
of activity and furthermore become amorphous and larger in size (Yadava et al., 2008). In terms of 
the ELISPOT similar results were observed; in the absence of cryoprotectant with a significant 
reduction in spot number. The stability of liposomes with trehalose has previously been reported to 
have allowed the retention of 100 % of the encapsulated material subsequent to lyophilisation (Crowe 
et al., 1987). In this study large unilamellar vesicles (LUV) liposomes composed of Palmitoyloleoyl- 
phosphatidylcholine (POPC) and phosphatidylserine (PS) at 90:10 mol % were used with trehalose 
and increasing retention of isocitrate was observed with increasing trehalose concentrations which 
was optimal at 1.8 g trehalose/g of phospholipid. This stability was attributed to the depression of the 
transition temperature of the lipids in the dry phase in the presence of trehalose. 
Although these formulations showed a good level of reproducibility across the three batches (Figure 
6.4 and 6.5), the issue of elevated background highlighted that the presence of the cryoprotectants was 
an issue. When the sucrose at 200 mM concentration was placed in wells without the reference 
standards, there was no observed background or spots (Figure 6.6 a) and there were instances of batch 
failures (e.g. Figure 6.6 b and c). Thus producing liposomes in a lyophilised format requires further 
optimisation, as even at lower lyoprotectant concentrations the observed background levels were high 
(Figure 6.6 d). Thus for further work, frozen formulations were used with 100 mM trehalose as the 
final concentration. 
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Figure 6.6 Representative ELISPOT results for assays post-lyophilisation (a) control sucrose 
concentration at 200 mM (b and c) results for no observed spots and elevated background levels 
attributed to batch failure (d) PC and PC:Chol wells for trehalose concentrations of 50 mM and 100 
mM (1:3 w/w lipid to lyoprotectant ratio). 
 
6.3.3 External assessment of formulations 
 
To enable a direct comparison of the liposomal standards with the commonly used peripheral blood 
mononuclear cells, pre-formulated controls (PC 32 μMol and PC: Chol 16:16 μMol) were sent to 
NIBSC. For the study, liposome formulations that offered both high and low spot numbers that 
differed by a 1 in 3 dilution were used. Liposomes were prepared in RPMI and trehalose 100 mM, 
frozen and sent on dry ice to the operator. The assay plan details the layout of the artificial liposomes 
and the cell based controls (Figure 6.7 a).  
a 
b 
c 
d 
PC 50 mM 
trehalose 
PC 100 mM 
trehalose 
PC:Chol 50 
mM trehalose 
PC:Chol 50 
mM trehalose 
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Briefly, the artificial reference standards (Figure 6.7 a) sent from Aston were in rows A-C (column 1-
6) and cells added to the assay included stimulated cells as high positive controls. In Figure 6.7 b in 
rows F 1-3 (cell based positive control) there were too many cells for the automated reader to detect, F 
4-6 labelled as high positive 1 were cells stimulated with PMA and G 1-3 were also stimulated cells 
for a positive control. Cells without any additional stimuli were included as the negative control for 
cells and shown in H 1-6 (figure 6.7 b). From the results of the assay, the background levels were 
appropriate (Figure 6.7 b) across both the cell based controls and the artificial reference standards. 
There were low levels of spots observed for the negative controls included in the assay for both the 
artificial reference standards and unstimulated cells. RPMI medium alone also showed no spots again 
confirming that there was no contamination or non-specific spot formation (Figure 6.7 b). In terms of 
spot number for the controls sent to NIBSC (Figure 6.8), there was a significantly (p <0.001) higher 
spots formed with the PC ‘high’ formulations which were 2.5 fold higher than PC:Chol preparations 
(82 ± 4 and 32 ± 5 spot numbers generated respectively; Figure 6.8). The spot numbers generated for 
the PC:Chol ‘low controls’ were 31 ± 7 spots and not significantly different to the PC:Chol 
formulation at 3 fold higher concentration (PC:Chol Low control; Figure 6.8). 
Liposomes are able to encapsulate a wide variety of biological molecules although generally tailored 
for in vivo release (Gregoriadis and Allison, 1974, Gregoriadis et al., 1971).The results in Figure 6.7 b 
and Figure 6.8 have shown that it is feasible to use artificial reference standards within an ex-vivo 
ELISPOT assay. For current controls within ELISPOT assays, cell preparations have been frozen and 
stored in liquid nitrogen, without significantly affecting their morphology or their maturation signal 
(Kalyuzhny, 2005) suggesting that using frozen rather then freeze-dried formulations is an option. In a 
recent study, it was shown that the viability of blood cells (PBMCs) collected from 285 patients was 
assessed for effects following cryopreservation and shipment (Olson et al., 2011). A significant 
reduction in cell recovery was observed (p<0.001) and decreased cell viability and the authors 
attributed this to damage occurring during shipment and would not be evident prior to cryo-
preservation or even immediately after. 
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Figure 6.7 (a) Plate layout of the ELISPOT detailing where the artificial and live controls were ran 
within the assay (b) ELISPOT results for the assay of controls.  
a
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Figure 6.8 ELISPOT results for spot numbers observed with artificial liposomal and live cell 
reference standards  of PC: Chol ‘high’ controls, PC ‘high’ controls, PC: Chol ‘low’, liposomal 
negative control Results represent mean ± SD for n=3 vials. Cell based positive high control 1, cell 
based positive control 2 and unstimulated cells as a negative control. The cell based controls are n=1 
in triplicate wells. 
 
6.3.4 The feasibility of scale up of liposomal reference standards 
 
To assess the feasibility of scaling up the production of the ELISPOT reference standards, BSA-FITC 
(5 µg/mL) was used as a model protein to investigate producing a larger batch of liposome reference 
standards. The process used detailed in Figure 6.9, shows the procedure for production. A larger batch 
was made of PC:Chol 160:160 μMol to a total volume of 40 mL and the small batch of 16:16 μMol 
PC:Chol of a 4 mL volume. Assessments were made of particle size, entrapment efficiency and the 
morphology of the vesicles.  
In terms of the scale up procedure, some adaptations to the basic protocol were necessary to account 
for the increased volumes. Due to the larger volume of lipids, it was necessary to use a 500 mL flask 
size and the time on the rotary evaporator increased to 45 minutes with further additional time for the 
flushing of N2 for the removal of any residual solvents. Lipid hydration was for 30 minutes as 
modifications at this stage may affect the integrity of the protein.  
P<0.001 
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Small batch 4mL (5 μg/mL)      
STEP 1: Rotary evaporation of solvents.  
In order to accommodate for the larger volume of solvent for the large 
batch the time was extended from 20 to 45 minutes. 
 
STEP 2: Hydration of the dry lipid film. 
Lipids were hydrated at 45 °C for 30 minutes with 
intermittent periods of vortexing. 
 
STEP 3:  Lyophilisation of large batch 
The large batch was centrifuged as protocol 5 (Table 2.4) and then resuspended in the 
original volume. 500 μL was aliquoted into freeze drying vials and an equal volume of 
lyoprotectant was then added to each vial to a final concentration of 50 mM, 100 mM or 
200 mM in various buffers per vial. Three vials contained no lyoprotectant. 
 
1 2 
3 4 5 6 
Figure 6.9 Scale up procedure and lyophilisation of large-scale batch of 40 mL PC: Chol 160:160 μMol with encapsulated BSA-FITC 5 µg/mL and 
production of a smaller batch of PC:Chol 16:16 μMol (4 mL).             
 
Large batch 40mL (5 μg/mL)      
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Table 6.1 Particle size data for the batch of PC:Chol 16:16 μMol and PC:Chol 160:160 μMol. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 Confocal images using the 40X objective and the Leica Confocal microscope of the (a 
and b) small batch PC:Chol 16:16 μMol and (c and d) large batch PC: Chol 160:160 μMol with 
entrapped BSA-FITC 5 µg/mL. 
 
Batch Size Lipid Composition (μMol) Volume (mL) Size (µm) 
Large 160:160 40 7.00 ± 0.1 
Small 16:16 4 8.04 ± 0.2 
 Small batch 4mL    
(5 μg/mL) 
Large batch 40mL 
(5 μg/mL) 
a 
b 
c 
d 
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Figure 6.11 Entrapment and recovery of BSA-FITC 5 µg/mL for the large scale-up batch of PC: Chol 
160:160 μMol and the small batch 16:16 μMol. 
 
The particle sizes for the small and large batch (Table 6.1) were similar at 8.04 ± 0.02 µm and 7.00 ± 
0.1 µm. The liposomes morphology and entrapment of the fluorescent marker was confirmed by 
confocal microscopy which also further confirmed that the vesicles from the small batch (Figure 6.10 
a) were a similar size to the vesicles of the large batch (Figure 6.10 c). The fluorescent images clearly 
confirm that both the small and large batch were able to entrap fluorescent marker (Figure  6.10 b and 
d respectively). 
Further to the confocal microscopy pictures, which confirmed the presence of the protein, 
quantification of the entrapped fluorescently labelled protein also confirmed that the entrapment of the 
marker had occurred using the previously validated assay detailed in chapter 3. For the purposes of 
quantification a calibration curve was constructed. The extrapolated values for the amount entrapped 
shown in Figure 6.11 for the small and large batch were 7.58 % and 8.34 % respectively. The total 
amount of protein recovered was also similar for the small and large batch of 93 % and 97 % 
respectively. Thus, the results have confirmed that scale-up with the lipid hydration method is 
achievable with minimal differences in the characterisation or entrapment values obtained. 
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In this study the feasibility of producing a larger batch of PC:Chol liposomes was assessed. These 
were produced via the lipid hydration method and although it is a relatively simple manufacturing 
process for the formulation of liposomes, it would not normally be considered for large scale 
production due to the low encapsulation efficiencies and the presence of multilamellar vesicles which 
are of limited clinical use (Lasic,1998). However, for the purposes of producing rIFNγ liposomes for 
use in the ELISPOT assay, MLV liposomes have been shown to be effective thus the lipid hydration 
method can be adopted. A study by Justo and Moraes, (2011) has shown that scale up of laboratory 
based methods was achievable, the method used was the ethanol injection method which produces 
small unilamellar vesicles (SUV) through ethanol mixing of dissolved lipids (PC and cholesterol at a 
molar ratio of 60:40), with an aqueous solution by fast injection. Smaller batches produced were 10 
mL and scale-up was carried out by using 4:76 volume ratio of organic to aqueous solution and it was 
shown that liposomes of the larger batch were a comparable size to the small batch 132-146 nm and 
122 nm respectively. 
 
6.4  Conclusion 
Overall, the results observed suggest that storage of the artificial reference standards produced from 
liposomes can be either in a frozen or a lyophilised format. However, there were drawbacks for both 
methods, as reductions in spot numbers were observed both upon freezing and with lyophilisation. 
Investigations into the optimisation of the type of lyoprotectant, the lipid to lyoprotectant ratio and the 
buffers used revealed that 100 mM concentration of either trehalose or sucrose were appropriate with 
no advantages of using higher concentrations in terms of spot numbers generated. Trehalose at 100 
mM concentration was chosen when an assessment was made across both PC and PC:Chol liposome 
formulations. 
As an assessment for the feasibility of sending controls externally for testing, liposomal formulations 
were frozen using 100 mM trehalose and sent to NIBSC. These artificial reference standards were ran 
alongside the ‘live cell’ controls and although spot numbers were lower than anticipated particularly 
for the PC:Chol ‘high’ control although with PC formulations spot numbers of just over 80 were 
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achieved. Thus, the results are promising in terms of feasibility for the production of reference 
standards that can be tested at different laboratories. The studies highlighted the further need for 
optimisation to enhance the activity of the ‘recovered’ liposomes subsequent to freezing and freeze-
drying. Another important aspect of achieving a batch of controls that could be assessed externally 
was carried out by scaling up the process from 4 mL to 40 mL using a model protein BSA-FITC and 
was shown to be feasible both in terms of protein loading and maintaining the size of the liposomes.  
 There are many liposomal products on the market today successfully produced on an industrial scale 
including Doxil (Sequus), Ambisome (Nexstar), Visudyne (QLT) and Marqibo (Talon) (Allen, 2012) 
In 2001, the FDA published guidelines particularly referring to liposomal products including defining 
lipid components, excipients, characterisation and manufacture (Wagner and Vorauer-Uhl, 2011). 
Thus, the transition from the lab bench to commercial applications is viable with liposomal reference 
standards. Although in terms of the present study optimisation of storage protocols would be required. 
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Chapter 7 
 
General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
277 
 
The focus of this study has been on the ELISPOT assay, which is now one of the leading 
immunological assays used in the assessment of immune responses for vaccine clinical trials (Moodie 
et al., 2006). Based broadly on the sandwich ELISA principle, it is an assay that was first described in 
1983 and has become one of the most widely used methods to measure antigen-specific T-cell 
responses (Slota et al., 2011). The assay plays an important role in the concerted drive to find an 
effective vaccine for the treatment of HIV amongst other diseases. The advantages of the assay 
include its capability for rapid screening, its cost effectiveness and the ability to carry out large scale 
screening for vaccine candidates (Streek et al., 2009). It is a quantitative assay able to assess the 
cellular responses to vaccine candidates at a single cell level (Janetzki et al., 2005). In the last few 
decades there has been hundreds of promising vaccine candidates found within laboratories with over 
a dozen entering into clinical trials. Although there have been successful developments of novel 
vaccines (Keith et al., 2013) there have been some high profile failures of HIV vaccine candidates 
such as at the phase II stage for Merck (Harris, 2009). Such failures are costly on both a social and a 
political level, with estimated financial losses running into several hundred million dollars for Merck, 
and last year alone 34 million people worldwide were living with HIV (Harris, 2009). In the search to 
find answers for such large scale failures questions have been raised in regards to the future role of the 
ELISPOT IFNγ assay within the field of vaccine trials (Streek et al., 2009). This is primarily because 
the ex vivo assay was unable to serve as a successful correlate for the protective immune response of 
the vaccine (Streek et al., 2009).  
The transition of this assay within thirty years from a newly developed technique into an integrated 
part of vaccine clinical trials has led to more demands of the assay in terms of performance, 
repeatability, and reliability that naturally lead to a focus on validation and standardisation of the 
assay (Janetzki et al., 2005). Due to the nature of the ELISPOT assay, the results are dependent upon 
a number of technical variables that can influence the precision of the assay if not highly standardised 
(Almeida et al., 2009). The large-scale studies in which the assay is used are particularly challenging 
in ensuring this, especially due the number of steps involved, and if there is a lack of automated 
procedures in place (Almeida et al., 2009). This lack of standardisation across laboratories for the 
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ELISPOT assays have highlighted through harmonisation studies the wide range of variability 
observed (Janetzki and Britten, 2012). The issues highlighted through the studies have included the 
lack of a commonly defined consensus to determine the level of the immune response observed, 
variability in the reagents used and other protocol procedures (Moodie et al., 2006, Smith et al., 
2009). The overall results of such differences across laboratories inevitably lead to a lack of 
harmonisation between laboratory data, which highlights the need for greater standardisation. 
Standardisation is the process for ensuring that all the methods for determining a particular 
concentration of analyte are able to give the same results and to achieve agreement between different 
methods particular reference standards are required (Wild, 2001).  
The concept of producing a novel reference standard that would be feasible within the ELISPOT 
assay was the challenge for this study. The vehicle selected to achieve this aim had to be as similar to 
the cells as possible to be successful. A possible option to achieve this was with liposomes, 
considered ideal as models for biological membranes (Johnson and Bangham, 1969). The hydration of 
a dry lipid film formed enclosed vesicles with lipid bilayers and thus resembled cellular membranes 
(Lian and Ho, 2001). In terms of applications, a significant development came with the realisation of 
their capability to encapsulate biological materials such as drugs, protein and enzymes (Gregoriadis 
and Ryman, 1971). The aim was to design a reference standard, which could use these existing 
liposomal carriers through the entrapment of rIFNγ and they would therefore mimic the actions of 
cells. 
Ordinarily in the development stages of a product the ‘proof of concept’ can be one of the first aims of 
a project; however, in this case the developmental stages began with pre-design considerations 
(Figure 7.1). The flow diagram shows the stages of development for the reference standard and this 
began with pre-design considerations. This stage encompassed considering how such a novel 
application for the liposomes would be successful. Although the liposomes offered a model biological 
membrane, they were not cells and had inherent structural differences.  
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From the outset, it seemed unlikely that placing the liposomes into ELISPOT wells and simply 
expecting them to reach the well membrane in similar time to the cells was unlikely, and thus careful 
consideration of the sedimentation characteristics of the liposomes was necessary. Therefore, the 
work in chapter 1 focused on assessing the sedimentation behaviour of liposomes. The results 
confirmed that they took a few hours to show complete settling thus in order to increase the efficiency 
of sedimentation a cholesterol analogue was synthesised. The basic premise was to sustain the 
inherent characteristics of cholesterol whilst modifying the liposomes to have a slightly increased 
density compared to more traditional liposomal formulations that incorporated cholesterol. 
Subsequent to the successful synthesis and characterisation of the brominated cholesterol formulations 
results showed there were improvements to the sedimentation efficiency of liposomes at specific 
ratios of the dibromocholesterol. In these initial stages, it was important to show that indeed the 
method for liposome formulation chosen could encapsulate proteins especially with the formulation 
containing synthesised dibromocholesterol. The entrapment of the protein was feasible as shown 
through a validated fluorescent assay. 
Another parameter taken into consideration as a pre-design assessment (Figure 7.1) was the size of the 
liposomes. The method chosen for the formulation of the liposomes was the lipid film, hydration 
method (Bangham et al., 1965). This method produces multilamellar vesicles which can range in size 
from 0.1 - 15 µm, have varying size distributions and lamerallity (Gomez-Hens and Fernandez-
Romero, 2005). The aim was assessing the impact of various techniques in order to remove the 
smaller vesicles and retain the larger vesicles. A variety of techniques were assessed which would be 
applicable for cells such as differential centrifugation, centrifugation with sucrose gradients and 
filtration. 
The aim was not to produce a homogenous population of smaller vesicles, which is invariably the case 
for in vivo applications of liposomes thus extrusion, homogenisation and sonication were avoided 
(Szoka and Papahadjopoulos, 1980). The techniques assessed were those generally used for cellular 
applications, so were more compatible considering that the liposomes were artificial cells.
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Figure 7.1 Flow diagram summarising the stages for the development of a novel artificial reference standard.
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The conclusions from this work indicated that size separation was achievable using all the 
techniques to some extent; however, in terms of recovery of the liposomes and ease of procedure 
the most effective was slow speed centrifugation for short periods. The pre-design considerations 
were an important stage for examining the potential effect of the differences between liposome 
formulations and cells.  
The next stage of development involved establishing the ‘proof of principle’ (Figure 7.1) and 
whether it was feasible that liposomes could encapsulate rIFNγ, whether the recombinant cytokine 
could retain its activity subsequent to the formulation process and the assessment of a wide range 
of liposomal compositions in conjunction with triggered release mechanisms. Similarly, to other 
studies, which had used interferon gamma within liposomes, entrapment was successful, and in 
agreement with the studies after the formulation process sufficient levels of cytokine activity were 
sustained (Van Slooten et al., 2001, Anderson et al., 1981). From the assessments of a wide range 
of liposome formulations of varying composition for thermo-triggered release, enzymatic release 
using PLA2 and PLC and detergent triggered release, using Triton-X it became apparent that 
differences in the liposomal composition did affect spot formation on the ELISPOT assay. The 
utilisation of mechanisms other than thermo-triggered release was not effective overall. In terms of 
thermo-triggered release, all formulations tested showed some spot formation other than the 
formulations with the synthesised dibromocholesterol. These results were disappointing as the 
successful synthesis and incorporation of the dibromocholesterol within liposomes were achieved 
yet in its application within the ELISPOT assay the formation of spots had been unsuccessful. 
However, the ‘proof of principle’ was established, the incorporation of liposomes encapsulated 
with rIFNγ was not only feasible but their utilisation within an ex vivo ELISPOT assay was shown. 
At these stages liposome formulations of PC and PC:Chol were promising candidates for further 
optimisation. In terms of the other triggered release mechanisms it was observed that Triton-X was 
detrimental to spot formation and that the presence of enzymes only caused a significant increase in 
spot formation for two of the formulations of PC: Chol and DMPC. The results were an early 
indication that it wasn’t simply about releasing all of the liposomal contents immediately but that 
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the kinetics of release was important. Thus, triggered release mechanisms for the liposome 
formulations were not successful within the assay. 
Thus the introduction of a novel reference standard within an ELISPOT assay was shown, however 
these preliminary assays although promising were not part of an optimised protocol thus the 
subsequent stages of development (Figure 7.1) was to work on producing a protocol that was 
robust, offered reduced background levels and was feasible enough for scale-up procedures at a 
later stage. Through the introduction of the novel reference standard within the ELISPOT assay the 
membrane came into direct contact with ‘foreign’ material, which was not ordinarily used within 
the assay. It became evident that variability introduced such as automated reading increased 
background levels. The optimised protocol that could still produce reference standards that were 
similar to the spots produced from live cells was feasible. One of the limitations of the artificial 
reference standard highlighted at this point, was the difficulty in achieving increased numbers for a 
positive control. The spot numbers for positive controls using PBMCs can reach up to 500 spots 
(Zhang et al., 2009). However, alterations in the lipid or the cytokine concentration did not result in 
increased spot numbers in this region. The general spot number observed for liposome formulations 
has been in the region of up to 100 spots. This is due to the numbers of liposomes, which do not 
have enough entrapped protein to form spots but are perhaps impeding the spot formation of those 
vesicles that do, by taking up space on the membrane well. However, the spot numbers obtained 
were sufficient for some studies in which the general cut-off for positive response was 55 spots 
(Hendrik et al., 2009). 
The difficulties for having a reference standard for the ELISPOT assay lies in the nature of the 
assay itself. The assay method involves adding cells directly into the wells and these cells will 
secrete appropriate levels of cytokine dependent upon the responses to antigens (Almeida et al., 
2009). Thus normally a standard which is used within an assay follows the broadly accepted rule of 
‘like versus like’ where the material acting like the reference is as similar to the material being 
tested. Thus, the lack of such a reference standard within the ELISPOT assay explains the problem 
tackled within this study. 
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Previous attempts to find robust reference standards for the assay have included T-Cell lines, 
clones or other PBMCs but these are limited due to both their wider applicability and lack of 
definitive spot numbers for the actual number of cells (Janetzki and Britten, 2012). Currently many 
assays use positive controls as their cells stimulated with mitogens such as PHA, ConA or 
PMA/Ionomycin, as they can induce secretion of cytokine from cells however they can result in 
overstimulation and thus too many spots within a well (Janetzki and Britten, 2012). The problem of 
not knowing how many spots are produced from the positive controls remains the issue with all 
available reference standards for the ELISPOT assay. More recently studies have focused on the 
production of a pool of viral peptides made from a panel of epitopes from the Influenza virus (Flu), 
Cytomegalovirus (CMV) and Epstein Bar Virus (EBV) that were used to elicit IFNγ release from 
T-cells (Currier et al., 2002). The results were promising as the size, shape and appearance of the 
spots could be used for establishing acceptance criteria; however, again they are unable to provide 
the answer for placing a reference standard on the assay which can give a definitive response say of 
100 spots which can then be compared between laboratories. The aim of this study was to produce 
a reference standard that from assay to assay could give a defined response, so that even 
inexperienced ELISPOT users would be confident from the control values that they have followed 
the ELISPOT protocol correctly. By the optimisation stage of the protocol, the idea of an artificial 
reference standard within the ELISPOT assay had moved from a concept to a reality. 
In Figure 7.1, the stages of the project that followed optimisation of the protocol were about 
application. Proving that liposomes could encapsulate rIFNγ and be used within the ELISPOT 
assay was not sufficient if they were used as part of a validation process, it would also be important 
to establish a storage format for the reference standards. Many reference standards arrive 
lyophilised, and for the liposomal rIFNγ formulations, this option was also possible in the presence 
of lyoprotectants such as sucrose and trehalose. Although background levels were elevated once 
more and consistency from one freeze-drying cycle to the next was not shown, lyophilisation was 
achievable. However, the studies highlighted that extensive further work was required in order to 
optimise such a process. Due to the unreliability observed with the freeze-drying cycles the 
reference standards sent externally were frozen and sent on dry ice. The external operator ran the 
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controls alongside live cells and demonstrated that spot formation occurred and that the spots were 
of a sufficient size and morphology for detection by automated reading procedures. This again 
highlights the feasibility of the reference standards as controls for the ELISPOT assay. The 
feasibility of scaling-up production for larger batches with a model protein with similar 
physicochemical characteristics and entrapment levels to the smaller batch was demonstrated 
although the final stages of storage and testing require further investigative work. 
The ‘proof of principle’ that an artificial reference standard that can entrap rIFNγ and release the 
cytokine within the confines of an ELISPOT well to produce a spot on a membrane was 
demonstrated. This brings a promising and novel reference standard that could aid standardisation 
within the field of immune response assessment. The studies have highlighted the necessity for 
extensive further investigations in particular with the storage requirements for the assay; once 
optimised then further testing can be carried out. There is still much scope for investigating the 
lyophilisation process by examining optimised cycles, assessing freezing protocols, and possibly 
looking at a wider range of cryoprotectants and buffers. The possibility of using cytokine within the 
formulation process that has not previously been freeze-dried may also substantially help to retain 
the activity of the protein upon lyophilisation within liposome vesicles. Another area that requires 
investigation is the possibility of freezing the liposomes in a similar way to cells. Currently such 
processes have ensured the integrity of the cells and may prove to be more beneficial for liposomes 
encapsulating rIFNγ. Once such optimisation has taken place, the production of larger batches of 
liposomal reference standards with rIFNγ is feasible and thus more extensive testing with carefully 
designed validation studies to assess the robustness of the controls. The requirements of reference 
standards are stringent and even more so for the ELISPOT assay where there has been a wide 
variability in results observed. Although the incorporation of the synthesised dibromocholesterol 
within the formulations was not successful in this instance (or necessary due to the successful 
release of cytokine promoted by temperature) perhaps, other options for increasing the density of 
the liposomes without affecting the integrity of the cytokine or the release kinetics could further 
enhance the performance of the artificial reference standards. Assigning a fixed range for the 
controls would remain an ultimate objective but would only be feasible once effective storage of 
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the reference standards has been achieved This may ultimately lead to the elusive ‘true gold 
reference standard for the ELISPOT’. 
In summary, the objectives of the research were to show that liposomes could encapsulate cytokine 
and then release the encapsulated material within the confines of the ELISPOT assay to produce 
defined spots of an appropriate morphology. The results from this study have shown that this was 
feasible across a wide range of formulations with liposomes composed of phosphatidylcholine and 
phosphatidylcholine with cholesterol being particularly effective. Thus, ‘proof of principle’ was 
established however, challenges in terms of high background levels were observed. These were 
overcome through the optimisation of the protocol for the production of the reference standards, 
which allowed clear visualisation of spots both by automated and manual reading procedures. 
Furthermore, external assessment of the liposomes with ‘live cells’ showed they could be 
incorporated within the assay as an integrated part of the normal protocol for the operator. The final 
objectives of considering product storage were shown as a frozen and lyophilised format although 
optimisation is still required in this area, in addition the feasibility of scale-up procedures to 
produce a larger batch were demonstrated. Overall, the main objective to produce artificial 
reference standards for use within the ELISPOT assay has been shown. 
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